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A b s t r a c t
FMDV infection is initiated by virus binding to integrin receptors at the cell surface. 
Virus binding to the integrin triggers internalization of the virus-receptor complex 
which enters the cell via clathrin-dependent endocytosis. The low pH within 
endosomes triggers capsid disassembly and translocation of the viral RNA across the 
endosomal membrane into the cytosol. The precise identity of the endocytic 
compartment from which infection by FMDV takes place is currently unknown.
Rab GTPases are central regulators of endocytosis. Each rab protein is enriched in 
one or more specific membrane compartments. In this study dominant-negative 
versions of a number of rabs are used to investigate the early events in FMDV 
infection of a pig kidney cell line (IBRS2). Infection is inhibited by expression of 
dominant-negative rab5 (which inhibits formation of early endosomes) but not by 
dominant-negative rab4 (which inhibits rapid recycling from early endosomes to the 
plasma membrane) 0 1 * by dominant-negative rab9 (which inhibits trafficking from 
late endosomes to the Golgi). Dominant negative rabl 1, which inhibits a slower 
recycling pathway via recycling endosomes inhibits FMDV infection to an extent, 
although the effect of dominant-negative rab5 on infection is greater.
While a dominant-negative form of rab7 (which regulates trafficking from early- to 
late endosomes) unable to bind membranes inhibits FMDV infection, a membrane 
binding but inactive rab7 does not. This inhibition is shown to be at the stage of 
replication rather than entry. It is suggested that rab7 may be required for 
intracellular virus replication, possibly anchoring the replication complex to the 
replication vesicle.
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Chapter One Introduction
Chapter ones Introduction
1.1 Foot-and-mouth disease virus
Foot-and-mouth disease virus (FMDV) is the type species of the aphthovirus genus 
within the Picornaviridae family, the only other member of this genus being equine 
rhinitis A virus (King, 2000). FMDV is the causative agent of foot-and-mouth 
disease, a highly contagious condition affecting cloven hoofed animals. Due to its 
highly contagious nature and economic importance for many countries, FMD is the 
first disease on the Office International des Epizootics (QIE) list o f notifiable 
diseases. Outbreaks in developed countries have a significant economic impact due 
to loss of animals through culling and restrictions on trade.
The disease causes a high rate of mortality in young animals although it is rar ely 
fatal in the adult. Over 70 mammalian species can be infected, many sub-clinically. 
This may lead to a wild animal acting as a reservoir for the virus, infecting domestic 
livestock (Thomson et a l, 2003). Infected cattle exhibit the most obvious symptoms 
(vesicular lesions on the mouth and feet) although these are rarely seen in sheep or 
goats. Sheep are thought to have been responsible for tr ansmission of the virus 
during the 2001 outbreak in the UK as the disease is so difficult to diagnose 
clinically in these animals (Hughes et a l, 2002).
The infectious nature of the virus has made it notoriously difficult to control. There 
are many reasons for this, including the large amount of infectious material produced 
by infected animals, high susceptibility o f host species (particularly cattle) and the 
short incubation time. Sheep and cows are able to become persistently infected 
(Burrows, 1966; Salt, 1993) enabling them to act as asymptomatic carriers. The
1
virus can also survive outside the host for long periods of time, up to several weeks 
in a sheltered environment. This means that the vims can be passed by 
contamination of vehicles and clothing of people attending affected livestock. 
However, due to the narrow pH range tolerated by the vims (6.0-9.0), it can be 
destroyed by sterilisation with acid.
Transmission from animal to animal is usually via aerosol (Donaldson et al., 1987), 
although it can also be passed by direct contact through skin or mucosal abrasions. 
Infected animals excrete large amounts of vims, especially pigs (Alexandersen & 
Donaldson, 2002), and under favourable conditions, the vims may travel in the air 
distances up to 10km over land, or 250km over water.
The route of infection is via the respiratory tract, with the initial site of replication 
thought to be in the epithelial cells o f the pharynx and dorsal soft palate 
(Alexandersen et al., 2001; Brown et al., 1992; Burrows et a l, 1981). The vims 
then spreads thr oughout the animal, tar geting mainly epithelial tissues in the feet and 
mouth (Alexandersen et al., 2001; Brown et a l,  1995; Brown et a l , 1996; Burrows 
et a l, 1981). Infected animals often have a fever, and most develop viremia. After 
infection, a neutralising antibody response can be seen by 4-5 days, peaking at 28 
days. The immune response varies according to host species, age and health together 
with vims dose, strain and route of infection. It is thought that interferons a, (3 and y 
are involved in host defence, along with other cytokines (Brown et a l, 2000; 
Chinsangaram et al., 2001).
Most of the world has seen outbreaks of FMDV, with New Zealand as the only 
exception (see figur e 1.1). It is endemic in Africa, Asia and South America. The EU
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Figure 1.1 Geographical distribution of FMDV serotypes during 2001
N.J. Knowles 03 March 2002
This figure shows the distribution of the seven serotypes of FMDV.
is usually FMDV free, except for occasional incursions such as the UK outbreak in 
2001 which spread to France, Holland and the Republic of Ireland. There are 
sporadic outbreaks in Russia. Australia and North America are currently free of 
FMDV. There are seven serotypes of FMDV: A, O, C, South African Territories 
(SAT) 1,2, 3 and Asia 1. These are further sub-divided into strains and grouped by 
topotype (Bachrach, 1968). The UK outbreak was caused by serotype O.
FMDV diagnosis and control by vaccination are made more difficult as the error- 
prone nature of the viral RNA dependent RNA polymerase leads to frequent 
mutations (Drake & Holland, 1999). This means that new variants often appear in 
the field. The major site of sequence variation is in the PI region, giving rise to 
antigenic variation. Diagnosis of FMDV is currently by quantitative real-time RT- 
PCR and virus isolation on primary cells. RT-PCR methods are hoped to be able to 
diagnose FMDV in the field (Callahan et ah, 2002; Hearps et al., 2002; Reid et a l , 
2003).
Vaccines are available against FMDV based on inactivated virus. Vaccination 
programmes control the virus in many countries, but vaccination is unpopular in an 
emergency outbreak situation. When vaccination is used, disease-free status is lost 
and hence trade with disease free countries is restricted. Tt can be difficult to 
distinguish between vaccinated and recovering animals. Vaccinated animals may 
also cany the virus and potentially infect other animals although this is as yet 
unproven. Further problems with vaccination are that the vaccine virus must be 
matched precisely with the outbreak strain and the high rate of antigenic variation 
caused by frequent mutations means that viruses may evolve to evade vaccines.
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Picornaviruses are small non-enveloped RNA viruses. There are nine genera in the 
Picornavirus family, containing a number of important human and animal pathogens 
(See Table 1.1). Apart from FMDV, notable members of the picornavirus family 
include poliovirus (PV), human rhinovirus (HRV), hepatitis A virus (HAV) and 
swine vesicular disease virus (SVDV).
Poliovirus is the causative agent of poliomyelitis (Popper, 1909), a contagious 
disease of the nervous system with few obvious symptoms other than paralysis in 
less than 1% of cases, leading to death. It affects mainly children under the age of 
five and can spread rapidly through populations. A global vaccination programme 
begun in the 1950s has all but eradicated poliovirus, but some reservoirs exist where 
populations cannot be reached to be vaccinated, especially in war-torn areas. Two 
vaccines have been developed, the inactivated vaccine (IPV) by Jonas Salk (Salk et 
al., 1954) and the live attenuated oral vaccine (OPV) by Albert Sabin (Sabin, 1957).
Human rhinovirus is the main cause of the common cold, thought to account for up 
to 80% of infections during peak cold season (Turner, 2001). It is estimated that 
time off work due to infection with human rhinovirus accounts for millions of work 
days in the USA alone (Monto et a l . , 2001), and the market for over-the-counter 
remedies is worth billions of dollar s (Bertino, 2002). The virus is also associated 
with other more serious conditions including sinusitis and pneumonia and 
exacerbation of asthma, chronic bronchitis and cystic fibrosis (Abzug et a l ., 1990; 
Couch, 2001; Ghosh et a l , 1999; Johnston et a l ,  1995; McMillan et a l , 1993).
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Genus Species (proposed)
Enterovirus Poliovirus (combined with Human 
enterovirus Q  
Human enterovirus A 
Human enterovirus B 
Human enterovirus C 
Human enterovirus D 
Simian enterovirus A 
Bovine enterovirus 
Porcine enterovirus B
(from former Rhinovirus genus) 
Human rhinovirus A 
Human rhinovirus B
Cardiovirus Encephalomyocarditis virus Theilovirus
Aphthovirm Foot-and-mouth disease virus Equine rhinitis A virus
Hepatovirus Hepatitis A virus Avian encephalomyelitis-like viruses
Parechovirm Human parechovirus Ljungan virus
Erbovirus Equine rhinitis B virus
Kobuvirus Aichi virus Bovine kobuvirus
Teschovirus Porcine teschovirus
Sapelovirus
Porcine enterovirus A (to be renamed) 
"SV2-like viruses1' (yet to be named) 
"duck picomavirus TW90A" (yet to be 
named)
Unassigned species Seneca Valley virus
Table 1.1 Picomavirus classification
Proposed in 8th ICTV Report (Stanway, 2005). The Rhinovirus genus was suggested 
to merge with the Enterovirus genus.
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Hepatitis A virus (HAV) is the causative agent of type A viral hepatitis with the 
virus targeting the liver. Recovery can be complete in 4-6 weeks (Ross & Anderson, 
1991), but occasional fatalities do occur. Increasing standards in public health and 
sanitation have lead to a decrease in the number o f cases in the developed world, 
with most being contracted while travelling abroad.
All picomaviruses have certain features in common. They are all single stranded 
RNA viruses (Drake & Holland, 1999), with positive sense genomes between 7 and 
8.5kb in length. The genome organisation of the picomavirus is shown in figure 1.2. 
Instead of a 7-methyl guanine (m7G) cap as in cellular mRNAs, the 5’ end of the 
picomavirus genome is covalently linked to a small viral encoded protein known as 
viral genome-linked protein (VPg) (Flanegan et al., 1977; Lee et a l,  1977). The 
5TJTR of the picomavirus genome is highly structured with a number of notable 
features. The 5’UTR is followed by a single open reading frame. This can be 
divided into three regions: PI which encodes the structural proteins, plus P2 and P3 
which yield the non-stractural proteins (Rueckert & Wimmer, 1984).
1.3 FMDV genome organisation
1.3.1 The 5’UTR
The 5’ UTR (untranslated region) of FMDV is shown in figure 1.3. It begins with 
the S-fragment, a 350-380nt region which is predicted to form a long hairpin (Clarke 
et a l , 1987). There is no known function for this structure, but it has been suggested 
that the equivalent element in poliovirus (the cloverleaf) aids genome stability 
(Barton et a l , 2001), and that proteins involved in genome replication bind to it, 
circularising the genome (see section 1.4.7 ‘Genome replication’).
Chapter One Introduction
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Figure 13 The FMDV 5’UTR
The 5’UTR of FMDV contains many notable features, including regions of high 
secondary structure.
• VPg/3B-viral genome-linked protein
• S-ffagment-equivalent to poliovirus cloverleaf
• polyC tract of variable length
• PK-a number of pseudoknots
• cis-acting replication element (ere)
• internal ribosome entry site (HIES)
This is followed by the open reading frame (ORF) and the 3’UTR and polyA tail. 
These features are discussed in section 1.3.1.
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Some picomavirus genomes contain a polyC tract of varying length, longest in the 
cardio- and aphthoviruses. It is composed of over 90% C-residues and its function is 
unknown. However, viruses engineered to have a shortened polyC tract revert to a 
longer version on passaging in cell culture (Rieder et a l, 1993). After the polyC 
tract are three or four tandemly repeated pseudoknots with unknown function 
(Clarke et a l, 1987; Escarmis et a l,  1995).
The FMDV 5’UTR contains a cA-acting replication element (ere), a hairpin structure 
required for genome replication (Mason et a l,  2002). In other picomaviruses, the 
ere is in the coding region, but its location has little effect on its function 
(Goodfellow et a l , 2000). This element will be further discussed in section 1.4,7 
‘Genome replication*.
The ere is followed by the highly structured internal ribosome entry site (IRES), 
whose function is to enable translation of picomavirus proteins to proceed while host 
cell mRNA translation is inhibited (Jang et a l,  1988; Pelletier et a l, 1988). This 
element will be discussed in section 1.4.5 ‘Polyprotein translation’
1.3.2 The polyprotein
The FMDV RNA genome is infectious (Belsham & Bostoclc, 1988). On virus 
uncoating and release of the genetic material into the cytoplasm, translation of the 
open reading frame is the first step and the viral proteins are derived from a single 
polyprotein (Summers & Maizel, 1968). This is cleaved during synthesis by viral 
proteases into the viral structural and non-stmctural proteins (Clarke & Sangar, 
1988). The cleavage reactions occur as shown in figure 1.4. Some precursors have 
their own distinct functions, which will he discussed later. The majority of cleavage
Chapter One Intf'oduction
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reactions are mediated by the 3C protease. Cardio-, aphtho- and teschoviruses 
encode an additional protein, the leader (L) protein at the 5’ end of the genome. In 
FMDV and erboviruses, the L protein is an active protease and mediates its own 
cleavage from the polyprotein (Strebel 8t Beck, 1986) along with cleavage of the 
eukaryotic translation initiation factor eIF4G (Devaney et ah, 1988; Hinton et a l,
2002). This activity is directed by the 2A protease in some other picornaviruses. 
This will be further discussed in section 1.4.5 ‘Polyprotein translation*. The leader 
protein from cardioviruses is released by 3C cleavage and its function is unknown, 
but it is not an active protease.
1.3.3 Structural proteins
During FMDV infection, P1-2A is cleaved from 2BC and the P3 region, followed by 
release of the 2 A protease from P I . It is thought that this is not a proteolytic event, 
but a ribosomal ‘skip’ which releases the P1-2A peptide and then re-initiates 
translation of the downstream product without forming a peptide bond (Donnelly et 
a l, 2001). PI is cleaved by 3C into VP1, VP3 and VPO. VPO is cleaved on 
encapsidation by an unknown mechanism to give the two remaining structural 
proteins, VP2 and VP4. VP1-VP4 form the viral capsid, with 60 copies of each 
protein present. VP1, VP2 and VP3 combine to form the outer face of the capsid 
structure, with VP4 on the inside. This will be further discussed in section 1,4.1 
‘FMDV capsid structure7.
1.3.4 Non-structural proteins
There are 14 mature FMDV proteins, along with a number of precursors with their 
own distinct functions. The P2 proteins (2B and 2C) are released by 3C protease
Chapter One Introduction
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cleavage of the 2BC precursor. This precursor has its own function in FMDV, 
inhibition of the secretoiy pathway (Moffat et al., 2005). This is similar to the 
function of 3 A in poliovirus (Doedens & Kirkegaard, 1995). Expression of 2BC is 
sufficient to block trafficking of the VSV G protein from the ER to the Golgi 
(Moffat et al., 2005). This may be advantageous to the virus in many ways. Such 
inhibition may downregulate secretion of interferons and proinflammatory cytokines 
or may prevent cell surface MHC class 1 expression and antigen presentation. This 
may help to shield the infected cell from the host immune response. It has also been 
shown that poliovirus 3 A reduces expression of the TNF receptor at the cell surface 
thus protecting cells from TNFa-induced apoptosis (Neznanov et a l,  2001).
The P3 region is composed of 3A, 3B, 3C and 3D. Protein 3A is believed to be 
involved in formation of the replication complex, along with 2B and 2C. These 
proteins are also implicated in formation of the vesicles required for viral RNA 
replication. 2B has no assigned activity and 2C has both helicase and nucleotide 
binding motifs. Although helicase activity has yet to be shown, some picornavirus 
2C proteins do have NTPase activity (Klein et a l, 1999; Rodriguez & Carrasco, 
1993), 3A contains hydrophobic sequences that may facilitate membrane association 
o f 3B. 3B is the viral genome-linked protein, also known as VPg. In its uridylylated 
form, 3B acts as the primer for viral RNA synthesis (see section 1.4.7 ‘Genome 
replication’). There ar e three distinct copies of this protein in FMDV, in contrast to 
the single copy in other picornaviruses. Each of these is functional (King et a l,
1980) and deletion of any one o f the three impairs virus replication (Falk et a l,
Chapter One Introduction
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3CD is cleaved into 3C and 3D. The precursor 3CD is needed for proteolytic 
activity in poliovirus infection (Leong, 2002), and in human rhinovirus (HRV), PV 
and FMDV it is required for the uridylylation of VPg (Nayak et a l, 2005). During 
infection by FMDV, 3CD is rapidly cleaved to 3Cpro and 3Dpol (Grubman et al., 
1984). 3D is the RNA dependent RNA polymerase (RdRP) responsible for 
replication of the viral RNA. It is used for initial negative strand synthesis, creating 
a template for the subsequent rounds of positive strand synthesis, also catalysed by 
3Dpol (Paul, 2002).
The protease 3C is a member of the trypsin-like family of serine proteases and is 
responsible for the cleavage reactions within PI, P2 and P3. It also has protease 
activity towards a number of cellular proteins. In FMDV, it has been shown to 
cleave histone H3 in the nucleus, presumably to inhibit host cell transcription (Falk 
et al., 1990). It also cleaves eIF4A and eIF4GI, but at a slower rate than the leader 
protease (Belsham et a l, 2000). This will be further discussed in section 1.4.5 
‘Polyprotein translation’.
1.3.5 The 3’UTR
The 3’UTR is specific to each picomavirus. FMDV has a stem-loop structure 
followed by a poly(A) region of varied length. This region stimulates translation in 
FMDV (Lopez de Quinto et al., 2002) and replication in poliovirus (Herold & 
Andino, 2001).
Chapter One Introduction
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1.4 The FMDV life cycle
The life cycle of FMDV is shown in figure 1.5. The whole process from infection to 
virion release can take as little as 4-6 hours in cultured cells (Rueckert, 1996).
FMDV binds to the cell surface via integrin receptors and is internalised by clathrin- 
dependent endocytosis. The virus enters endosomes where the prevailing low pH 
causes capsid disassembly and the viral RNA genome is translocated into the 
cytoplasm. In the cytoplasm, the viral RNA is translated via an internal ribosome 
entry site as a single polyprotein, which is processed into structural and non- 
structural proteins. This translation is allowed to proceed while host cell mRNA 
tr anslation is inhibited. Non-structur al proteins cause rearrangement of membranes 
to form vesicles that are believed to serve as ‘platforms’ for formation of the 
replication complex and subsequent virus replication. The genome is then packaged 
and mature virions are released from the cell.
1.4.1 FMDV capsid structure
The FMDV capsid is 30nm in diameter and the crystal structure was first solved at 
2.9A resolution in 1989 (Acharya et al, 1989). Since this work carried out on a type 
O vims, the structur es of type A and type C viruses have also been published (Curry 
et al., 1996; Lea et al., 1995,1994). The sequences for these serotypes are around 
86% identical, with most differences being in the side chains (Lea et al., 1995). The 
FMDV capsid is made up of four structural proteins, VP1-VP4, with 60 copies of 
each. The VP1 proteins are located around the 5-fold axis, with VP2 and VP3 
alternating around the 2-and 3-fold axes (see figure 1.6). This gives the virus capsid
Chapter One Inttvduction
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Figure 1.5 The FMDV life cycle
FMDV enters the cell through integrin-mediated endocytosis. The virus enters 
endosomes where the prevailing low pH causes the capsid to dissociate. The RNA 
genome is translocated into the cytoplasm where translation of the viral polyprotein 
occurs, followed by processing by 3Cpro into structural and non-structural proteins. 
Non-structural proteins cause rearrangement of membranes to form replication 
vesicles. Positive strands are copied into negative strands by 3Dpol. These are used 
as a template for multiple rounds of positive strand synthesis. The genome is then 
packaged and mature virions are released from the cell. This is discussed in section 
1.5.
1 6
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Figure 1.6 Structure of a Picornavirus capsid
Shown above is a representation of a picomavirus capsid such as FMDV. VP1 is in 
blue, VP2 is in green and VP3 is in red. VP4 is not shown as it is on the inside of 
the capsid.
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a pseudo T=3 icosahedral structure. VP4 is found exclusively on the inside of the 
capsid. VP1-VP3 adopt the RNA virus fold (RVF) common to the majority of RNA 
viruses, a wedge-shaped eight stranded p-barrel. VP1 is the most var iable of the 
structur al proteins in terms of sequence, and contributes most to antigenicity and 
receptor binding (Cavanagh et a l, 1977) (Liebermann et a l, 1991).
VP1 contains a loop structure known as the GH loop, from residue 140-160 and 
named for the two p-strands it joins together. The FMDV structural proteins are 
smaller than those in other picomaviruses, leading to the formation of a much 
smoother capsid. FMDV also lacks the pit and canyon structures seen in other 
picomaviruses, which leads to a difference in the way FMDV interacts with its 
receptor. In some picomaviruses, receptor binding occurs at the canyon (Hogle et 
a l,  1985) (Luo et a l, 1987) (Rossmann et a l, 1985). In FMDV, receptor binding is 
via the previously mentioned GH loop (Jackson et a l, 1997). This will be discussed 
in section 1.4.2 ‘Receptors’.
While VP1 contributes most towards antigenicity, VP3 contributes the most towards 
capsid stability. The N-termini of VPS knit together at the 5-fold axis to form 
pentamers of VP1-VP4, leaving a pore or channel in the centre. The FMDV capsid 
is very sensitive to acid, dissociating from the intact 160S particle into 12S 
pentameric subunits on exposure to pH lower than 6.8 (Brown & Cartwright, 1961). 
The Entero-and rhinovimses have an additional 135S intermediate known as the 
altered or ‘A’ particle which FMDV does not (see section 1.4.3 ‘Virus entry by 
formation of ‘A’ particles’).
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1.4.2 Receptors
The first clue as to the identity o f the cellular’ receptor for FMDV began with the 
observation that the GH loop of VP1 contained a highly conserved RGD motif, 
which is also found on the ligands for integrin receptors (Fox et a l , 1989; Pfaff et 
a l , 1988). Integrins are type I transmembrane glycoproteins. They are made up of 
two subunits, a and p, which are noncovalently linked. There are 18a and 8p 
subunits that interact to form 24 integrin heterodimers (Hynes et al., 1987). Some a 
subunits contain an inserted (I) domain, which is a major ligand-binding site (Tagaki 
et al., 2002). Integrins are composed of a long extracellular’ domain, a 
transmembrane domain and a short cytoplasmic domain (Hynes et al., 1992; Sastry 
and Horwitz, 1993.) One exception is the p4 subunit, whose cytoplasmic domain is 
1000 amino acids in length as compared to around 50 in other subunits. Whereas the 
shorter subunits tar get actin and therefore microfilaments, the longer p4 subunit 
contacts with the intermediate filaments of the cytoskeleton.
Integrins are involved in both cell-cell adhesion and in interactions between cells and 
the extracellular matrix (ECM). There ar e two forms of signalling mediated by 
integrins, the classic “outside-in” as a consequence of ligand binding, which leads to 
remodelling o f the cytoskeleton and cell differentiation. Other effects of ligand 
binding to integrins include cell movement, survival, growth and proliferation.
There is also “inside-out” signalling, where signals from inside the cell can affect the 
conformation of the integrin’s extracellular ligand-binding domain and thus its 
activation state (Hynes et al., 1992; Schwartz et al., 1995). Known ligands for 
integrins are numerous, but include fibronectin, vitronectin, laminin and collagen 
(Plow et al., 2000). Some integrins are widely expressed, for example aVp3, which
Chapter One Inti'oduction
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is found on many cell types. In contrast, pi and p2 integrins are found only on 
leukocytes (Gahmberg et al., 1997).
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The fu st evidence for the involvement of the RGD in receptor recognition came 
from a number o f studies using RGD containing peptides (Baxt & Becker, 1990; Fox 
et a l,  1989; Surovoi et a l, 1988). The first integrin receptor implicated in FMDV 
entry was aVp3, the vitronectin receptor (Berinstein et a l,  1995). This was 
previously shown to be recognised by coxsackie A9 (Roivainen et a l,  1994). Three 
other integrins have since been identified as receptors for FMDV: aV pl, aVp6 and 
aVp8 (Jackson et a l, 2000; Jackson et a l,  2002; Jackson et a l,  2004). A recent 
study has shown that the integrin binding loop of FMDV is more highly adapted to 
binding to aVp6 than aVp3 or aVp8 (Burman et a l, 2006). The aVp6 integrin is the 
most likely candidate for FMDV cell entry in vivo as it is expressed on epithelial 
cells, the target tissue for FMDV (Monaghan et a l,  2005). A recent study showed 
expression of aVp6 but not aVp3 on epithelial tissue targeted by FMDV infected 
cattle (Monaghan et a l,  2005). Heparan sulphate proteoglycans have also been 
identified as FMDV receptors (Jackson et a l,  1996), but this is thought to be a tissue 
culture adaptation and is unlikely to be significant in vivo. Viruses adapted to using 
heparan sulphate were found to be attenuated in cattle (Sa-Carvalho et a l,  1997).
On binding to its receptor, FMDV does not form 6 A’ particles (see below). Instead, 
capsid uncoating is triggered by the low pH within endosomes. Other examples of 
picomaviruses that do not form ‘A’ particles include the human rhinovirus (HRV) 
minor receptor group, which use the non-immunoglobulin superfamily (IgSF) 
receptor very-low-density lipoprotein receptor (VLDL-R) which does not bind in the 
canyon (Hofer et a l, 1994). A number of studies have shown a requirement for low
2 0
pH during infection by these minor receptor group human rhinvoviruses (Brabec et 
a l, 2003; Schober e ta l,  1998).
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Like FMDV, human parechovirus-1 (HPEV-l)also uses integrins (aVp3 and aVpi) 
as receptors (Triantafilou et a l, 2000). The virus is thought to be taken up into 
endosomes, as it co-localises with a marker for early endosomes, although a 
requirement for low pH has not yet been demonstrated (Joki-Korpela et a l,  2001).
1.4.3 Virus cell entry by formation of6A 9 particles
For several piconaviruses, binding to their receptor not only attaches the vims to its 
host cell, but also triggers formation of the altered, or ‘A’ particle and release of the 
viral RNA. ‘A’ particle formation is dependent on how the vims capsid interacts 
with the receptor. Receptors that bind in the canyon of the vims capsid, a depression 
in the surface of the virus particle that encircles the fivefold axes of symmetry, 
generally trigger formation o f 4A’ particles. The ‘A’ particle has a sedimentation 
coefficient of 135S as opposed to 160S for the intact virion and their formation is 
believed to be a prerequisite for release of the RNA genome. The conformational 
change involved in ‘A’ particle formation leads to the extemalization of both VP4 
and the amino terminus of VP 1 (Chow et a l,  1987; Fricks 8c Hogle, 1990).
Poliovirus forms ‘A’ particles on binding to its receptor. All three PV serotypes 
utilise the same receptor, termed the poliovirus receptor (PVR), or CD 155 
(Mendelsohn et a l,  1989). This receptor belongs to the immunoglobulin 
superfamily (IGSF), a family of receptors which are known to be able to bind in the 
canyon of the picomavirus capsid. Poliovirus has been seen in endosome-like
2 1
structures (Kronenberger et al., 1998), but does not seem to require exposure to low 
pH for infection (Perez & Carrasco, 1993).
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Coxsackie B viruses (CVB) shar e a receptor with adenoviruses, known as the 
coxsackie-adenoviras receptor (CAR) (Bergelson et al., 1997). CAR is thought to 
have a role in cell adhesion (Hondo, 2000). Although in CVB infection, CAR is 
needed for both attachment and infection (Martino et al., 2000), it is needed only for 
attachment in adenoviruses, with aV integrins required for cell entry (Bai et a l,
1993; Nemerow, 2000). CVB uses decay accelerating factor (DAF) as a co-receptor, 
but ‘A’ particle formation can only be triggered by CAR (Goodfellow et a l,  2005; 
Milstone et al., 2005). A recent study suggests that CVB binds to DAF on the 
surface of polarised epithelial cells where rac signalling is activated and actin 
remodelling allows the virus to travel to the tight junction, where it binds to CAR 
and enters the cell. ‘A’ particle formation can then be induced inside cellular* 
compartments (Coyne & Bergelson, 2006).
Coxsackie A9 virus uses the integrin aVp3 as a receptor, but may also require 
interaction with GRP78 and MHC-I molecules for targeting of the virus to its 
internalisation pathway (Triantafrlou et al., 2002). It has recently been shown that 
coxsackie A9 can also use integrin aVp6 as a receptor (Williams et a l, 2004). 
Coxsackievirus A21 binds to both intercellular- adhesion molecule-1 (ICAM-1) and 
DAF, but DAF expression alone is insufficient for infection (Shafien et a l, 1997). 
This is because ICAM-1 is needed to induce ‘A5 particle formation and the role of 
DAF is thought to be concentration of virus particles at the cell surface (Newcombe 
et a l, 2004).
2 2
The major receptor group human rhinoviruses (HRV) use ICAM-1 as their receptor 
(Greve et a l,  1989; Staunton et a l,  1989), and receptor binding triggers 4 A’ particle 
formation (Hoover-Litty & Greve, 1993). The HRV3 and -14 serotypes can convert 
to ‘A’ particles at neutral pH, whereas HRV 16 requires a more acidic environment. 
This is thought to be due to the presence of a ‘pocket factor’, a fatty acid-like 
molecule in a hydrophobic cavity of VP1 in HRV 16 (Zhao et a l ,  1996). The acidic 
environment in endosomes may enhance major group rhinovirus infection (Nurani et 
a l, 2003).
1.4.4 Internalisation via clathrin-dependent endocytosis
After attachment, virus particles can enter the cell via direct penetration at the 
plasma membrane or through endocytosis. Endocytosis can be through clathrin 
coated pits, caveolae or other pathways. Viruses requiring low pH for infection 
usually enter cells via clathrin-dependent endocytosis. The first acidic compartment 
encountered by viruses using this pathway is the early endosome. The pH in early 
endosomes is 6.0-6.5, sufficient for several viruses to uncoat. Others must traffic to 
late endosomes which are more acidic, pH 5.5-6.0. Other viruses entering cells by 
cholesterol dependent pathways are targeted to the caveosome, a compartment 
comparable to the early endosome but with a neutral pH. The goal for the virus on 
entering the cell is to deliver its genome to the site of replication, which in the case 
of FMDV is the cytoplasm. To do this, the vir us must cross one or more 
membranes. Enveloped viruses such as influenza, VSV and SFV fuse their outer 
membranes with the endosomal or plasma membrane to release their genome, but 
non-enveloped viruses must adopt other strategies. Adenovirus is a non-enveloped
Chapter One Introduction
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virus which has been shown to completely disrupt the endosomal membrane (Oliver 
Meier, 2003).
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The FMDV capsid does not have a canyon and does not form ‘A’ particles. Instead, 
it binds to its integrin receptors via the GH loop of VP1. The FMDV capsid is 
extremely sensitive to acid and rapidly dissociates at less than neutral pH, 6.8-6.5 
(Curry et a l , 1995). Capsid disassembly is thought to be triggered by exposure to 
acidic conditions in the endosome as agents raising endosomal pH such as monensin 
and concanamycin A can inhibit FMDV infection (Baxt, 1987; Berryman et a l , 
2005; Miller et a l , 2001). FMDV has been shown by a variety of methods to enter 
cells via clathrin-dependent endocytosis, and not to require caveolae (Berryman et 
a l , 2005). These studies were carried out in cells expressing the integrin receptor 
aVp6, a primary candidate for FMDV binding in vivo. It is not known how the viral 
RNA crosses the endosomal membrane, however it is likely to occur by a different 
mechanism to poliovirus (see below) as the N-terminal region o f VP1 externalised 
on poliovirus binding to it receptor is absent from FMDV VP1. At early times 
during infection, FMDV has been co-localised with markers for early- and recycling 
endosomes (Berryman et al., 2005), making these candidates for penetration by the 
viral RNA. Virus did not co-localise with LAMP-2, a marker for lysosomes, and 
treatment of cells with nocodazole has no effect on FMDV infection, suggesting that 
late endosomes are not a site of viral RNA release (Berryman et a l, 2005).
Human parechovirus-1 (HPEV) is also taken up into endosomes by clathrin- 
dependent endocytosis. Treatment of cells with the drug chlorpromazine, which is 
an inhibitor of clathrin-dependent endocytosis inhibited infection, and virus was seen 
to co-localise with markers of both early and late endosomes (Joki-ICorpela et a l,
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2001). However, treatment with nocodazole to inhibit trafficking from early to late 
endosomes did not affect infection (Joki-Korpela et a l . 2001). This implies that 
release of the viral RNA can occur at the early endosome. although the mechanism is
unknown.
Infection by human rhinovinis-2 (HRV-2), a minor receptor group rhinovirus also 
requires low pH. with capsid disassembly occuring at pH 5.5, This is lower than the 
pH found in the early endosome, suggesting that uncoating takes place in the late 
endosome. Raising the endosomal pH using bafilomycin inhibits infection, with the 
virus particles seemingly trapped in the early endosome and unable to access the 
lower pH in the late endosome (Prchla et a l , 1994). A requirement for clathrin 
dependent endocytosis was shown by multiple methods, including drug treatments 
and expression of dominant-negative proteins that inhibit endocytosis (Snyers et a l ,
2003). HRV-2 infection occurs from late endsomes. At low pH, the N-terminus of 
VP1 and VP4 become externalised and may interact with the endosomal membrane 
to form a pore o f defined size which is thought to allow the viral RNA to pass 
through (Prchla et a l , 1995). A study comparing HRV-2 and adenovirus using 
single organelle flow analysis (SOFA) confirmed that HRV-2 makes small pores in 
the membrane whereas adenovirus disrupts the endosome completely (Brabec et a l , 
2005).
The poliovirus capsid is stable when exposed to acid and does not appear to require 
exposure to low pH for infection (Perez 8c Carrasco, 1993). However, poliovirus has 
been seen to be taken up into endosome-like structures (Kronenberger et a l, 1998) 
and the endosomal route for infection has been reported by other studies (Ohka et a l, 
2004; Zeichhardt et al., 1985). In contrast, infection by poliovirus is not dependent
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on dynamin, a molecule required for formation of both clathrin-coated pits and 
caveolae (DeTulleo & Kirehhausen, 1998). Taken together, these results suggest 
that polioviras may use multiple pathways to enter cells (Arita et a l, 1999). 
Poliovirus is also thought to form pores via the extemalisation of VP1 and VP4, a 
consequence of ‘A’ particle formation, as mutations in these proteins abolish RNA 
release (Danthi et a l , 2003; Kirkegaard, 1990). VP1 and VP4 can integrate into 
membranes and form pores, presumably to allow the RNA genome to pass into the 
cytoplasm (Danthi et a l, 2003; Tosteson & Chow, 1997). It is not known which 
membrane (plasma membrane or internal vesicles) the viral RNA crosses. The N~ 
terminus of VP1 has been shown to bind membrane in systems using artificial 
membrane vesicles (Bubeck et al., 2005; Tuthill et a l,  2006).
1.4.5 Polyprotein translation
Once inside the cytosol the viral genome is translated to produce the viral proteins. 
The FMDV 5’UTR contains a type II internal ribosome entry site, or IRES. Its 
function is to enable translation of FMDV proteins to proceed while host cell mRNA 
translation is inhibited (Belsham & Jackson, 2000). Cellular* mRNAs require a 7- 
methyl guanine (m7G) 5’ cap and an intact eIF4F complex for translation initiation 
(Shatkin, 1976). The eIF4F complex is composed of 3 proteins; eIF4E which binds 
to the 5’ cap structure, eIF4A which binds to the viral RNA and has helicase activity 
and eIF4G which acts as a scaffold protein between these two factors (see figure 
1.6a). The eIF4F complex also recruits eIF3, which binds to the 40S ribosomal 
subunit. The methionyl-primed tRNA then binds the 40S subunit via interaction
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Figure 1.7(a) Cellular (cap-dependent) mRNA translation
The eIF4F complex associates with the 5’ cap (via eIF4E) and the mRNA (via 
eIF4A). The 40S ribosomal subunit binds via eIF3 and the methionyl-primed tRNA 
binds to the complex via eIF2. This 48S pre-initiation complex scans down to the 
AUG initiation codon where the translation factors dissociate, the 60S ribosomal 
subunit associates, and translation begins.
V Pg
Figure 1.7(b)Translation initiation by internal ribosome entry
The C-terminal fragment of the cleaved eIF4G protein, bound to eIF4A, is recruited 
directly to the highly structured IRES. This can then recruit the 48S pre-initiation 
complex, and translation of the FMDV polyprotein proceeds. This is discussed in 
section 1.4.5 ‘Polyprotein translation’
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with eIF2. This completes the formation of the 48S pre-initiation complex. This 
complex scans along the mRNA until it reaches an AUG initiation codon in a good 
context (Kozak, 1989). The initiation factors then dissociate, the 60S ribosomal 
subunit joins to form the 80S complex, and translation begins (Hershey, 2000). 
Translation of the picomavirus genome is initiated in a different way. As it does not 
have a 5’ cap structure, it cannot initiate translation in the same way as cellular 
mRNAs (Jackson et al., 2005). A viral protease (L or 2A) modifies the eIF4F 
complex by cleaving the bridging protein, eIF4G. The N-terminal fragment bound to 
eIF4E, the cap binding protein, dissociates from the complex. The C-terminal 
fragment of eIF4G remains bound to eIF4A, and targets the cleaved eIF4F complex 
to the highly structured IRES (see figure 1.6b). These factors are sufficient to 
initiate translation of the genome (Ohbnann et a l, 1995). Cellular mRNAs (with a 
few exceptions) do not contain IRES elements and therefore cleavage of the eIF4F 
complex is sufficient to inhibit their translation. IRES elements can be divided into 
multiple types, based on sequence and secondary structure. Type I IRES elements 
are found in entero- and rhinoviruses, type II elements in cardio-, aphtho- and 
parechovimses and type III elements in hepatoviruses. A new class of IRES element 
has been proposed for picomaviruses including sapelo- and teschoviruses as they 
more closely resemble the IRES element of hepatitis C vims (a flavivirus) in 
sequence, secondary structure and requirements for host translation initiation factors 
(Chard et a l, 2006). In entero- and rhinovirus infection, the 2A protease is 
responsible for cleavage of eIF4G, whereas in FMDV infection it is the leader, or L 
protease. The leader protease is a papain-like cysteine protease (Roberts & Belsham, 
1995) which can be translated from two different start sites to give two forms, Lab 
and Lb (Sangar et a l, 1987) both of which are functional (Medina et a l, 1993),
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1.4.6 Replication membranes
Introduction
Infection by most positive-strand RNA viruses causes extensive host cell membrane 
rearrangements and vesiculation. The replication complex is stabilised on these 
membranes, which allows the viral replication proteins to be concentrated in one 
place and/or to protect them from host antiviral responses. The vesicles that form 
during infection can, in some cases, be induced by expression of one or more viral 
non-structural proteins. The virus induced vesicles are thought to form from existing 
membranes, although the precise cellular origin of these vesicles cannot be agreed on 
as they appeal* to exclude most markers of cellular compartments. For poliovirus, 
the vesicles may originate from the ER, but other organelles implicated include early 
and late endosomes (Kujala et at., 2001), mitochondria (Miller & Ahlquist, 2002), 
and the Golgi apparatus (Mackenzie et a l, 1999).
The membranes induced on viral infection vary between viruses. In the case of 
poliovirus, the vesicles are double membraned and around 200-400nm in diameter 
(Dales et a l, 1965). Poliovirus genome replication takes place on the cytoplasmic 
face of these vesicles (Egger et a l , 2000). Expression of non-structural proteins 3 A 
and 2BC are sufficient to induce membrane rearrangements similar to those seen in 
poliovirus infection (Suliy et a l,  2000). These proteins are localised to the ER 
(Doedens et a l, 1997), and vesicles can be seen budding from the ER in infected 
cells (Bienz et a l, 1987; Rust et a l,  2001). The usual pathway involving vesicles 
budding from the ER is COPII dependent retrograde transport. Poliovirus vesicles 
have been shown to contain COPII proteins Secl3p and Sec31p; although poliovirus 
sensitivity to brefeldin A also suggests a role for COPI vesicles (Gazina et a l, 2002). 
PV-induced vesicles have also been reported to acquire LC3 and LAMP1 later in
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infection, suggesting an autophagosome-like origin (Suhy et a l , 2000). The 
observation that the vesicles are double membraned also supports this view. Co­
localisation of poliovirus non-structural proteins with a marker for cellular 
autophagy has been seen in infected cells (Jackson et a l , 2005).
In the case of human parechovims 1 (HPEV-1), replication membranes label for 2C 
and a trans-Golgi marker, GalT. Some unusual elongated, branching membranous 
structures can be seen, in addition to the typical vesicles. Although these structures 
contain 2C, no associated vRNA was seen, suggesting that these are not a site of 
replication (Krogerus et a l, 2003). HRV2 infected cells contain vesicles that appear 
to be single rather than double membraned (Harris <& Racaniello, 2005). A number 
of other positive-strand RNA viruses such as nidoviruses also replicate on double 
membraned vesicles similar in appearance to autophagosomes (Gosert et a l, 2002; 
Pedersen et a l, 1999; Prentice et a l, 2004).
The vesicles induced on infection with FMDV were first described in 1983 and 
found to be associated with viral RNA and the RNA dependent RNA polymerase 
(RdRP) (Polatnick & Wool, 1983a; Polatnick 8c Wool, 1983b). They most closely 
resemble those of HPEV-1, being less numerous than those seen in PV infected cells, 
and not clustered (Monaghan et a l,  2004). The vesicles are sometimes double, but 
more often single membraned (see figure 1.7). Some vesicles have been seen 
associated with ER-like structures and have a granular appearance (Monaghan et a l,
2004). The most striking feature of FMDV infected cells is the accumulation of 
virtually all cytoplasmic organelles in a perinuclear area of the cell, described as the 
replication site (Monaghan et a l, 2004).
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Figure 1.8 Comparison of vesicles formed during FMDV and BEV infection
(Monaghan et a l , 2004)
A) Vesicles formed during FMDV infection B) Vesicles formed during BEV 
infection.
The vesicles induced on infection with FMDV are less numerous than those seen in 
BEV infected cells and are not clustered The vesicles are sometimes double, but 
more often single membraned. They can be seen associated with ER-like structures 
and have a granular appearance. Both pictures ffom infection in baby hamster kidney 
(BHK) cells. This is discussed in section 1.8.1.
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There are differences in sensitivity to the fungal metabolite brefeldinA in 
picomaviruses, with FMDV and EMCV being resistant (Barton et a l , 2001; Gazina 
et a l , 2002), IiPEV-1 partially resistant (Gazina et a l , 2002) and most rhino- and 
enteroviruses, including PV and BEV being sensitive. This is possibly related to the 
origin of the vesicles, with COPI vesicle formation being inhibited in brefeldinA 
treated cells (Rothman, 1994), although the picture is likely to be much more 
complicated than this.
1.4.7 Genome replication
The first stage of FMDV genome replication is synthesis of negative strand copies of 
the viral genome which then serve as templates for further rounds of positive strand 
synthesis. The positive strand RNA genome of picomaviruses must function as a 
template for both translation and replication. It is assumed there must be a ‘switch’ 
between the two processes as they cannot take place simultaneously on the same 
molecule (Gamarnik & Andino, 1998).
Initiation and elongation of the negative strand is catalysed by 3Dpol (Flanegan et 
a l, 1977). The 3D polymerase requires a protein primer, provided by 3B (or VPg) 
(Paul, 2002). In order to act as a primer, VPg must first be modified by the addition 
of one or two uridyl residues. It was not known how this was achieved until a 
sequence in HRV-14 was found to be required for genome replication (McKnight & 
Lemon, 1996). This was traced to a stem-loop structure now termed the c/s-acting 
replication element, or ere, which is now known to act as a template for uridylylation 
of VPg through a conserved AAACA motif (McKnight & Lemon, 1998). The viral 
3Dpol catalyses the addition of the uridyl residues to VPg in PV (Paul et a l,  2000)
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and HRV (Gerber et a l , 2001) using a “slide-back” mechanism (Paul et a l, 2003). 
Equivalent ere elements have now been identified in a number of picornaviruses 
(Goodfellow et a l, 2000; Lobeit et a l, 1999), and interestingly, are not found in the 
same region of the genome and can even be moved to other sites without destroying 
then* activity (Goodfellow et a l , 2000). In fact, it has been found that they can act in 
tt'ans, making the name ere misleading and leading to the suggestion of an 
alternative name-3 B uridvlvlation site, or bus (Tiley et al., 2003). The FMDV ere is 
situated in the 5’ UTR rather than the coding region as in other picornaviruses 
(Mason et a l, 2002). FMDV requires uridylylated VPg for both positive- and 
negative strand synthesis and the uridylylation reaction requires the ere as a template 
and unlike poliovirus, cannot use the polyA tail (Nayak et a l, 2005). The factors 
required for uridylylation of FMDV VPg are UTP, 3B peptide (each of the three 
copies is functional but VPg3 has the highest activity), RNA transcripts containing 
the cre/bus, 3Dpol, and the 3CD precursor, although this is known to be rapidly 
cleaved in FMDV infected cells (Nayak et a l, 2005). The uridylylated VPg is 
proposed to translocate to the 3’UTR in order to initiate negative strand synthesis 
(Paul et a l , 2000).
Once the negative strand has been made, multiple rounds of positive strand synthesis 
follow. Free single-stranded, negative sense RNA is not detectable in the cell, but 
exists as the double stranded ‘replicative form’ (RF) (Agol et a l, 1999). This must 
be unwound prior to positive str and synthesis, possibly by 2C. The ratio of positive 
to negative strands in poliovirus infected cells is 50:1 (Novak & Kirkegaard, 1991), 
suggesting that one negative strand acts as a template for multiple positive strands.
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1.4.8 Genome packaging and virus release
Once genome replication has occurred, the final stages of picomavirus infection are 
packaging of newly generated positive-strand RNA genomes and release of virus 
particles from the cell. These processes are not well understood.
Encapsidation of the viral RNA begins with association of VPO, VP2 and VP3. Five 
of these associate to form a pentamer. Twelve pentamers then associate to form the 
viral capsid. The RNA is encapsidated and the final maturation is achieved by 
cleavage of VPO into VP2 and VP4. This step is required in order for virus to be 
infectious (Lee et a l , 1993).
It is assumed that there must be a way in which the viral RNA is selected for 
encapsidation rather than cellular RNA molecules. Poliovirus positive-strand RNA 
is specifically packaged with the exclusion of negative strands (Novak &
Kirkegaard, 1991). Coxsackievirus A21, coxsackievirus B3 or enterovirus 
70 capsids would not encapsidate poliovirus RNA when supplied in tram  (Porter et 
a l,  1998). It has been suggested that RNA packaging is coupled to replication in 
poliovirus (Nugent et a l, 1999), and that there may be a physical interaction between 
the replication complex and the capsid, possibly through 3D or 2C (Diamond & 
Kirkegaard, 1994; Vance et a l,  1997). Aichi virus was found to have an 
encapsidation signal in the 5’UTR, the first discovered in a picomavirus (Sasaki & 
Taniguchi, 2003).
Release of picomavirus particles has always been thought to be via cell lysis, except 
in the case of hepatitis A vims (Vallbracht et a l, 1984). Cell lysis in poliovirus has 
been suggested to be triggered by 3A or 3AB, through disruption of membrane
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potential (Lama et a l, 1998), although a theory has been put forward that poliovirus 
can release particles without lysis by fusion of the outer membrane of its double- 
membraned replication vesicles with the plasma membrane (Jackson et a l,  2005)-see 
above, section 1.4.7 ‘FMDV replication membranes’. This view is supported by 
previous work showing vectorial release of poliovirus in polarised epithelial cells 
(Tucker e ta l,  1993).
1.5 Rab GTPases
Dominant-negative rab GTPases are increasingly being used to dissect vesicular 
trafficking through the endocytic pathway. Rab GTPases are members of the ras 
superfamily (ras-related in brain (Touchot et a l, 1987)), and are homologous to the 
YP7Y/SEC4 family of GTPases which regulate membrane trafficking in yeast. The 
human genome encodes over 70 different rab proteins (Bock et a l ,  2001) and at least 
13 have been identified as regulators of the endocytic pathway (Harrison et a l,
2003). As with all GTPases, they cycle between active, GTP-bound and inactive, 
GDP-bound forms. They are involved in formation, movement and fusion of 
endocytic vesicles. Each rab GTPase is specific to a particular stage, or stages of 
endocytosis (Seabra et a l,  2002)(Lombardi et a l,  1993). They attach to the target 
membrane and the active form recruits effector proteins for specific downstream 
functions.
Figure 1.8 shows the stage or stages at which individual rab GTPases act during 
endocytosis. Rab5 is involved in formation of the early endosome. Rab4 and rabl 1 
are involved in recycling of receptors back to the plasma membrane. Rab4 controls 
a rapid recycling pathway directly from the early endosome to the plasma membrane
Chapter One Introduction
35
and rabl 1 controls a slower recycling pathway via the perinuclear recycling 
endosome. Rab7 is involved in trafficking from early- to late endosomes and from 
late endosomes to lysosomes. Rab9 controls trafficking from the late endosome to 
the Golgi. There is evidence that different rab GTPases can exist on the same 
vesicle, occupying separate domains on the membrane. In this way, rab4, rab5 and 
rabl 1 can all exist on the same early endosome, as shown by three colour imaging 
(Sonnichsen et al., 2000). Rab7 and rab9 have also been shown to exist on the same 
late endosome (Barbero et a l,  2002).
Rab proteins cycle between active and inactive forms, and are at different stages 
either membrane bound or cytosolic. The state of activation and localisation of rab 
proteins are regulated by a number of factors (see figure 1.9). Rabs are synthesised 
as soluble proteins in the cytosol, and are sequestered by rab escort proteins (REPs), 
which act as chaperones. These factors deliver the rab protein to a rab 
geranylgeranyl transferase enzyme for prenylation. One (or sometimes two), 
geranylgeranyl groups are added (Anant et a l , 1998). REPs then tar get the rab 
protein to the appropriate membrane where these lipid attachments allow the rab 
protein to integrate into the lipid bilayer (Alexandrov et a l, 1994).
Guanine nucleotide exchange factors (GEFs) facilitate the activation of membrane 
bound rab proteins by exchanging GDP for GTP. The effector can then bind to the 
activated rab protein. After vesicle movement or fusion, GTP hydrolysis occurs, 
restoring the rab protein to its inactive state. The GDP dissociation inhibitor (GDI), 
then removes the inactive rab protein from the membrane back into the cytosol 
(Ullrich et a l,  1993). The dissociation of the REP (in the case o f newly synthesised
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Figure 1.9 Localisation of rabGTPases in the endocytic pathway
Rab5 is involved in formation of the early endosome.
Rab4 controls a rapid recycling directly from the early endosome to the plasma 
membrane.
Rabl 1 controls a slower recycling via the perinuclear recycling endosome and 
movement from the Golgi to the cell surface.
Rab7 is involved in trafficking from early to late endosomes and from late 
endosomes to lysosomes.
Rab9 controls movement from the late endosome to the Golgi. This is discussed in 
section 1.6.
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proteins), or GDI (in the case of existing rab proteins) when the rab-GDP binds to 
the membrane is aided by a GDI displacement factor (GDF) intrinsic in the 
membrane (Dirac-Svejstrup et al., 1997). Only one such factor has been identified 
so far, Yip3 (Sivars et al., 2005).
Rab proteins have a low intrinsic GTPase activity and rely on a variety of GTPase- 
activating proteins (GAPs) to facilitate GTP hydrolysis. Each rab protein may be 
regulated by a number of different GAPs and GEFs. GAPs are thought to function 
by allowing a catalytically important glutamine residue to align properly, inserting 
an ‘arginine finger residue5 into the active site. This stabilises the transition state of 
the hydrolysis reaction. This glutamine residue can be replaced with a leucine to 
block this GTP hydrolysis, locking the rab protein in its active state. All rab GAPs 
have a conseived TBC (Tre-2/Bub2/Cdcl6) domain, enabling their identification in 
BLAST searches. A total of 51 putative GAPs have been identified (Bernards, 2003) 
but most have not been assigned their interacting rab partner.
Another group of interacting proteins are the effectors. These interact with active, 
GTP-bound rab proteins on membranes (Harrison et a l, 2003). Rabs can interact 
with multiple effectors, and some effectors can bind more than one rab protein (de 
Renzis et a l, 2002; Segev, 2001). The downstream events resulting from effector 
binding include vesicle fusion and movement.
The effectors involved in membrane fusion events are known as soluble N- 
ethylmaleimide-sensitive factor (NSF) attachment protein receptors (SNAREs) 
(Brodsky et a l, 2001; Jahn & Grubmuller, 2002; Sollner, 2004). SNARE proteins 
interact with one another to fonn extremely stable complexes. It is thought that two
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Figure 1.10 Membrane recycling of rabGTPases. (Seabra & Wasmeier, 2004)
(a) GDP-bound rab proteins in the cytosol are bound to chaperone proteins, REP 
(when newly synthesised) and GDI. (b) Bound rab-GDP is delivered to the target 
membrane where GDF causes displacement o f GDI. Other factors may be involved, 
(c) Nucleotide exchange catalysed by GEF leading to rab activation, (d) Effectors 
bind to activated rab-GTP. (e) GTP hydrolysis catalysed by GAP causing rab to 
return to its inactive state. rab-GDP extracted from membrane by  G D I. T h is  is 
discussed in section 1.6.
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SNARE proteins on different membranes may ‘zipper up’ with one another, and this 
interaction is sufficient to drive fusion. SNAREs are specific to certain 
compartments and pathways, in the same way that rabs are. The pairing of two 
similar SNAREs will lead to homotypic endosome fusion, as in the case of two early 
endosomes fusing with one another. The fusion of different vesicles, for example 
early and late endosomes, would require two different SNAREs to interact.
Another function of rab proteins is vesicle movement. There ar e two tr ansport 
networks in cells, microtubule-based and actin-based. Microtubules facilitate long 
range, rapid movement of cargo and the actin network aids slower movement over 
shorter distances. Effector proteins bound to active, GTP-bound rab proteins can 
recruit molecular- motors such as either myosin (for actin) or dynein and kinesin (for 
microtubules). Rab GTPases recruiting myosins include rabl 1 (Hales et a l , 2001), 
rab27 (Fukuda et a l , 2002) and possibly rab8 (Seabra & Coudrier, 2004). Rab7 can 
recruit dynamin (Jordens et a l, 2001), as can rab6, a Golgi-associated rab GTPase 
(Short et a l , 2002).
1.5.1 RabS
Rab5 is the rab GTPase involved in the biogenesis of the ear ly (or sorting) endosome 
(Bucci et a l, 1992; Gorvel et a l, 1991). It is found on the sorting endosome and 
also on clathrin coated vesicles. It interacts with up to 30 different effector proteins 
to facilitate endosome-endosome docking and fusion (Christoforidis et a l, 1999). In 
addition to regulating endosome-endosome fusion, rab5 is also thought to have roles 
in formation of vesicles at the cell surface (McLauchlan et a l, 1998), and movement
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of vesicles within the cell via interaction with molecular motors (Nielsen et ah, 
1999).
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One of the effector proteins first identified for rab5 was rabaptin-5, thought to have a 
role in membrane docking (Mu et a l,  1995). This protein also binds to rab4, which 
is involved in receptor recycling from the sorting endosome back to the cell surface. 
Rabaptin-5 downregulates rab5 activity through both direct inhibition and by 
association with rabex-5, a rab5-specific GEF (Alexandrov et a l, 1994). In this way, 
it is thought to create areas of active, membrane-associated rab5.
Another rab5 effector is early endosomal antigen-1 (EEA-1) (Simonsen et a l, 1998). 
This protein is used as a marker specific for early endosomes and has two binding 
sites for rab5. It is closely related to the FYVE zinc finger protein family. These 
proteins bind the lipid phosphatidylinositol-3-phosphate (PI(3)P) and are all 
localised to endosomes (Simonsen et a l,  1998). Levels of PI(3)P are controlled by 
signalling cascades. EEA-1 is thought to act as a tethering protein, and brings 
together rab5 and SNAREs (Christoforidis et a l,  1999). There is also cross-linking 
evidence for a high molecular weight complex containing rab5 and both EEA-1 and 
rabaptin-5, prior to endosome fusion. A further rab5 effector protein, rabankyrin5 
was found to function in macropinocytosis, but does not co-localise with EEA-1. 
Therefore there must exist in cells a population o f rab5-positive, EEA-1 negative 
compartments (Schnatwinkel et a l,  2004).
A genome screen for the TBC (Tre-2/Bub2/Cdcl6) containing motifs found in all rab 
proteins identified two GAPs thought to act on rab5: RN-Tre and PRC 17 (Bernards,
2003). However, a further study showed RN-Tre to be a GAP for rab41 but
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identified a further GAP for rab5, known as RabGAP-5 (Haas et a l , 2005). The p85 
alpha subunit of PI3K has also been identified as having GAP activity towards rab5 
(Anderson et a l ,  2005). Another rab5 GEF has been identified as RAP6 (Rab5- 
activating protein 6) (Hunker et a l , 2006).
1.5.2 Rab4/ll
Rab4 and rabl 1 are involved in recycling of receptors to the plasma membrane. 
There are two recycling pathways with different kinetics; a rapid recycling process 
from the early endosome directly to the plasma membrane as well as a slower 
recycling activity via the perinuclear recycling endosome. There appears to be some 
overlap in the functions of the two factors, as rabl 1 controls movement from the 
early endosome to the perinuclear recycling endosome (Ullrich et a l ,  1996) and rab4 
regulates the more rapid pathway, but both are responsible for trafficking from the 
perinuclear recycling endosome to the plasma membrane (Sonnichsen et a l, 2000). 
Rabl 1 is also involved in trafficking from the trans-Golgi network (TGN) to the 
plasma membrane (Chen et a l, 1998).
A role for rab4 in receptor recycling was first identified by co-fractionation with the 
transferrin receptor, a well known marker for endocytic recycling (van der Sluijs et 
a l, 1991). It was later shown that overexpression of wild-type or dominant-negative 
rab4 could perturb transferrin recycling (van der Sluijs et a l, 1992). Some effector 
proteins have been identified for rab4, many also being effectors for rab5. These 
include Rabaptin 5 (Vitale et a l, 1998), Rabip4 (Cormont et a l,  2001), Rabaptin4 
(Nagelkerken et a l,  2000) and Rab coupling protein (RCP) (Lindsay et a l, 2002). 
Many of these have been shown to affect recycling of cargoes such as transferrin and
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GLUT4. A GTPase activating protein termed rab4-GAP has been identified on 
membranes in 3T3 cells (Bortoluzzi et a l, 1996).
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Rabl 1 was shown to control transferrin recycling via the perinuclear recycling 
endosome in a slower process than rab4 dependent recycling (Ullrich et a l, 1996). 
The first direct comparison of their respective rates showed that rab4 dependent 
recycling had a half-life o f 5-10 minutes compared to 15-30 minutes for rabl 1 
dependent recycling (Hopkins & Trowbridge, 1983). A role for rabl 1 in exocytosis 
from the Golgi was shown by expression of dominant-negative rabl 1, which caused 
VSV-G protein to accumulate in the Golgi (Chen et a l, 1998). Rabl 1 effectors 
identified to date include Rabl lBP/rabphilin-11, (Mammoto et a l, 1999; Zeng et a l, 
1999) and EF-hands-containing Rabl 1-interacting protein (Eferin) (Prekeris et a l, 
2001). A further study identified four effectors for rabl 1: Rabl 1-Family Interacting 
Protein 1 (Rabl 1-FIP1), Rabl 1-Family Interacting Protein 2 (Rabl 1-FIP2), Rabl 1- 
Family Interacting Protein 3 (Rabl 1-FIP3) and pp75/Ripll. Rabl 1 has known 
myosin binding activity through the effector FIP2 (Hales et a l, 2001).
1.5.3 Rab9
Rab9 is found on the late endosome and Golgi, and regulates movement of cargoes 
including mannose 6-phosphate receptors (Lombardi et a l, 1993). Mannose 6- 
phosphate receptors (MPRs) transport lysosomal hydrolases from the Golgi to 
prelysosomes and then return to collect more car go. One requirement for this 
movement from late endosomes to Golgi is an effector protein known as tail- 
interacting protein of 47 kD (TIP47). Another is an effector present on the Golgi 
known as p40 (Diaz et a l,  1997).
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1.5.4 Rab?
Intt'oduction
When rab? was first identified, it was observed to localise to the late endosome 
(Chavrier et a l, 1990). It was later found to regulate trafficking from the early to 
late endosome with dominant-negative forms of rab? (N125I and T22N) blocking 
movement of the VSV-G protein and causing it to accumulate in transferrin-positive 
early endosomes (Feng et al., 1995). These mutants also blocked degradation of I12:>- 
low density lipoproteins (LDL) but not their uptake (Vitelli et al., 1997). Rab7 is 
also required to maintain the integrity of the lysosome (Bucci et al., 2000).
Rab7 effectors have been identified, the first of which is rab-interacting lysosomal 
protein (RILP), a 45kDa protein that specifically binds to rab7-GTP at its C- 
terminus. Expression of a truncated form of RILP slows degradation of LDL and 
causes dispersal of lysosomes, similar to the effects seen when dominant-negative 
rab7 is expressed (Cantalupo et al., 2001). It has further been shown that RILP 
recruits dynein/dynactin and therefore connect the late endosome/lysosome to the 
microtubule network (Jordens et al., 2001).
Another recently identified rab? effector is Rab7-interacting RING finger protein 
(Rabring7), which is speculated to act on the homotypic fusion and vacuole protein 
sorting (HOPS) complex. This complex regulates heterotypic fusion of late 
endosomes with lysosomes and homotypic fusion of lysosomes leading to lysosome 
biogenesis (Mizimo et al., 2003). Rabring? also appeals to have a role in lysosomal 
acidification, possibly by acting on the vacuolar ATPase, whereas RILP does not 
affect this process.
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T h ere  is  o n ly  o n e  rab 7  G E F  id e n tif ie d  so  fa r, th e  V p s3 9  su b u n it o f  th e  c la ss  C  
V P S /H O P S  co m p lex  (W u rm se r et a l,  2 0 0 0 ) a n d  o n e  G A P , T B C  d o m a in  fam ily , 
m e m b e r 15 (T B C 1 D 1 5 ) (Z h an g  e ta l,  2 0 05)..
R ab 7  h as  recen tly  b e e n  sh o w n  to  b e  re q u ire d  fo r  th e  la te  m a tu ra tio n  o f  au to p h ag ic  
v acu o le s  (G u tie rrez  et a l , 2 0 0 4 ; Ja g e r et a l, 2 0 0 4 ). T h is  w ill b e  fu r th e r  d iscu ssed  in  
se c tio n  1.7 ‘A u to p h a g y 5.
1.5.5 Rahs and viruses
A  n u m b e r o f  s tu d ie s  h a v e  b e e n  ca rried  o u t in v es tig a tin g  th e  e ffec ts  o f  d o m in an t- 
n eg a tiv e  rab  G T P ases  o n  v iru s  in fec tio n . T h e  f irs t o f  th e se  w as  a  s tu d y  in v o lv in g  
ad en o v iru s . D o m in an t-n eg a tiv e  rab5  w a s  sh o w n  to  im p a ir  v im s  u p tak e , w h e reas  
o v e rex p re ss io n  o f  w ild -ty p e  rab 5  in c re a se d  i t  (R a u m a  et a l,  1999). A  s tu d y  o f  
en v e lo p ed  v iru se s  sh o w ed  a  re q u ire m e n t fo r  b o th  rab 5  an d  ra b 7  in  in flu e n z a  v im s  
in fec tio n , b u t o n ly  fo r  rab 5  in  S em lik i F o re s t v im s  (S F V ) a n d  v e s ic u la r  s to m atitis  
v im s  (V S V ). T h is  o b se rv a tio n  su p p o rts  th e  o b se rv a tio n  th a t in flu e n z a  req u ire s  a  
m u c h  lo w e r p H  fo r  u n c o a tin g  th a n  th e  o th e r  v iru se s  an d  w as th e re fo re  th o u g h t to  
tra ff ic  to  th e  la te  en d o so m e  (S ieczk a rsk i & W h ittak e r, 2 003). A  sc re e n  o f  ce llu la r 
g en es  re q u ire d  fo r  M arb u rg  v im s  in fe c tio n  sh o w e d  rab 9  as  a  can d id a te , a n d  R N A i 
d e p le tio n  o f  rab 9  w a s  sh o w n  to  in h ib it in fe c tio n  o f  a  n u m b e r o f  en v e lo p ed  v iru ses  
in c lu d in g  E b o la , M arb u rg , a n d  m e a s le s  v iru se s , b u t  n o t th e  n o n -e n v e lo p e d  re o v im s  
(M u rray  et a l, 2 0 0 5 ). R a b l  1 w a s  a lso  sh o w n  to  b e  req u ired  fo r  H IV  in fec tio n , 
co n s is te n t w ith  th e  v ie w  th a t H IV  a sse m b ly  in itia te s  fro m  th e  la te  en d o so m e  and  
th e n  th e  G o lg i p r io r  to  b u d d in g  fro m  th e  p la sm a  m em b ran e  (M u rray  et a l,  2005).
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1.6  A u to p h a g y
Chapter One Introduction
R ab 7  is a lso  in v o lv ed  in  reg u la tin g  th e  au to p h ag ic  pa th w ay . A u to p h ag y  is  a  ce llu la r 
re sp o n se  to  s tre ss  c o n d itio n s  su c h  a s  a m in o  ac id  s ta rva tion . T h e  p ro c e ss  o f  
au to p h ag y  o ccu rs  in  s tag es , w ith  m u ltip le  fac to rs  reg u la tin g  e a c h  stag e . T h e  
m e c h a n ism  o f  fo rm a tio n  o f  th e  char a c te ris tic  d o u b le -m em b ran ed  v e s ic le s  is a  c u rren t 
‘h o t  to p ic ’, a s  au to p h ag y  h a s  b e e n  lin k e d  to  m a n y  d iseases  (in c lu d in g  can ce r)  as w e ll 
as b e in g  im p lica ted  in  th e  life  c y c le s  o f  b a c te ria  an d  v iru ses .
1 .6 .1  T h e  a u to p h a g ic  p a th w a y
T h e  p ro cess  o f  a u to p h ag y  a llo w s  th e  ce ll to  su rv iv e  dur in g  sh o rt te rm  a m in o  ac id  
s ta rv a tio n  (M iz u sh im a  et al. , 2 0 0 2 ). A n  ar e a  o f  cy to p la sm  a n d /o r o rg a n e lle s  is 
e n g u lfed  b y  a n  iso la tio n  m e m b ra n e  an d  th e  au to p h ag o so m e  m a tu re s  th ro u g h  a  se ries 
o f  s tep s  b e fo re  b e in g  d ire c te d  to  th e  ly so so m e  w h ere  th e  c o n ten ts  a re  d eg rad ed  and  
re c y c le d  (see  f ig u re  1 .10). In  y e a s t c e lls , au to p h ag o so m es fo rm  fro m  th e  
p reau to p h ag o so m a l s tru c tu re  (P A S ), b u t in  m a m m a lia n  ce lls  th e  o rig in  o f  th e  
m em b ran es  is  u n c lea r , so m e  e v id e n c e  su g g estin g  th a t  th e  m em b ran es  a re  d e riv ed  
fr o m  th e  en d o p la sm ic  re tic u lu m  (D u n n , 1994). T h e  p ro cess  o f  au to p h ag y  b eg in s  
w ith  th e  d e p h o sp h o ry la tio n  a n d  th u s  in a c tiv a tio n  o f  T o R  (ta rg e t o f  rap am y c in ). T h is  
is  a n  in h ib ito r  o f  a u to p h ag y  u n d e r  n o rm a l c o n d itio n s  an d  d ep h o sp h o ry la tio n  ca n  be  
in d u c e d  e ith e r  b y  s ta rv a tio n  o r  tre a tm e n t w ith  th e  d ru g  rap a m y c in  (N o d a  &  O h su m i, 
1998). T h e  fo rm a tio n  o f  th e  iso la tio n  m em b ran e  req u ire s  th r ee  p ro te in s : A tg5  
co n ju g a ted  to  A tg l2  an d  A tg 8 (M iz u sh im a  et a l, 1998). A tg  (au to g h ag y -re la ted ) 
g en es  w e re  id en tif ied  in  y e a s t s tra in s  d e fec tiv e  fo r  au to p h ag y . A fte r  th e
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Figure 1.11 Cellular autophagy
A n  iso la tio n  m em b ran e  fo rm s a ro u n d  a n  a re a  o f  cy to p la sm  a n d /o r o rg an e lle s . T h is  
b eco m es d o u b le  m em b ran ed  an d  L C 3 c an  be  d e tec ted  a t th is  p o in t. L A M P  
asso c ia te s  w ith  th e  m a tu re  au to p h ag o so m e. R a b 7 is req u ired  fo r la te  m a tu ra tio n , 
p rio r  to  fu s io n  w ith  th e  ly so so m e. T h is  is d isc u sse d  in  sec tio n  1.7.
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au to p h ag o so m e  is  sea led , A tg 5 /1 2  c a n  n o  lo n g e r b e  d e tec ted  (M iz u sh im a  et al, 
2 0 0 1 ). T h e  m am m alian  h o m o lo g u e  o f  A tg 8 is  k n o w n  as m ic ro tu b u le  a sso c ia ted  
p ro te in -1 lig h t-ch a in  3 (L C 3 ). T h is  is  req u ire d  fo r  (an d  is a  sp ec ific  m a rk e r  of), 
a u to p h a g y  (K ab ey a  et a l,  2 0 0 0 ). A lth o u g h  L C 3 in  th e  o u te r  m em b ran e  o f  th e  ea rly  
au to p h ag o so m e  a p p e a ls  to  b e  c le a v e d  an d  p o ss ib ly  recy c led , it  re m a in s  b o u n d  to  th e  
in n e r m em b ran e  a t a ll s tag es  o f  au to p h ag y . T h e  o u te r  m em b ran e  h a s  n o  p a rtic u la r  
m ark e rs  a t  e a r ly  s tag es , b u t ly so so m a l p ro te in s  c a n  b e  d e tec ted  in  th e  m o re  m atu re  
au to p h ag o so m es. T h ese  in c lu d e  ly so so m a l m e m b ra n e  p ro te in s  L A M P 1 a n d  L A M P 2  
(T a n a k a  et a l , 2 0 0 0 ) an d  ly so so m a l e n zy m es  C a th ep s in  D , B  an d  L  (K o ik e  et a l , 
2 0 0 0 ). I t  is  th o u g h t th a t m a tu ra tio n  o f  th e  au to p h ag o so m e  is a  s tep w ise  p ro cess  
b e g in n in g  w ith  fu s io n  w ith  e a rly  e n d o so m e s  (L io u  et a l, 1997; T o o z e  et al, 1990) 
an d  th e n  w ith  m u ltiv e s ic u la r  la te  e n d o so m e s  (B e rg  et a l,  1998), fo rm in g  th e  
am p h iso m e . T h is  is p r io r  to  fu s io n  w ith  ly so so m e s  (G o rd o n  et a l,  1992). T he  
m ark e rs  fo u n d  in  la te  a u to p h ag ic  v a c u o le s  c o u ld  th e re fo re  h a v e  c o m e  fro m  la te  
en d o so m es  o r  ly so so m es. In  ea rly  a u to p h a g o so m e s  th e  p H  h as b e e n  m e a su re d  a t
6 .4 , d ro p p in g  to  5 .7  in  th e  a u to ly so so m e  (T a n a k a  et a l,  2 0 0 0 ). T h is  m a y  b e  d u e  to  
th e  a cq u is itio n  o f  p ro to n  p u m p s  an d  ly so so m a l p ro te in s  th ro u g h  fu s io n  ev en ts .
O n e  fa c to r  p re se n t in  b o th  e a r ly  an d  la te  a u to p h ag o so m es is  rab 7  (see  se c tio n  1.9 
‘R ab  G T P a se s’) , a lth o u g h  its  a s so c ia tio n  is  g re a te r  a t la te  tim e  p o in ts  (Ja g e r et a l, 
2 0 0 4 ). In  ce lls  tra n sfe c te d  w ith  a  d o m in an t-n eg a tiv e  rab 7  o r  ra b 7 -sp e c if ic  s iR N A , 
e a rly  au to p h ag o so m es accu m u la te , in d ic a tin g  th a t rab 7  is req u ired  fo r  th e ir  fina l 
m a tu ra tio n  (G u tie rrez  et a l,  2 0 0 4 ; Ja g e r  et a l, 2 0 0 4 ). A  tra c e r  ta k e n  u p  in to  ea rly  
en d o so m es  c a n  b e  d e liv e re d  to  a u to p h ag o so m es  in  rab 7  d e fic ie n t ce lls , b u t a  
ly so so m a l tra c e r  c a n n o t (G u tie rre z  et a l , 2 0 0 4 ). R ab 2 4  is a lso  im p lic a te d  in
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au to p h ag y  a s  i t  red is tr ib u te s  o n  in d u c tio n  o f  au to p h ag y  to  L C 3 p o s itiv e  
co m p artm en ts  (M u n afo  &  C o lo m b o , 2 0 0 2 ).
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1.6 .2  B a c te r ia  r e p l ic a t io n  v e s ic le s
B a c te r ia  h av e  e v o lv ed  a  n u m b e r  o f  s tra teg ie s  in  o rd e r to  in filtra te  h o s t c e lls  (F in lay  
&  F a lk o w , 1997). S o m e e n te r  th e  e n d o cy tic  p a th w a y  an d  re p lic a te  in  en d o so m es, 
w h ile  o th e rs  su b v e rt c e llu la r  au to p h ag y . In  b o th  cases  th e  b a c te r ia  re q u ire  a  v e s ic le  
w h e re  th e y  c an  b e  h id d e n  fro m  th e  h o s t  c e ll re sp o n se  d u rin g  rep lica tio n . M an y  
b a c te ria  h a v e  m e c h a n ism s  to  im p a ir  th e  m a tu ra tio n  o f  au to p h ag o so m es, th u s  
p re v e n tin g  th e ir  fu s io n  w ith  ly so so m es w h ic h  w o u ld  lead  to  d e g ra d a tio n  o f  th e  
b ac te ria . F o r  ex am p le , Mycobacterium tuberculosis rep lica te s  in  v e s ic le s  lack in g  th e  
V -A T P ase , p re v e n tin g  a c id if ic a tio n  (S tu rg ill-K o szy ck i et a l,  1994). Salmonella 
typhimurium tra ff ic s  to  a  la te  e n d o so m e-lik e  v a c u o le  th a t c an n o t fu se  w ith  th e  
ly so so m e  (M eresse  et a l, 1999). T h e  b a c te r iu m  sec re tes  a  p ro te in  k n o w n  as  S ifA  
th a t m im ics  th e  rab 7  e ffec to r, R IL P . S ifA  b in d s  to  rab7  in  th e  p la c e  o f  R IL P , 
p re v e n tin g  re c ru itm e n t o f  m ic ro tu b u le s  an d  fu s io n  w ith  th e  ly so so m e  (H a rriso n  et 
al, 2 0 0 4 ). O th e r b a c te r ia  ab le  to  e x p lo it au to p h ag y  in c lu d e  Coxiella burnetii 
(G u tie rrez  e t a l., 2 0 0 5 ), Brucella abortus (D o rn  e t  a l., 2 0 0 2 ), Legionella 
pneumophila (A m er &  S w an so n , 2 0 0 5 ) a n d  Porphyromonas gingivalis (D o rn  e t al., 
2001).
1 .6 .3  A u to p h a g y  a n d  v iru s e s
T h e re  is  in c rea s in g  ev id en ce  fo r  th e  in v o lv e m e n t o f  au to p h ag y  in  v ira l in fec tio n .
T w o  g ro u p s  o f  v iru se s , th e  n id o v ira le s  an d  th e  p ic o m a v irid a e , in d u c e  th e  fo rm a tio n  
o f  d o u b le  m e m b ran ed  v es ic le s . T h e  n id o v ira le s  (a rte riv irases  an d  c o ro n a v ira se s )
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rep lica te  o n  v e s ic le s  sm a lle r  th a n  au to p h ag o so m es , ab o u t 1 0 0 -3 0 0 n m  as  o p p o sed  to  
500-1 OOOnm (G o se rt et a l , 2 0 0 2 ; P e d e rse n  et a l , 1999; P ren tice  et a l, 2 0 0 4 ). In  
p o lio v iru s  in fec ted  ce lls , d o u b le  m em b ra n e d  v e s ic le s  o f  a ro u n d  2 0 0 -4 0 0 n m  c an  b e  
seen  (D a le s  et a l, 1965; S u h y  et a l,  2 0 0 0 ). T h e se  v es ic le s  c o -lo ca lise  w ith  L C 3 , 
a n d  v iru s  in fec tio n  is  re d u c e d  in  L C 3 o r  A tg l2  k n o c k o u t ce lls  (Ja c k so n  et a l, 2005). 
T h is  im p lie s  an  au to p h ag ic  o rig in  fo r  th e  re p lic a tio n  v es ic le s , in  c o n tra s t to  th e  
p re v io u s  su g g es tio n  th a t th ey  a re  d e riv e d  fro m  C O P II v e s ic le s  (R u s t et a l,  2 001).
1 .7  A im s
F M D V  in fe c tio n  re q u ire s  c la th rin -d e p en d e n t en d o cy to s is  an d  th e  lo w  p H  w ith in  
en d o so m es. H o w ev e r, th e  p re c ise  e n d o so m a l c o m p artm en ts  w h e re  cap sid  
d isa sse m b ly  an d  v R N A  m e m b ra n e  p e n e tra tio n  ta k e  p lace  a re  n o t k n o w n . T h e  
p rim a ry  o b jec tiv e  o f  th e  w o rk  d esc rib e d  in  th is  th e s is  is  to  ch a ra c te rise  fu r th e r  th e  
e n try  o f  F M D V  in to  ce lls . T h e  m a jo r  a p p ro a c h  h a s  b e e n  th e  u se  o f  d o m in an t- 
n e g a tiv e  ra b  G T P ases. R a b  G T P ases  re g u la te  m a n y  asp ec ts  o f  in tra c e llu la r  
m em b ran e  tra n sp o rt an d  a  n u m b e r  o f  ra b s  h a v e  b e e n  id en tified  th a t reg u la te  sp ec ific  
s tep s  o f  en d o cy to s is . E x p re ss io n  o f  d o m in a n t-n e g a tiv e  ra b s  c a n  th e re fo re  b e  u se d  to  
in v es tig a te  v iru s  en try  a n d  tra ff ic k in g  p a th w ay s .
Chapter One Intf'oduction
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Chapter two Methods
2.1 C e ll  c u l tu r e
T h e  p o rc in e  k id n e y  ce ll lin e  IB R S 2  w a s  c u ltu re d  in  G la sg o w  E ag le s  m e d ia  (G M E M - 
IA H ) su p p lem en ted  w ith  10%  a d u lt b o v in e  se ru m  (A B S -S ig m a), 2 0 m M  g lu tam in e , 
100 s i u n its  p e r  m l p e n ic illin  an d  lO O pg p e r  m l s trep tom ycin .
B a b y  h a m ste r  k id n ey  ce lls  (B H K ) w e re  g ro w n  in  D u lb e c c o ’s m o d if ie d  E a g le s  m ed ia  
(D M E M -S ig m a) su p p lem en ted  w ith  10%  fo e ta l c a l f  se ru m  (F C S -S ig m a), 2 0 m M  
g lu tam in e , 100 s i u n its  p e r  m l p e n ic illin  an d  lOOpg p e r  m l strep to m y c in .
2 .1 .1  C e ll  p a s s a g e
O n ce  c o n flu en t, c e ll m o n o la y e rs  w e re  w a sh e d  w ith  0 .2 5 %  v e rs in e -try p s in  and  
in cu b a ted  a t 37°C  fo r  ap p ro x im a te ly  5 m in u te s  in  th e  p re sen ce  o f  0 .2 5 %  v ers in e - 
try p sin . C ells  w e re  c o llec ted  a n d  p e lle te d  u s in g  a  S o rv a l L eg en d  R T  cen trifu g e  fo r  3 
m in u te s  a t lOOOrpm. C e lls  w e re  re su sp e n d e d  in  cu ltu re  m e d iu m  an d  seed ed  a t th e  
req u ired  d ilu tio n  in to  a  f re sh  t is su e  cu ltu re  flask .
2 .2  V iru s
A ll ex p erim en ts  u se  th e  F M D V  s tra in  0 1 K c a d 2 , a  n o n -h ep a ran  su lp h a te  b in d in g  
v iru s . W o rk in g  s to ck s  w e re  g ro w n  u s in g  p rim a ry  b o v in e  th y ro id  ce lls  (B T Y ) and  
p u rif ie d  v im s  w a s  p re p a re d  o n  su c ro se  g rad ien ts . A ll v iru s  s to ck s  w e re  s to red  a t - 
80°C.
Chapter two: Methods
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2 .2 .1  P r e p a r a t io n  o f  v i r u s  w o r k in g  s to c k s
P rim a iy  b o v in e  th y ro id  c e lls  (B T Y ) w e re  g ro w n  in  175 c m 5 tis su e  c u ltu re  f la sk s  u n til 
co n flu en t. T h e  ce lls  w e re  th e n  w a sh e d  w ith  P B S  an d  a n  a liq u o t o f  a  p re v io u s  v iru s  
s to ck  w a s  a d d ed  to  th e  ce lls . T h is  w a s  in cu b a ted  in  a  3 7 ,’C  in c u b a to r w ith  5%  C 0 2 
fo r  15 m in u te s  b e fo re  a d d in g  2 0 m l p re -w a rm e d  v ira l g ro w th  m e d iu m  (V G M ) 
co n sis tin g  o f  n o rm a l g ro w th  m e d iu m  w ith  1%  serum . T h e  ce lls  w e re  re tu rn e d  to  
3 7 °C  u n til cy to p a th ic  e ffe c t (C P E ) w a s  o b se rv ed . T h e  ce lls  w e re  freeze  th a w e d  to  
in c rea se  y ie ld . W o rk in g  s to ck s  o f  v iru s  w e re  cen tr ifu g ed  b e fo re  u se  to  rem o v e  ce ll 
d eb ris . T h e  su p e rn a tan t w as  a liq u o te d  in to  1 .5m l sc rew  c ap p ed  e p p e n d o rf  tu b es  an d  
s to red  a t -80°C .
2 .2 .2  V ir u s  t i t r a t i o n  b y  p la q u e  a s s a y
6 0 m m  tissu e  cu ltu re  d ish es  o f  B H K  c e lls  w e re  c u ltu re d  o v e rn ig h t in  o rd e r  to  reach  
ap p ro x im a te ly  8 0 %  co n flu en cy . T h e  ce lls  w e re  w a sh e d  w ith  P B S  a n d  lOOpl v iru s  
d ilu ted  in  D M E M  ad d ed  a t te n fo ld  d ilu tio n s . T h e  d ish es  w ere  in cu b a ted  a t 37°C  fo r 
15 m in u te s  b e fo re  b e in g  o v e rla id  w ith  4 m l E a g le ’s  o v erlay  (see  a p p e n d ix  I) a t 4 5 °C. 
T h e  o v e rlay  w a s  a llo w ed  to  se t a t  ro o m  te m p e ra tu re  an d  th e  ce lls  re tu rn e d  to  37°C  
fo r  48  h o u rs . P laq u es  w e re  v isu a lise d  b y  f ix in g  an d  s ta in in g  w ith  m e th y len e  b lu e  
an d  4 %  p ara fo rm a ld eh y d e  in  P B S  fo r  2 4  h ours.
2 .3  A n tib o d ie s , f lu o re s c e n t  l ig a n d s  a n d  p h a rm a c o lo g ic a l  in h ib i to r s
A n ti-F M D V  an tib o d ie s  u se d  w e re  m o n o c lo n a l an tib o d y  D 9  (m o u se  Ig G 2 a), w h ich  
reco g n ise s  a n tig en ic  site  1 o f  ty p e  O  F M D V , an ti-3  A  m o n o c lo n a l a n tib o d y  2C 2  
(m o u se  Ig G 2 a) an d  a  ra b b it p o ly c lo n a l se ru m  w h ic h  reco g n ise s  th e  F M D V  ty p e  O
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ca p s id  p ro te in s . In teg rin  aV(38 w a s  d e te c te d  u s in g  m o n o c lo n a l an tib o d y  14E5 
(m o u se  Ig G l) .  A  v a rie ty  o f  an tib o d ie s  w h ic h  rec o g n ise  p ro te in s  lo c a lis in g  to  
sp ec ific  cellu lar’ c o m p artm en ts  w e re  u se d  in  th is  study . E a rly  e n d o so m es w ere  
la b e lle d  u s in g  a n ti-E E A l c lo n e  14 (m o u se  Ig G l-B D  T ran sd u c tio n  L ab o ra to rie s).
T h e  tra n sfe rr in  re c e p to r  w a s  d e te c te d  u s in g  a  m o n o c lo n a l a n tib o d y  H 6 8 .4  (m ouse  
Ig G l-Z y m e d ) . T h e  m a n n o se  6-p h o sp h a te  re c e p to r  w as  d e tec ted  w ith  a  m o n o c lo n a l 
a n tib o d y  (m o u se  Ig G 2 a -A ffin ity  B io R cag en ts) . F o r  th e  A P 1 8 0 C  ex p e rim en t, m y c- 
ta g g e d  A P 1 8 0 C  p ro te in  w a s  d e te c te d  u s in g  th e  an ti-c -m y c  a n tib o d y  9 E 1 0  (m o u se  
Ig G -D ev e lo p m en ta l S tu d ies  H y b rid o m a  B an k ). A ll A lex a -flu o r seco n d a ry  
an tib o d ie s  w e re  o b ta in e d  fro m  M o le c u la r  P ro b es  (In v itro g en ), as  w e re  th e  A lex a- 
f lu o r  co n ju g a ted  tra n sfe rr in , D ilL D L  an d  ly so tra c k e r red . P h a rm aco lo g ica l 
in h ib ito rs  u se d  w e re  n o c o d a z o le  (S ig m a) a t lO m g /m l in  D M S O  a n d  c o n can am y c in  A  
(F lu k a ) a t lO m g/m l in  D M S O . A n tib o d ie s  u se d  fo r  w es te rn  b lo ttin g  w e re  a n  an ti- 
ra b ?  a n tib o d y  (o b ta in ed  fro m  S u zan n e  P fe ffe r) , a  ra b b it p o ly c lo n a l an ti-rab 5  
an tib o d y  (S tressg en ) an d  a  m o u se  m o n o c lo n a l an ti-p -ac tin  a n tib o d y  (S ig m a).
2 .4  V ir u s  in fe c tiv ity  a ssa y s
In fe c tio n  w a s  q u a n tif ie d  u s in g  tw o  m e th o d s; E L Isp o t a ssay  o r  im m u n o flu o rescen ce .
2 .4 .1  E L I s p o t  a s sa y
F o r  q u an tif ic a tio n  o f  e ffec ts  o f  p h a rm a c o lo g ic a l in h ib ito rs  o n  th e  n u m b e r o f  F M D V  
in fec ted  ce lls , th e  E L Isp o t a ssa y  w a s  u sed . C e lls  w ere  cu ltu red  in  96  w e ll p la te s  
o v e rn ig h t u n til ap p ro x im a te ly  7 0 -8 0 %  c o n flu en t. T h e  ce lls  w e re  w a sh e d  a n d  p re ­
trea ted  w ith  D M E M  w ith  o r  w ith o u t d ru g  fo r  30  m in u te s  a t 37°C . T h e  ce lls  w ere  
w ash ed  w ith  D M E M  b e fo re  ad d in g  F M D V  0 1 K c a d 2  w ith  o r  w ith o u t d ru g  fo r 1
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h o u r. T h e  ce lls  w e re  w a sh e d  an d  in cu b a ted  a t 37°C  fo r a  fu rth e r  fo u r  h o u rs  in 
D M E M  in  th e  p re sen ce  o r  a b sen ce  o f  d rug . A s  th e  s to ck  d ru g  so lu tio n s  w ere  
p re p a re d  in  D M S O , th e  e q u iv a le n t c o n c e n tra tio n  o f  D M S O  w a s  a d d e d  to  th e  D M E M  
in  ‘n o  d ru g 5 co n tro ls . T h is  w a s  to  d isc o u n t th e  p o ss ib ility  th a t e ffec ts  o n  in fec tio n  
c o u ld  b e  a ttrib u ted  to  th e  D M S O . T h e  ce lls  w e re  th e n  fix ed  fo r  1 h o u r  u s in g  4 %  
p a ra fo rm ald eh y d e . F o r  v iru s  la b e llin g , c e lls  w e re  w ash ed  5 tim e s  w ith  P B S  th e n  
p e rm e a b lise d  u s in g  0 .1 %  T rito n  X -1 0 0  in  P B S  fo r  15 m in u tes . T h ey  w e re  w ash ed  
ag a in  an d  in cu b a ted  in  b lo c k in g  b u ffe r  fo r  30  m in u te s  (1 4 0 m M  N a C l, Im M  C aC fr, 
0 .5 m M  M gCfy, 10%  n o rm a l g o a t se ru m  a n d  1%  f ish  g ela tin ) to  re d u c e  n o n -sp ec ific  
b in d in g . P rim ary  an tib o d y  2 C 2  (m o u se  Ig G 2 a) d ilu ted  1 /1000  in  b lo c k  b u ffe r  w as 
th e n  ad d ed  fo r  1 h o u r  a t ro o m  tem p era tu re . M a b  2 C 2  reco g n ise s  F M D V  n o n - 
s tru c tu ra l p ro te in  3 A , w h ic h  is  a  m a rk e r  fo r  v iru s  rep lica tio n . T h e  c e lls  w ere  w ash ed  
a n d  in cu b a ted  fo r  1 h o u r  w ith  a  b io tin ly a te d  g o a t an ti-m o u se  Ig G  seco n d a ry  an tib o d y  
a t  1 /500  in  b lo c k  bu ffe r. T h is  w a s  fo llo w e d  b y  in cu b a tio n  w ith  a  s trep tav ad in - 
co n ju g a ted  a lk a lin e  p h o sp h a ta se  (C a ltag  lab o ra to rie s)  a t 1 /1000  in  b lo c k  b u ffe r  fo r  
45  m in u tes . T h e  a lk a lin e  p h o sp h a ta se  su b s tra te  (B IO -R A D ) w a s  th e n  a d d e d  fo r 6-7  
m in u te s  u n til a  c o lo u r ch an g e  w a s  o b se rv e d  b y  lig h t m ic ro sco p y . C e lls  w e re  th e n  
w a sh e d  w ith  d is tille d  w a te r  a n d  a llo w e d  to  d ry . In fec ted  ce lls  a p p e a r  b lu e  u n d e r  a  
lig h t m ic ro sco p e  an d  w e re  c o u n te d  u s in g  a n  E L Isp o t p la te  re a d e r  (Z eiss),
2 .4 .2  Im m u n o f lu o re s c e n c e  a s s a y
C e lls  w e re  seed ed  o n  13m m  g la ss  c o v e rs lip s  (B D H ) to  b e  ap p ro x im a te ly  80%  
c o n flu e n t an d  tra n s ie n tly  tra n sfe c te d  (see  se c tio n  2.6.2) u s in g  lip o fec tam in e  2000 
(In v itro g en ) w ith  m a m m a lia n  e x p re ss io n  p la sm id s  e x p re ss in g  a  n u m b e r o f  en h an ced  
g reen  f lu o re scen t p ro te in  (E G F P ) fu se d  ra b  G T P ase  p ro te in s  o r  m y c -tag g ed
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A P 1 8 0 C . A fte r  in c u b a tio n  a t 37°C  fo r  6 h o u rs , c e lls  w e re  w a sh e d  a n d  in fec ted  w ith  
F M D V  0 1 K c a d 2  fo r  3 horn’s  a t M O I= l .  W h e re  b o v in e  en te ro v iru s  (B E V ) w as  u sed , 
th e  in fec tio n  tim e  w a s  e x ten d ed  to  6 h o u rs . T h e  ce lls  w ere  th e n  fix e d  w ith  4%  
p a ra fo rm a ld eh y d e  in  P B S  fo r  4 0  m in u te s  a n d  p ro cessed  fo r  co n fo ca l m ic ro sco p y . 
C e lls  ex p re ss in g  E G F P  fu se d  ra b  G T P ase  p ro te in s  appeal’ g reen , an d  A P I  SOC 
e x p ress in g  ce lls  w e re  la b e lle d  w ith  a n  an ti-c -m y c  an tib o d y  (9 E 1 0 ) a n d  A lex a-4 8 8  
c o n ju g a ted  g o a t a n ti-m o u se  Ig G  seco n d a ry  an tib o d y . In fec ted  ce lls  w e re  lab e lled  
w ith  ra b b it p o ly c lo n a l se ru m  to  th e  F M D V  c a p s id  an d  a n  A lex a -5 6 8  c o n ju g a ted  g o a t 
an ti-ra b b it Ig G  seco n d a ry  a n tib o d y . T h e  n u m b e r  o f  ce lls  ex p re ss in g  th e  tra n sfe c te d  
p ro te in  (A P 1 8 0 C  o r  ra b  G T P ase ) th a t  w e re  in fe c te d  an d  th e  n u m b e r o f  n o n ­
ex p ress in g  ce lls  in fec ted  w ere  co u n ted .
2.5 Im m u n o f lu o re s c e n c e  m ic ro s c o p y
2 .5 .1  D e te c tio n  o f  in t r a c e l lu la r  a n t ig e n
C e lls  w e re  seed ed  o v e rn ig h t o n  1 3 m m  g la ss  c o v e rs lip s  (B D H ) to  b e  ap p ro x im a te ly  
80%  c o n flu e n t an d  fix e d  w ith  4 %  p a ra fo rm a ld eh y d e  in  P B S  fo r  4 0  m in u te s . C ells 
w e re  w ash ed  th re e  tim e s  w ith  P B S  a n d  p e rm e a b lise d  u s in g  0 .1 %  T rito n  X -1 0 0  in  
P B S  fo r  30  m in u tes . T h e  c e lls  w e re  w a sh e d  a g a in  an d  in cu b a ted  in  b lo c k in g  b u ffe r  
(see  ap p en d ix  I) fo r  30  m in u te s  to  re d u c e  n o n -sp ec if ic  b in d in g . T h e  ce lls  w ere  
in cu b a ted  w ith  p rim a ry  an tib o d ie s  d ilu te d  in  b lo ck in g  b u ffe r  a t th e  a p p ro p ria te  
c o n c e n tra tio n  fo r  1 h o u r  a t  ro o m  te m p e ra tu re . T h is  w as  fo llo w ed  b y  th r ee  fiv e  
m in u te  w ash es  w ith  P B S  to  re m o v e  u n b o u n d  an tib o d y . T h e  A le x a  f lu o r  co n ju g a ted  
seco n d a ry  an tib o d ie s  (4 8 8 n m -g re e n  o r  5 6 8 n m -red ) w ere  d ilu ted  in  b lo c k in g  b u ffe r  a t 
a  c o n cen tra tio n  o f  1:200 a n d  in c u b a te d  w ith  th e  ce lls  fo r  a  fu rth e r 1 h o u r  a t ro o m  
tem p era tu re . T h e  ce lls  w e re  th e n  w a sh e d  a g a in  in  P B S  fo r fiv e  m in u te s , th ree  tim es.
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F in a lly , th e  ce lls  w e re  w a sh e d  w ith  d is tille d  w a te r  an d  m o u n te d  in  V ec ta sh ie ld  
m o u n tin g  m e d iu m  c o n ta in in g  D A P I (fo r  D N A  lab e llin g ) an d  sea led  u s in g  c lea r na il 
varn ish .
2 .5 .2  D e te c tio n  o f  s u r f a c e  a n t ig e n
T h e  p ro ced u re  ab o v e  w a s  m o d ifie d  fo r  d e te c tio n  o f  su rface  an tig en . C e lls  w ere  
seed ed  o n  co v e rs lip s  as b e fo re , a n d  c o o le d  o n  ice . N o n -sp e c if ic  b in d in g  w a s  b lo ck ed  
b y  in c u b a tio n  w ith  co ld  b lo c k in g  b u ffe r  o n  ic e  fo r  30  m in u tes . F o r  d e te c tio n  o f  
re c e p to r  a V p 8, th e  p r im a ry  an tib o d y  14E5 w a s  d ilu ted  a t 1:1 in  c o ld  G M E M  and  
in cu b a ted  w ith  th e  c e lls  o n  ice  fo r  1 h o u r, fo llo w e d  b y  w ash in g  th re e  tim e s  fo r  fiv e  
m in u te s  each , w ith  co ld  G M E M . A  g o a t a n ti-m o u se  Ig G l A le x a  co n ju g a te d  
seco n d a ry  an tib o d y  w a s  th e n  a d d e d  a t 1 :200  in  c o ld  G M E M  an d  ce lls  w ere  
in cu b a ted  on  ice  fo r  a  fu r th e r  1 h o u r. T h e  c e lls  w e re  th en  fix ed  w ith  4 %  co ld  
p a ra fo rm a ld eh y d e  a t th e  en d  a n d  m o u n te d  as d e sc rib ed  in  sec tio n  2 .5 .1 .
2 .5 .3  L ig a n d  in te r n a l is a t io n
2 .5 .3 .1  V iru s  b in d in g  a n d  in te r n a l i s a t io n
C e lls  w e re  in cu b a ted  w ith  p u rif ie d  F M D V  a t 5 p g /m l d ilu ted  in  c o ld  G M E M  fo r 45 
m in u te s  o n  ice. U n b o u n d  v iru s  w a s  re m o v e d  b y  w ash in g  w ith  co ld  G M E M  th ree  
tim es , fo r  fiv e  m in u te s  ea c h  tim e . F o r  in te rn a lisa tio n  s tu d ies , w a rm  G M E M  w as 
th e n  a d d e d  a n d  th e  ce lls  w e re  in c u b a te d  a t 3 7 °C  fo r  th e  tim e s  in d ica ted , th e n  fix ed  
w ith  4 %  c o ld  p a ra fo rm a ld eh y d e  a n d  p e rm e a b lise d  u s in g  0 .1 %  T rito n  X -1 0 0  in  P B S  
fo r 3 0  m in u tes . V iru s  w a s  d e te c te d  u s in g  M ab  D 9  (5 p g /m l) a n d  a  g o a t an ti m o u se  
Ig G 2 a  A le x a  c o n ju g a ted  seco n d a ry  an tib o d y . F o r  lab e llin g  o f  su rface  v iru s , th e
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w a rm in g  s tep  w a s  rem o v ed , a n d  la b e llin g  w ith  D 9  w a s  ca rried  o u t im m ed ia te ly  
u s in g  co ld  reag en ts , o n  ice . F ix a tio n  w ith  4 %  c o ld  p a ra fo rm a ld eh y d e  w a s  a t th e  end  
o f  th e  ex p erim en t. C o v e rs lip s  w e re  p ro c e sse d  a s  d e sc rib ed  in  se c tio n  2 .5 .1 .
2 .5 3 .2  T r a n s f e r r in  b in d in g  a n d  in te r n a l i s a t io n
C e lls  w e re  w a sh e d  w ith  G M E M  an d  in cu b a ted  a t 3 7 °C  fo r  45  m in u te s  in  G M E M  to  
d ep le te  th e  c e lls  o f  iro n . T h is  p ro c e ss  w ill en h an ce  tra n sfe rr in  u p tak e . A le x a  5 6 8 n m  
co n ju g a ted  tra n sfe rrin  w a s  d ilu te d  in  G M E M  a t  2 5 p g /m l a n d  a d d ed  to  th e  ce lls  a t 
4 °C  fo r  45  m in u te s  to  a llo w  b in d in g . T h e  c e lls  w e re  w ash ed  w ith  c o ld  G M E M  to  
rem o v e  u n b o u n d  tra n sfe rr in  an d  in te rn a lisa tio n  in itia te d  b y  w ash in g  w ith  w arm  
G M E M , fo llo w e d  b y  in c u b a tio n  a t 3 7 °C  fo r  th e  tim e s  ind ica ted . F o r  so m e  
ex p e rim en ts , lab e lled  tra n sfe rr in  w a s  ch a se d  o u t o f  th e  ce lls  u s in g  h o lo -tra n sfe rr in  
(u n lab e lled ), a lso  d ilu ted  in  G M E M  a t a  co n c e n tra tio n  o f  2 5 p g /m l. A t th e  e n d  o f  th e  
ex p e rim en t, ce lls  w e re  f ix e d  w ith  4 %  c o ld  p a ra fo rm a ld eh y d e  a n d  th e  co v erslip s  
p ro c e sse d  as d e sc rib e d  in  se c tio n  2 .5.1,
2 .5 .3 3  L D L  b in d in g  a n d  in te rn a l is a t io n
C e lls  w e re  in cu b a ted  w ith  D ilL D L  a t  lO p g /m l d ilu ted  in  c o ld  G M E M  fo r  45  m in u tes  
o n  ice . U n b o u n d  L D L  w a s  re m o v e d  b y  w a sh in g  w ith  co ld  G M E M  thr ee  tim e s , fo r 
f iv e  m in u te s  each  tim e . W arm  G M E M  w a s  th en  a d d e d  an d  th e  ce lls  w e re  in cu b a ted  
a t 3 7 °C  fo r  th e  tim e s  in d ica ted . A t th e  e n d  o f  th e  ex p erim en t, c e lls  w e re  fix e d  w ith  
4 %  co ld  p a ra fo rm a ld eh y d e  a n d  th e  c o v e rs lip s  p ro c e sse d  as d e sc rib e d  in  sec tio n
2 .5 .1 .
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2 .5 3 .4  L a b e l l in g  o f  a c id ic  c o m p a r tm e n ts  w i th  ly s o t r a c k e r  r e d
C e lls  w e re  in cu b a ted  w ith  ly so tra c k e r re d  a t lOOnM  d ilu ted  in  w a rm  G M E M  a t 37 °C  
fo r  th e  tim e s  in d ica ted , th e n  f ix e d  w ith  4 %  co ld  p a ra fo rm ald eh y d e . T h e  co v e rs lip s  
w ere  p ro c e sse d  as d esc rib ed  in  se c tio n  2 .5 .1 .
2 .5 .4  Im a g e  c o lle c tio n
A ll im m u n o flu o re scen ce  im ag es  w e re  c o lle c te d  u s in g  th e  6 3 X  o b je c tiv e  len s  o f  a  
L e ic a  S P 2  co n fo ca l m ic ro sco p e . E a c h  im ag e  re p re se n ts  a  s in g le  co n fo c a l sec tio n  
th ro u g h  th e  ce ll(s) in  q u es tio n , w ith  th e  e x c e p tio n  o f  fig u re s  5 .8  an d  5 .9  w h ic h  sh o w  
a n  o v e rlay  o f  a  n u m b e r o f  sec tio n s  th ro u g h  th e  ce ll. In  o rd e r to  re d u c e  c ro ss ta lk  
b e tw e e n  d e te c tio n  c h an n e ls , d a ta  w e re  c o lle c te d  seq u en tia lly . Im ag es  w ere  
p ro c e sse d  u s in g  A d o b e  P h o to sh o p  so ftw are .
2 .6  D N A  te c h n iq u e s
2 .6 .1  M a m m a lia n  e x p re s s io n  p la s m id s
P la sm id s  fo r  e x p re ss io n  o f  c an in e  ra b  p ro te in s  fu se d  to  E G F P  w e re  o b ta in e d  fro m  D r
S .S . F e rg u so n  (R o b a rts  R e se a rc h  In s titu te , C an ad a). T h e  p la sm id s  w e re  co n stru c ted  
u s in g  p E G F P -C l o r  p E G F P -C 2  (C lo n tech ). T h e se  p la sm id s  w ere  tra n sfo rm e d  in to  
c o m p e te n t E.coli JM 1 0 9  an d  g ro w n  u p  o v e rn ig h t in  100m l L B  w ith  k an am y c in  
(5 0 p g /m l). P la sm id  D N A  w a s  e x tra c te d  u s in g  th e  Q iag en  m id i-p re p  sy s tem  
a cco rd in g  to  th e  m a n u fa c tu re r’s  in s tru c tio n s .
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2 .6 .2  T r a n s ie n t  t r a n s f e c t io n  o f  m a m m a l ia n  ce lls  w i th  p la s m id  D N A
C ells  w ere  seed ed  o v e rn ig h t o n  1 3 m m  g la ss  co v e rs lip s  (B D H ) in  th e  a b sen ce  o f  
P e n ic illin /S trep to m y c in  to  b e  a p p ro x im a te ly  8 0 %  co n flu en t. F o r  e a c h  co v ers lip , lp g  
p la sm id  D N A  w a s  d ilu te d  in to  5 0 p l O p ti-M E M  (G ib co ) in  o n e  m ic ro fu g e  tu b e , w ith  
3 p i lip o fec tam in e  2 0 0 0  tra n sfe c tio n  re a g e n t (In v itro g en ) d ilu ted  in to  5 0 p l O p ti- 
M E M  (G ib co ) in  a  sep a ra te  m ic ro fu g e  tu b e . T h e se  w ere  in cu b a ted  a t  ro o m  
te m p e ra tu re  fo r  5 m in u te s . T h e  c o n ten ts  o f  b o th  tu b e s  w e re  th e n  c o m b in e d  and  
in cu b a ted  fo r  a  fu rth e r  20  m in u te s . T h is  m ix tu re  w a s  a d d ed  to  th e  ce lls  an d  m ed ia . 
T h e  ce lls  w e re  th e n  in c u b a te d  a t 3 7 °C  fo r  s ix  h o u rs . A t th is  p o in t, c e lls  w ere  e ith e r 
f ix e d  w ith  4 %  p a ra fo rm a ld eh y d e  o r  in fec ted  w ith  v iru s  fo r  3 h o rn s  (F M D V ) o r  6 
h o u rs  (B E V -see  sec tio n  2 .4 .2 ). C o v e rs lip s  w ere  p ro cessed  as d esc rib ed  in  sec tio n
2 .5 .1 .
2 .7  R N A  te c h n iq u e s
2.7 .1  T ra n s fe c t io n  o f  m a m m a lia n  ce lls  w ith  s iR N A
C ells  w e re  seed ed  o v e rn ig h t in  2 4 -w e ll o r  9 6 -w e ll p la te s  in  th e  ab sen ce  o f  an tib io tic s  
to  b e  ap p ro x im a te ly  3 0 -5 0 %  co n flu en t. F o r  e a c h  w e ll o f  a  2 4 -w e ll p la te , 2 0 p m o l 
s iR N A  w as d ilu te d  in to  5 0 p l O p ti-M E M  (G ib co ) in  one  m ic ro fu g e  tu b e , w ith  I p l  
s iP O R T am in e  tra n sfe c tio n  re a g e n t (A m b io n ) d ilu ted  in to  5 0 p l O p ti-M E M  (G ib co ) in  
a  sep a ra te  m ic ro fu g e  tu b e . F o r  a  9 6  w e ll p la te , th is  w as  sca led  d o w n  to  5p m o l 
s iR N A  in  lO pl O p ti-M E M  (G ib co ) in  o n e  m ic ro fu g e  tu b e , an d  0 .2 5 p l s iP O R T am in e  
tra n sfe c tio n  re a g e n t (A m b io n ) in  lO pl O p ti-M E M  (G ib co ) in  th e  o ther. T h ese  w ere  
in cu b a ted  a t ro o m  te m p era tu re  fo r  10 m in u te s . T h e  co n ten ts  o f  b o th  tu b e s  w ere  th en  
c o m b in ed  an d  in cu b a ted  fo r  a  fu r th e r  10 m in u tes . A ll reac tio n s  w e re  c a rr ied  ou t
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u s in g  R N ase-fi'ee  tu b e s  a n d  tip s . T h e  co m p le x e s  w ere  th e n  ad d ed  to  th e  ce lls  an d  
m ed ia . T h e  c e lls  w e re  th e n  in c u b a te d  a t  3 7 °C  fo r  72  h o u rs . A t th is  p o in t, c e lls  in  
2 4 -w e ll p la te s  w e re  in fe c te d  w ith  F M D V  fo r  3 h o u rs  an d  th e n  a c id  w a sh e d  to  
re m o v e  n o n -in te m a lise d  v iru s . V G M  w a s  a d d e d  an d  m e d ia  sam p les  ta k e n  a t v a rio u s  
tim e  p o in ts  to  a ssay  fo r  v iru s  p ro d u c tio n . T h e se  sam p les  w ere  titra te d  o n  BHIC ce lls  
a s  d esc rib ed  in  se c tio n  2 .2 .2 . T h e  ce lls  in  9 6 -w e ll p la te s  w ere  in fe c te d  w ith  F M D V  
an d  p ro c e sse d  fo r  th e  E L Isp o t in fe c tio n  a ssa y  a s  d e sc rib ed  in  se c tio n  2 .4 .1 .
2 .7 .2  T o ta l  R N A  e x tr a c t io n
B H K  ce lls  w e re  g ro w n  in  a  175cm 2 f la sk  u n til co n flu en t. 1m l F M D V  O IB F S  
(M O  1= 10)  w a s  th e n  ad d ed  an d  th e  f la sk  w a s  in cu b a ted  a t  3 7 °C  fo r  15 m in u te s . 10m l 
V G M  w a s  th e n  a d d ed  a n d  in fe c tio n  a llo w ed  to  p ro ceed  a t 3 7 °C  fo r  2  h o u rs . T o ta l 
R N A  w a s  ex trac ted  fro m  th e  ce lls  u s in g  T riz o l (L ife  T ech n o lo g ie s) a c c o rd in g  to  th e  
m a n u fa c tu re r’s in stru c tio n s . T h e  f in a l R N A  p e lle t w as re su sp e n d e d  in  R N ase-free  
w a te r  in  R N ase -free  tu b e s  an d  s to red  a t -8 0 6C.
2 .7 .3  E le c t r o p o r a t io n  o f  m a m m a lia n  ce lls  w i th  R N A
C ells  w e re  g ro w n  in  6m m  d ish e s  u n til 8 0 %  co n flu en t. T h ey  w ere  th e n  tran sfec ted  
w ith  m a m m alian  ex p re ss io n  p la sm id s  ex p re ss in g  ra b  p ro te in s  fu sed  to  E G F P . A fte r  
6 h o u rs , th e  ce lls  w e re  re m o v e d  u s in g  try p s in  a n d  p e lle ted  b y  c e n tr ifu g a tio n  at 
lOOOrpm fo r 3 m in u te s  a t 4 °C . C e lls  w e re  w a sh e d  o n ce  w ith  P B S  a n d  re -p e lle ted . 
C e lls  w e re  co u n ted  u s in g  a  h aem o c y to m e te r  an d  re su sp en d ed  a t 2  m illio n  ce lls  p e r  
m l in  co ld  s iP O R T  siR N A  E le c tro p o ra tio n  B u ffe r  (A m bion). T h e  ce lls  w ere  
tra n sfe rre d  in to  ice  co ld  e le c tro p o ra tio n  cu v e tte s  (B io R ad ) w ith  a  0 .4 c m  g ap  len g th  
a n d  1 p g  R N A  added . T h e  ce lls  an d  R N A  w e re  m ix ed  g en tly  an d  e lec tro p o ra ted  a t
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2 0 0 0 V  fo r  th re e  p u lse s  u s in g  a  B T X  T 8 2 0  e lec tro  sq u are  p o ra to r. T h e  cu v e tte s  w ere  
a llo w e d  to  s tan d  a t  ro o m  te m p e ra tu re  fo r  10 m in u te s  an d  th e n  th e  c o n ten ts  o f  e ach  
c u v e tte  sp lit b e tw e e n  tw o  c o v e rs lip s  in  a  2 4 -w e ll p la te . 5 0 0 p l V G M  w a s  th e n  ad d ed  
an d  th e  ce lls  w e re  in c u b a te d  a t 3 7 °C  fo r  6 h o u rs , a n d  th e n  f ix e d  w ith  4%  
p a ra fo rm ald eh y d e . C o v e rs lip s  w e re  p ro c e sse d  a s  d esc rib ed  in  se c tio n  2 .5 .1 . 
T ra n sfe c tio n  an d  in fe c tio n  w e re  a ssay ed  as in  se c tio n  2 .4 .2 .
2 .8  P r o te in  te c h n iq u e s
2 .8 .1  S D S -P A G E
S o d iu m  d o d ecy l su lp h a te  p o ly a c ry la m id e  ge l e lec tro p h o res is  (S D S -P A G E ) w a s  u sed  
fo r  p ro te in  an a lysis . S am p le s  w e re  p rep a r e d  b y  ly s in g  ce lls  w ith  ly s is  b u ffe r  C  (see  
a p p e n d ix  I) an d  c e n trifu g a tio n  to  p e lle t  c e ll d eb ris . T h e  su p e rn a ta n t w a s  th e n  m ix ed  
w ith  3 X  S D S  sam p le  b u ffe r  (N e w  E n g la n d  B io la b s)  an d  4 0 m M  d ith io th re ito l (D T T ) 
(N E B ). S am p les  w e re  th e n  h e a te d  a t  9 5 °C  fo r  5 m in u te s  a n d  1 5p l ru n  o n  a  10%  gel 
(se e  ap p en d ix  I). G e ls  w ere  c a s t an d  ru n  u s in g  a  B io R a d  m in i p ro te a n  III  sy stem , in  
S D S  ru n n in g  b u ffe r  (see  ap p e n d ix  I) a t  2 0 0 v o lts /4 0 0 m A  fo r a p p ro x im a te ly  1 h ou r.
2 .8 .2  W e s te r n  B lo tt in g
P ro te in s  w e re  tra n sfe rre d  fro m  th e  S D S -P A G E  ge l o n to  a  n itro c e llu lo se  m em b ran e  
(A m ersh am ) u s in g  tra n s fe r  b u ffe r  (see  a p p e n d ix  I)  a t 1 0 0 v o lts /4 0 0 m A  fo r 90 
m in u te s . T h e  m e m b ra n e s  w ere  b lo c k e d  to  re d u c e  n o n -sp ec ific  b in d in g  fo r 1 h o u r 
u s in g  P B S  co n ta in in g  5 %  M arv e l m ilk  p o w d er. P rim ary  an tib o d ie s  a t  1 /1000  (fo r 
rab 5  a n d  ra b ? )  o r  1 /5000  (fo r  ac tin ) w e re  a d d e d  to  5m l b lo ck in g  b u ffe r  an d  in cu b a ted  
a t 4 °C  o v ern ig h t o n  a  S p iram ax  5 (D en iey ). T h e  m em b ran e  w a s  w a sh e d  w ith  P B S  
an d  0 .1 %  T w een -2 0  fo u r  tim e s , fo r  15 m in u te s  e a c h  tim e , w ith  sh ak in g . T h e
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ap p ro p ria te  h o rse ra d ish  p e ro x id a se  (I IR P )-co iiju g a ted  seco n d a ry  an tib o d ie s  w ere  
th e n  a d d ed  to  5 m l b lo ck in g  b u ffe r  a t 3 /5 0 0 0  a n d  in cu b a ted  fo r  a  fu r th e r  1 h o u r  a t 
4 °C . T h is  w as fo llo w ed  b y  a n o th e r w a sh in g  s tep  a s  b e fo re . T h e  p ro te in s  w ere  
v isu a lise d  u s in g  e le c tro ch em ilu m in escen ce  (E C L ) reag en ts  (P ie rce ) a c c o rd in g  to  th e  
m a n u fa c tu re r’s  p ro to co l. T h e  m e m b ra n e s  w e re  e x p o se d  to  X -ra y  f ilm  (K o d ak ) 
w h ic h  w a s  p ro c e sse d  u s in g  a  C o m p a c t X 4  X -O g rap h .
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Chapter three: «vp8-mediated infection of IBRS2 cells by FMDV
Chapter three av/38-mediated infection o f  IBRS2 cells by FMDV
3.1 I n t r o d u c t io n
O n e  o f  th e  m a in  o b jec tiv es  o f  th is  th e s is  is  to  id en tify  th e  c e llu la r  c o m p a rtm e n t fro m  
w h ic h  F M D V  in fe c tio n  o ccu rs . T h e  c e llu la r  u p ta k e  p a th w ay  o f  F M D V  h a s  b e e n  
s tu d ied  u s in g  a  h u m a n  c a rc in o m a  ce ll lin e  e x p re ss in g  a V p 6 (S W 4 8 0 p 6 ). T h ese  
s tu d ie s  sh o w ed  th a t F M D V  in fe c tio n  re q u ire s  c la th rin -d ep en d en t en d o c y to s is  an d  th e  
lo w  p H  w ith in  en d o so m es. D u rin g  u p tak e , v iru s  w as se e n  to  c o -lo c a lise  w ith  
m a rk e rs  o f  e a rly  an d  re c y c lin g  e n d o so m es, b u t  n o t w ith  m a rk e rs  o f  la te  en d o so m es 
o r  ly so so m es. T h is  im p lica te s  o n e  o f  th e  tw o  fo rm e r co m p artm en ts  a s  p o ss ib le  s ite s  
o f  F M D V  in fec tio n . T h is  w a s  su p p o rte d  b y  th e  o b se rv a tio n  th a t ce ll tre a tm e n t w ith  
th e  d ru g  n o co d azo le , w h ic h  d is ru p ts  m ic ro tu b u le s  an d  in h ib its  v e s ic u la r  tra ff ick in g  
fro m  ea rly  to  la te  en d o so m es, h a d  n o  e ffe c t o n  F M D V  in fe c tio n  in  S W 4 8 0 p 6  ce lls  
(B e rry m a n  et ah, 2 0 0 5 ).
F o r  th e  w o rk  ca rrie d  o u t in  th is  th e s is , IB R S 2  c e lls  h a v e  b e e n  u sed . T h is  is  a  k id n ey  
ce ll lin e  d e riv ed  fro m  th e  n a tu ra l p o rc in e  h o s t o f  F M D V .
T h e  m a in  re c e p to r fo r  F M D V  o n  IB R S 2  c e lls  is  a V p 8. T h is  h as  b e e n  d e m o n s tra ted  
u s in g  an  a n ti-a V p 8 sp ec if ic  a n tib o d y  to  b lo c k  v im s  b in d in g  an d  in fe c tio n  (B u rm a n  et 
al, 2 0 0 6 ).
T h e  ex p e rim en ts  c a rrie d  o u t in  th is  c h a p te r  w ill p ro v id e  th e  f irs t ev id en ce  o f  the  
F M D V  c e ll en try  p a th w a y  m e d ia te d  b y  a V p 8.
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3 .2  a V p 8 " in e d ia te d  F M D V  in fe c t io n  o f  IB R S 2  cells  is d e p e n d e n t  o n  c la th r in -  
d e p e n d e n t  e n d o c y to s is
T h e  m e th o d  ch o sen  to  d e te rm in e  w h e th e r  F M D V  in fec tio n  o f  IB R S 2  ce lls  is 
d e p en d en t o n  c la th rin -d e p en d e n t en d o cy to s is  w a s  tran s ien t tra n sfe c tio n  w ith  th e  
A P I 80  C -te rm in a l (A P 1 8 0 C ). A P I 80  is  a n  a d a p to r m o lecu le , b in d in g  in o s ito l 
p o ly p h o sp h a te s  a t its  N -te rm in u s  a n d  c la th rin  a n d  A P -2  a t its  C -te rm in u s. T h is  a id s  
c la th rin  cag e  assem b ly  a n d  an ch o rs  c la th r in  to  fo rm in g  en d o cy tic  v es ic le s . O v e r­
ex p re ss io n  o f  th e  C -te rm in u s  o f  A P I  80  a lo n e  cau ses  in h ib itio n  o f  c la th rin -d ep en d en t 
en d o cy to s is  b y  seq u es te rin g  c la th r in  aw ay  fro m  th e  v es ic le s  (F o rd  et a l,  2001).
A  p la sm id  en co d in g  A P 1 8 0 C  fu se d  to  a  c -m y c  ta g  w as tran sfec ted  in to  IB R S 2  ce lls  
o n  co v erslip s . A t 6 h o rn s  p o s t- tra n sfe c tio n , th e  c e lls  w ere  in fec ted  w ith  F M D V  
0 1 K cad 2  (M O I= l)  fo r  3 h o u rs . C e lls  w e re  th e n  fix ed  an d  p ro c e sse d  fo r  
im m u n o flu o re scen ce  co n fo ca l m ic ro sco p y . A P I  80C  e x p re ss io n  w a s  d e tec ted  b y  
lab e llin g  w ith  th e  an ti-m y c  an tib o d y  9 E 1 0  a n d  a n  A lex a-4 8 8  co n ju g a te d  seco n d ary  
an tib o d y . In fec ted  ce lls  w e re  d e te c te d  b y  lab e llin g  w ith  a  ra b b it p o ly c lo n a l se ru m  
reco g n is in g  th e  F M D V  c a p s id  p ro te in s  an d  a n  A lex a-5 6 8  c o n ju g a ted  seco n d ary  
an tibody .
F ig u re  3.1 (A ) a n d  (B ) sh o w  re p re se n ta tiv e  c e lls  a t lo w  an d  h ig h  m a g n if ic a tio n  w ith  
A P 1 8 0 C  sh o w n  in  g reen  an d  F M D V  sh o w n  in  red . T h is  ex p e rim e n t sh o w ed  th a t th e  
m a jo rity  o f  A P 1 8 0 C  e x p ress in g  c e lls  a re  n o t  in fec ted  w ith  F M D V . T h is  o b se rv a tio n  
w a s  q u an tified  b y  co u n tin g  1) A P 1 8 0 C -ex p ress in g , F M D V -in fec ted  c e lls , a n d  2) 
n o n -ex p re ss in g  F M D V -in fec ted  ce lls  o n  ra n d o m ly  se lec ted  fie ld s  o f  v ie w  o n  th e
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Chapter three
A
av/38-mediated infection o f  IBRS2 cells by FMDV
B
C
Non-expressing AP180C
cells expressing cells
Total cells 3473 1417
infected cells 1031 61
%  Infected cells 30% 4%
Figure 3.1 Expression of dominant-negative AP180C inhibits FMDV infection
IBRS2 cells were transfected with an expression plasmid for AP180C fused to a c-m yc tag. At 6 
hours post-transfection the cells were infected with FM DV 01Kcad2 for 3 hours. Cells were fixed 
with paraformaldehyde, permeablised with Triton X -100 and labelled with an anti-myc antibody 
(9E10) and an Alexa 488nm conjugated secondary antibody (green). FMDV was labelled with rabbit 
polyclonal serum recognising the FM DV capsid proteins and an Alexa 568nm conjugated secondary 
antibody (red). Cell nuclei were stained with DAPI and are shown in blue. Bars=10pm.
Panel A shows a representative image o f  AP180C transfected cells infected with FMDV.
Panel B shows a higher power image. The majority o f  AP180C expressing cells are not infected by 
FMDV. Panel C shows quantification o f  these observations. A reduction in FM DV infection in 
AP180C expressing cells o f  approximately 87% was seen when compared to the non-expressing cells.
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co n fo ca l m ic ro sco p e . F ig u re  3.1 (C ) sh o w s th a t  c e lls  ex p re ss in g  A P 1 8 0 C  w e re  o n ly  
4 %  in fe c te d  (n = 1 4 1 7 ) a s  c o m p a re d  to  3 0 %  in  n o n -ex p ress in g  c e lls  (n = 3 4 7 3 ). T h is  
c o rre sp o n d s  to  a n  in h ib itio n  o f  ~ 8 7 % . T h is  in d ic a te s  th a t F M D V  re q u ire s  c la th rin - 
d e p e n d e n t en d o c y to s is  fo r  a V p 8-m e d ia te d  in fe c tio n  o f  IB R S 2  cells .
3 .3  a V p 8 -m e d ia te d  F M D V  in fe c tio n  o f  IB R S 2  ce lls  is d e p e n d e n t  o n  e n d o s o m a l 
a c id if ic a t io n
F M D V  in fe c tio n  o f  S W 4 8 0 p 6  c e lls  re q u ire s  a  lo w  p H  step  (B e rry m a n  et a l, 20 0 5 ) 
a n d  is  in h ib ite d  b y  ce ll tre a tm e n t w ith  c o n c a n a m y c in  A  w h ic h  ra ise s  e n d o so m a l p H  
b y  in h ib itin g  th e  v a c u o la r  F T -A T P ase  re sp o n s ib le  fo r  ac id if ic a tio n  o f  th e  en d o so m e 
(W o o  et a l,  1992). IB R S 2  c e lls  in  9 6 -w e ll p la te s  w e re  tre a te d  w ith  1 p M  
co n c a n a m y c in  A  u s in g  th re e  d iffe re n t tre a tm e n ts ; 1) th e  d ru g  w a s  a d d e d  to  th e  ce lls  
fo r  30  m in u te s  p r io r  to  in c u b a tio n  w ith  F M D V  0 1 K cad 2  a n d  re m a in e d  p re se n t 
th r o u g h o u t th e  1 h o u r  in c u b a tio n  w ith  v iru s . T h e  ce lls  w ere  th e n  w a sh e d  to  rem o v e  
e x c e ss  v im s  an d  in fe c tio n  w a s  a llo w e d  to  c o n tin u e  fo r  a  fu rth e r 4  h o u rs  a t 3 7 °C ; 2) 
th e  ce lls  w e re  tre a te d  a s  a b o v e  b u t  th e  d ru g  re m a in e d  p re se n t th ro u g h o u t th e  assay ; 
3 ) th e  d ru g  w a s  ad d ed  a f te r  th e  v im s  in o c u lu m  w a s  rem o v ed  an d  re m a in e d  p re sen t 
th ro u g h o u t th e  re s t  o f  th e  assay . In fe c tio n  w a s  q u an tif ied  b y  E L Isp o t in fe c tio n  assay  
(B e rry m an  et a l,  2 0 0 5 ). A n  an ti-3  A  an tib o d y  w as  u sed  to  lab e l F M D V  in fec ted  
c e lls , fo llo w e d  b y  a  b io tin y la te d  s e c o n d a ry  an tib o d y  an d  s trep tav ad in -co n ju g a ted  
a lk a lin e  p h o sp h a ta se  (see  c h a p te r  tw o , se c tio n  2 .4 .1 ). O n  a d d itio n  o f  en zy m e 
su b stra te  th e  in fec ted  c e lls  a re  s ta in e d  b lu e /b lack . O n  fig u res  3 .2  an d  3.3 th e  
n u m b e rs  o n  e a c h  p a n e l (p an e l A ) o r  b e lo w  th e  bar s (p an e l B ) in d ic a te  th e  ce ll 
tre a tm e n t w ith  co n c a n a m y c in  A  as d e sc rib e d  ab o v e .
Chapter three av/38-mediated infection o f  IBRS2 cells by FM DV
66
Chapter three avfiS-mediated infection o f  IBRS2 cells by FMDV
67
Chapter three avf$8-mediated infection o f  IBRS2 cells by FMDV
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Figure 3.2 Coucanamycin A inhibits FMDV infection
IBRS2 cells in a 96-w ell plate were incubated with FM DV 01Kcad2 for 1 hour at 37°C. The cells 
were washed to remove excess virus and infection was allowed to continue for a further 4 hours.
Cells were treated with 1 pM concanamycin A  either:
1) The drug was added to the cells for 30 minutes prior to incubation with FM DV 01Kcad2 and 
remained present throughout the 1 hour incubation with virus.
2) The cells were treated as above but the drug remained present throughout the assay
3) The drug was added after the virus inoculum was removed and remained present throughout the 
rest o f  the assay.
An anti-3 A antibody was used to label infected cells (see chapter two, section 2 .4 .1) follow ed by a 
biotinylated secondary antibody and streptavadin-conjugated alkaline phosphatase. On addition o f  die 
enzyme substrate, infected cells are stained blue/black. Numbers o f  infected cells were quantified 
using an ELIspot plate reader (see chapter two section 2.4 .1)
Panel A shows representative images o f  w ells read by the ELIspot reader at 2.5X  magnification. The 
number on each panel refers to the drug treatments described above. Each experiment was carried out 
in triplicate w ells, and on three separate occasions. Panel B shows mean infected cells +/- one 
standard deviation. On die figure, the number o f  infected cells in the drug treated w ells is expressed 
as a percentage o f  the number o f  infected cells in the mock-treated w ells (i.e. no drug treatment). 
‘Background’ refers to uninfected cells processed through the assay.
Concanamycin A inhibits FMDV infection by over 80% when cells were pre-treated with the drug, or 
in its presence throughout the experiment (treatment 1 and 2). The addition o f  concanamycin A after 
the virus inoculum had been removed has little effect on infection.
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F ig u re  3 .2  (A ) sh o w s a n  e x a m p le  o f  E L Isp o t w e ll im ag es  a t 2 .5 X  m ag n ifica tio n . 
B la c k  d o ts  re p re se n tin g  in fe c te d  ce lls  w e re  c o u n te d  b y  th e  E L Isp o t read er. E ach  
ex p e rim e n t w a s  ca rr ie d  o u t  in  tr ip lic a te  w e lls , a n d  o n  th re e  sep a ra te  o ccas io n s . T h is  
is  re p re se n te d  in  f ig u re  3 .2  (B ). O n  th e  f ig u re , th e  n u m b er o f  in fe c te d  ce lls  in  th e  
d ru g  tre a te d  w e lls  is  e x p re ssed  a s  a  p e rc e n ta g e  o f  th e  n u m b e r o f  in fe c te d  ce lls  in  th e  
m o c k -tre a ted  w e lls  (i.e . n o  d ru g  tre a tm e n t) . T h e se  re su lts  sh o w  th a t  co n can am y c in  
A  in h ib its  F M D V  in fe c tio n  b y  o v e r  8 0 %  w h e n  th e  ce lls  w e re  p re - tre a ted  w ith  th e  
d ru g , o r  w h e n  it  is  p re se n t th r o u g h o u t th e  e x p e rim e n t ( trea tm en ts  1 a n d  2, see  
ab o v e). In  c o n tra s t, w h e n  th e  d ru g  is  a d d e d  a f te r  th e  v im s  in o c u lu m  w a s  re m o v ed  
(trea tm en t 3), in fe c tio n  w a s  n o t in h ib ited . T h e se  d a ta  in d ica te  th a t a  lo w  p H  s tep  is 
re q u ire d  fo r  a n  ea rly  e v e n t in  in fec tio n , b u t  n o t  fo r  in trace llu la r v iru s  rep lica tio n .
3 .4  « V p 8 -m e d ia te d  F M D V  in fe c tio n  o f  IB R S 2  ce lls  is  n o t  d e p e n d e n t  o n  a n  in ta c t  
m ic r o tu b u le  n e tw o r k
A  re q u ire m e n t fo r  th e  m ic ro tu b u le  n e tw o rk  d u rin g  in fec tio n  h a s  b e e n  sh o w n  fo r a  
n u m b e r o f  v iru se s  in c lu d in g  h e rp e s  s im p le x  v iru s  (H S V ) (S o d e ik  et a l , 1997), 
h u m a n  im m u n o d e fic ien cy  v iru s  (H IV ) (M c D o n a ld  et a l,  2 0 0 2 ), ad e n o v iru s  (A d) 
(S u o m a la in e n  et a l,  1999), s im ia n  v iru s  4 0  (S V 4 0 ) (P e lk m an s et a l,  2 0 0 1 ) and  
in flu e n z a  v iru s  (S am p a io  et a l,  2 0 0 5 ). T h e se  v iru se s  a ll req u ire  tra ff ic k in g  to  th e  
n u c leu s  fo r  re p lica tio n , a  p ro c e ss  d e p e n d e n t o n  in ta c t m ic ro tu b u le s . H o w ev e r, 
v a c c in ia  v iru s  (V V ) re p lic a te s  in  c y to p la sm ic  v ira l fac to rie s  an d  a lso  req u ire s  
m ic ro tu b u le s  (C a rte r  et a l , 2 0 0 3 ). A n  in ta c t m ic ro tu b u le  n e tw o rk  is  re q u ire d  fo r 
vesicu lar' tra ff ic k in g  fro m  e a rly  to  la te  e n d o so m e s  (D e  B ra b a n d e r et a l , 1988). 
a V (36-m ed ia ted  in fe c tio n  o f  S W 4 8 0  ce lls  d o e s  n o t  req u ire  v iru s  tra n sp o rt to  la te  
en d o so m a l co m p artm en ts  an d  th e re fo re  d o e s  n o t  req u ire  in ta c t m ic ro tu b u le s  an d  is
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n o t in h ib ited  b y  n o co d azo le . N o c o d a z o le  d is ru p ts  th e  m ic ro tu b u le  n e tw o rk  by  
d ep o ly m eris in g  tu b u lin  (B o m se l et a l,  1990; G ru en b e rg  et a l,  1989).
IB R S 2  ce lls  in  9 6 -w e ll p la te s  w e re  p re -tre a ted  w ith  10p M  n o c o d a z o le  u s in g  th e  
sam e  ce ll- trea tm en ts  as d esc rib e d  a b o v e  fo r  co n can am y cin ; 1) th e  d ru g  w a s  a d d e d  to  
th e  ce lls  fo r  30  m in u te s  p r io r  to  in c u b a tio n  w ith  F M D V  0 1 K cad 2  an d  rem a in ed  
p re se n t th ro u g h o u t th e  1 h o u r  in c u b a tio n  w ith  v iru s . T h e  ce lls  w e re  th e n  w a sh e d  to  
re m o v e  ex cess  v im s  a n d  in fec tio n  w a s  a llo w ed  to  co n tin u e  fo r  a  fu rth e r  4  h o u rs  a t 
3 7 °C ; 2 ) th e  ce lls  w e re  tre a te d  a s  a b o v e  b u t th e  d ru g  rem a in ed  p re se n t th ro u g h o u t 
th e  a ssay ; 3 ) th e  d ru g  w a s  a d d e d  a fte r  th e  v im s  in o cu lu m  w as  re m o v e d  a n d  rem a in ed  
p re se n t th r o u g h o u t th e  re s t  o f  th e  a ssay . T h e  n u m b e r  o f  in fec ted  c e lls  w as  th e n  
q u an tif ied  u s in g  th e  E L Isp o t a ssay  as d e sc rib ed  ab o v e . D ism p tio n  o f  th e  
m ic ro tu b u le  n e tw o rk  w a s  v e rif ied  b y  im m u n o flu o re scen ce  la b e llin g  o f  tu b u lin  (d a ta  
n o t sh o w n ). F ig u re  3 .3 (A ) sh o w s a n  e x a m p le  o f  E L Isp o t w e ll im ag es  a t 2 .5 X  
m ag n ifica tio n . F ig u re  3 .3 (B ) sh o w s th e  n u m b e r o f  in fec ted  ce lls  in  th e  d ru g  trea ted  
w e lls  a s  a  p e rc e n ta g e  o f  th e  n u m b e r  o f  in fe c te d  ce lls  in  th e  m o c k -tre a ted  w e lls  (i.e. 
n o  d ru g  trea tm en t). T h e se  e x p e rim en ts  sh o w  th a t a t w h ic h e v e r s tag e  n o c o d a z o le  w as 
ad d ed , th e re  is  n o  s ig n if ican t e ffe c t o n  in fec tio n . T h is  su g g es ts  th a t F M D V  in fec tio n  
o f  IB R S 2  ce lls  d o es n o t re q u ire  th e  m ic ro tu b u le  n e tw o rk  an d  im p lie s  th a t v im s  d o es 
n o t tra ff ic  to  la te  en d o so m es  d in in g  en try .
3 .5  D isc u ss io n
T h e  e a rly  ev en ts  in  en try  o f  F M D V  in to  S W 4 8 0 p 6  ce lls  (m ed ia ted  b y  a V P 6) h av e  
b e e n  d o cu m en ted  p re v io u s ly  (B e rry m a n  et a l, 2 0 0 5 ). In  ch ap te r  th ree , th e  firs t 
ev id en ce  fo r  th e  ce ll-en try  p a th w a y  o f  F M D V  m e d ia te d  b y  a V p 8 is  desc rib ed . In
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Figure 3.3 Nocodazole does not inhibit FMDV infection
IBRS2 cells in a 96-w ell plate were incubated with FMDV 01Kcad2 for 1 hour at 37°C. The cells 
were washed to remove excess virus and infection was allowed to continue for a further 4  hours.
Cells were treated with 10 pM nocodazole either:
1) The drug was added to the cells for 30 minutes prior to incubation with FM DV 01 Kcad2 and 
remained present throughout the 1 hour incubation with virus.
2) The cells were treated as above but the drug remained present throughout the assay
3) The drug was added after the virus inoculum was removed and remained present throughout the 
rest o f  the assay.
An anti-3 A antibody was used to label infected cells (see chapter two section 2 .4 .1), follow ed by a 
biotinylated secondary antibody and streptavadin-conjugated alkaline phosphatase. On addition o f  the 
enzyme substrate, infected cells are stained blue/black. Numbers o f  infected cells were quantified 
using an ELIspot plate reader (see chapter tw o section 2.4.1).
Panel A shows representative images o f  w ells read by the ELIspot reader at 2.5X  magnification. The 
numbers refer to the drug treatments described above. Each experiment was carried out in triplicate 
wells, and on three separate occasions. Panel B shows mean infected cells +/- one standard 
deviation. On the figure, the number o f  infected cells in the drug treated w ells is expressed as a 
percentage o f  the number o f  infected cells in the mock-treated w ells (i.e. no drug treatment). 
‘Background’ refers to uninfected cells processed through the assay.
N ocodazole appears to have little effect on infection when present at any point during the experiment. 
This means that FMDV infection is unlikely to be microtubule-dependent, and that the virus is 
unlikely to traffic from early- to late endosom es during cell entry.
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S W 4 8 0 p 6  ce lls , in h ib itio n  o f  c la th rin -d e p en d e n t en d o cy to s is  b y  o v e r-e x p re ss io n  o f  
A P 1 8 0 C  in h ib ited  F M D V  in fe c tio n  b y  - 9 0 %  (B e rry m a n  et a l, 2 0 0 5 ). In  IB R S 2  
ce lls , th e  in h ib itio n  d u e  to  A P 1 8 0 C  e x p re ss io n  w a s  - 8 7 % , su g g es tin g  th a t F M D V  
a lso  re q u ire s  c la th rin -d ep en d en t en d o c y to s is  to  in fe c t IB R S 2  cells .
D u rin g  in fe c tio n  o f  SW 480j36 ce lls , F M D V  en te rs  ea rly  en d o so m es. F ro m  here , 
v iru s  tra ff ic s  to  re c y c lin g  e n d o so m es b u t  n o t to  la te  en d o so m es o r  ly so so m es.
H en ce , d is ru p tio n  o f  th e  m ic ro tu b u le  n e tw o rk  b y  n o co d azo le  h a d  n o  e ffe c t o n  
in fe c tio n  o f  SW 480(36. T h e  ex p e rim e n ts  in  c h a p te r  th ree  sh o w  th a t in fe c tio n  o f  
IB R S 2  ce lls  is  a lso  n o t in h ib ite d  b y  n o c o d a z o le , su g g es tin g  th a t m ic ro tu b u le s  a re  n o t 
req u ire d  fo r  F M D V  in fe c tio n  o f  th is  c e ll line . T h is  su g g ests  th a t, a s  fo r  SW 480|36 
ce lls , F M D V  d o e s  n o t tra ff ic  to  la te  e n d o so m es o r  ly so so m es d in in g  e n try  an d  th a t 
in fe c tio n  p ro b a b ly  o ccu rs  fro m  w ith in  e a rly  o r  re c y c lin g  en d o so m es.
C e ll tre a tm e n t w ith  co n c a n a m y c in  A  (w h ic h  ra ise s  en d o so m a l p H ) a lso  in h ib its  
in fe c tio n  o f  S W 4 8 0 p 6  ce lls , d e m o n s tra tin g  th a t F M D V  in fec tio n  re q u ire s  a  lo w  p H  
step . B lo ck in g  en d o so m a l a c id if ic a tio n  d id  n o t  in te rfe re  w ith  su rface  ex p re ss io n  o f  
a v p 6, v im s  b in d in g  to  th e  c e lls , u p ta k e  o f  th e  v iru s  in to  en d o so m es o r  cy to p la sm ic  
v iru s  rep lica tio n , su g g es tin g  th a t th e  lo w  p H  w ith in  en d o so m es is  req u ired  fo r cap sid  
d isa ssem b ly  a n d  d e liv e ry  o f  v R N A  a c ro ss  th e  e n d o so m a l m em b ran e  in to  th e  cy toso l. 
T h e  w o rk  d esc rib ed  in  c h a p te r  th re e  sh o w s th a t in fe c tio n  o f  IB R S 2  c e lls  is  a lso  
in h ib ited  b y  co n c a n a m y c in  A  w h ic h  su g g es ts  th a t, a s  fo r S W 4 8 0 p 6 , th e  p rev a ilin g  
lo w  p H  w ith in  en d o so m es  is  re q u ire d  fo r  c a p s id  d isa ssem b ly  a n d  d e liv e ry  o f  v R N A  
in to  th e  cy to so i.
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T o  co n c lu d e , th e  w o rk  d e sc rib e d  in  th is  c h a p te r  is  th e  f irs t to  d o c u m e n t th e  F M D V  
ce ll e n try  p a th w a y  m e d ia te d  b y  a V p 8. T h e se  s tu d ie s  sh o w  th a t tire ea rly  ev en ts  in  
a V p  8-m ed ia ted  in fe c tio n  o f  IB R S 2  ce lls  b y  F M D V  are  s im ila r to  th o se  o b se rv ed  in  
a V p 6-ex p re ss in g  S W 4 8 0  c e lls  a s  in fe c tio n  is  d e p e n d e n t o n  e la th rin -d ep en d en t 
en d o cy to s is  an d  th e  lo w  p H  w ith in  en d o so m es  b u t d o es n o t re q u ire  a n  in tac t 
m ic ro tu b u le  netw ork .
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Chapter four: Effects of rab GTPases on vesicular trafficking
4.1 I n t r o d u c t io n
T h e  d a ta  p re se n te d  in  c h a p te r  th re e  c o n firm s  th a t in fe c tio n  o f  IB R S 2  ce lls  b y  F M D V  
is  d ep e n d e n t o n  c la th rin -d e p en d e n t en d o c y to s is  a n d  th e  lo w  p H  w ith in  en d o so m es 
b u t d o es  n o t req u ire  a n  in ta c t m ic ro tu b u le  n e tw o rk . T h is  is  in  a g re e m e n t w ith  
p u b lish ed  o b se rv a tio n s  c o n c e rn in g  F M D V  in fe c tio n  o f  S W 4 8 0  ce lls  e x p re ss in g  
a V p 6 (B e rry m an  et al., 2 0 0 5 ). T o  fu r th e r  in v es tig a te  th e  ro u te  ta k e n  b y  F M D V  
d in in g  in fe c tio n  o f  IB R S 2  ce lls , d o m in a n t-n e g a tiv e  ra b  G T P ases  w ill b e  u sed .
R a b  G T P ases  a re  in v o lv ed  in  v e s ic u la r  tra ff ic k in g  b e tw een  d iffe re n t en d o cy tic  
co m p artm en ts  (Z eria l &  M cB rid e , 2 0 0 1 ). T h e y  a re  en rich ed  in  sp ec ific  m em b ran e  
v e s ic le s  an d  a re  in v o lv e d  in  e n d o so m e  fo rm a tio n , m o v em en t an d  d o ck in g  w ith  ta rg e t 
v es ic le s . A s w ith  a ll G T P ases , th e y  cy c le  b e tw e e n  ac tiv e , G T P -b o u n d  an d  in ac tiv e , 
G D P -b o u n d  fo rm s (see  c h a p te r  o n e , se c tio n  1.5). R ab5  is  in v o lv e d  in  th e  fo rm a tio n  
o f  e a rly  en d o so m es. R ab 4  an d  r a b l  1 a re  re q u ire d  fo r  fa s t a n d  s lo w  re c y c lin g  o f  
recep to rs  to  th e  ce ll su rface , re sp ec tiv e ly . R ab 9  co n tro ls  vesicular* tra ff ic k in g  fro m  
th e  la te  en d o so m e to  th e  G o lg i. R ab 7  is  in v o lv ed  in  v e s icu la r  tra ff ic k in g  fro m  early  
e n d o so m es to  la te  en d o so m es  an d  ly so so m e s  (see  ch ap te r  o n e , sec tio n  1.5). 
D o m in an t-n eg a tiv e  fo rm s  o f  each  o f  th e se  ra b  G T P ases  h av e  b e e n  u se d  to  s tu d y  
v e s ic u la r  tra ff ick in g  th ro u g h  th e  en d o so m a l p a th w a y  an d  th e ir  e ffe c ts  h a v e  b e e n  w e ll 
ch a rac te rised . T h e re  a re  tw o  d iffe re n t m u ta tio n s  u se d  to  c rea te  d o m in an t-n eg a tiv e  
ra b  p ro te in s . T h e  fir s t is  a  su b s titu tio n  o f  a sp a rag in e  fo r  e ith e r se rin e  o r  th reo n in e  in  
th e  G K T /S  re g io n  (rab S /T -N ), re su ltin g  in  a n  in c rea sed  a ffin ity  o f  th e  ra b  p ro te in  fo r 
G D P  ra th e r  th a n  G T P  (F e ig  &  C o o p er, 1988). T h is  cau ses  th e  ra b  p ro te in  to  be
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p re d o m in a n tly  G D P  b o u n d  a n d  th e re fo re  in ac tiv e . T h e  seco n d  d o m in an t-n eg a tiv e  is 
c re a te d  b y  a  m u ta tio n  o f  N -I  in  th e  N K X D  n u c le o tid e  b in d in g  re g io n  (rab N -I) w h ich  
ren d e rs  th e  p ro te in  u n a b le  to  b in d  n u c le o tid e s  an d  a g a in  in ac tiv e  (P a i et al., 1989). 
A n o th e r m u ta tio n  c re a te s  a  c o n s titu tiv e ly  ac tiv e  ra b  p ro te in , leu c in e  to  g lu tam in e  in  
th e  W D T A G Q E  re g io n  (rab Q -L ). T h is  in h ib its  th e  in trin s ic  G T P ase  a c tiv ity  o f  th e  
ra b  p ro te in  an d  cau ses it  to  b e c o m e  lo c k e d  in  its  ac tiv e  s ta te  (D e r et al., 1986).
T h e  w ild -ty p e  ra b  p ro te in s  a re  en ric h e d  in  th e  m em b ran es  o f  o n e  o r  m o re  ce llu la r 
co m p a rtm e n ts  an d  sh o u ld  c o -lo ca lise  w ith  sp ec if ic  m ark e rs  o f  th e se  co m p artm en ts . 
E x p re ss io n  o f  d o m in an t-n eg a tiv e  ra b  G T P ases  sh o u ld  in h ib it v e s ic le  tra ffick in g  a t 
th e  sp ec ific  s tag e  a t w h ic h  th e  w ild -ty p e  ra b  p ro te in  n o rm a lly  acts.
R ab 5  is  fo u n d  o n  e a rly  e n d o so m e s  a n d  w o u ld  b e  ex p ec ted  to  co -lo c a lise  w ith  
m a rk e rs  o f  th is  c o m p artm en t, su c h  a s  e a r ly  en d o so m a l a n tig e n -1 (E E A -1 ) (M u  et al., 
1995). T h e  d o m in an t-n eg a tiv e  fo rm  o f  rab 5  w o u ld  b e  ex p ec ted  to  b lo c k  fo rm a tio n  
o f, a n d  lig an d  (e .g . tra n s fe rr in  a n d  lo w -d e n s ity  lip o p ro te in ) tra ff ic k in g  th ro u g h , th e  
ea rly  e n d o so m e  (B u cc i et al., 1992).
R a b 4  an d  r a b l  1 a re  b o th  fo u n d  o n  ea rly - an d  rec y c lin g  en d o so m es an d  w o u ld  be  
ex p e c te d  to  co -lo ca lise  w ith  b o th  E E A 1 an d  th e  tr an sfe rr in  recep to r, a  m a rk e r  fo r 
re c y c lin g  en d o so m es. D o m in a n t-n e g a tiv e  fo rm s o f  th e se  ra b s  w o u ld  b e  e x p ec ted  to  
b lo c k  rec y c lin g  o f  tra n sfe rr in  to  th e  ce ll su rface  (v a n  d e r S lu ijs  et al., 1 9 9 2 )(U llrich  
etal., 1996).
R ab 7  is  p red o m in an tly  fo u n d  o n  la te  e n d o so m e s  a n d  ly so so m es, w ith  so m e  also  
b e in g  fo u n d  o n  ea rly  e n d o so m e s  (M eresse  et a l,  1995). M ark e rs  fo r  la te  en d o so m es 
an d  ly so so m es in c lu d e  th e  ly so so m e -a sso c ia te d  m em b ran e  p ro te in s  (L A M P s) an d
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th e  m a n n o se  6-p h o sp h a te  re c e p to r (C I-M P R ). D o m in an t-n eg a tiv e  ra b 7  w o u ld  be 
ex p ec ted  to  in h ib it t ra ff ic k in g  o f  lig an d s  su c h  a s  L D L  fro m  ea rly  e n d o so m e s  to  la te  
en d o so m es an d  ly so so m es (V ite lli e ta l,  1997).
R ab 9  co n tro ls  v e s ic u la r  tra ff ic k in g  fro m  la te  en d o so m es to  th e  G o lg i. I t w o u ld  be 
ex p ec ted  to  co -lo ca lise  w ith  C I-M P R  an d  G o lg i m ark ers  su c h  a s  G M 1 3 0  an d  
G M 1 3 0  (L o m b ard i e ta l , 1993).
T h e  e ffec ts  o f  d o m in an t-n eg a tiv e  rab 4 , 5 , 7 , 9  an d  11 ex p re ss io n  o n  v e s ic u la r  
tra ff ic k in g  w e re  d e te rm in ed  b y  tra n s ie n t e x p re ss io n  o f  w ild -ty p e  a n d  d o m in an t- 
n e g a tiv e  ra b  p ro te in s  fu se d  to  e n h an ced  g re e n  f lu o re scen t p ro te in  (E G F P ) in  IB R S 2  
ce lls . T h e  ce lls  w e re  tra n sfe c te d  w ith  m a m m a lia n  ex p re ss io n  p la sm id s  co n ta in in g  
th e  rab -E G F P  fu s io n  an d  th e  c e llu la r  lo c a tio n  o f  th e  rab  p ro te in , a n d  its  e ffec t o n  
v e s ic u la r  tra ffick in g , w e re  d e te rm in ed  b y  im m u n o flu o re scen ce  co n fo ca l m ic ro sco p y . 
S p ec ific  ce llu la r co m p artm en ts  w e re  id e n tif ie d  b y  lab e llin g  w ith  an tib o d ie s  to  
p ro te in s  fo u n d  p re d o m in a n tly  o n  o n e  p a rtic u la r  v esic le .
4 .2  E x p re s s io n  o f  E G F P - r a b  fu s io n  p r o te in s  in  IB R S 2  cells
T h e  m am m a lia n  ex p re ss io n  p la sm id s  u se d  in  th is  s tu d y  en co d e  ra b  p ro te in s  fu sed  to  
E G F P . I t  w as  im p o rtan t to  v e rify  th a t th e  rab  p ro te in s  w e re  n o t  c le a v e d  fro m  E G F P  
w h e n  th e  fu s io n  p ro te in  is  e x p re ssed  in  ce lls . IB R S 2  ce lls  w e re  tra n s fe c te d  w ith  
e ach  ex p re ss io n  p la sm id  an d  in c u b a te d  a t 3 7 °C  fo r  6 h o u rs . T h e  c e ll ly sa te s  w ere  
an a ly sed  b y  w e s te rn  b lo ttin g  u s in g  a n  an ti-E G F P  a n tib o d y  (see  c h a p te r  tw o , sec tio n  
2 .8 ). F ig u re  4.1 sh o w s a  w e s te rn  b lo t o f  th e  ra b  m u tan ts  u se d  in  th is  study . T h e  size  
o f  E G F P  a lo n e  is  2 7 k D a  an d  w h e n  fu se d  to  ra b  p ro te in s  sh o u ld  b e  b e tw e e n  4 6 k D a  
an d  53 k D a , d ep en d in g  o n  th e  s ize  o f  th e  ra b  p ro te in .
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F ig u re  4.1 in d ica te s  th a t th e re  is  little  c le av ag e  o f  E G F P  fro m  th e  ra b  p ro te in  in  
IB R S 2  ce lls  as th e re  is  a  s tro n g  b a n d  a t a ro u n d  50  k D a  in  e a c h  c a se  b u t  a t a ro u n d  
3 0 k D a  th e re  is  e ith e r  a  fa in t b a n d  o r  n o n e  a t a ll. T h is  d a ta  sh o w s th a t w h en  E G F P  is 
d e tec ted  in  IB R S 2  ce lls  b y  co n fo ca l m ic ro sc o p y , i t  c a n  b e  a ssu m ed  th a t i t  is  as  a  
fu s io n  p ro te in  w ith  th e  ra b  G T P ase  o f  in te res t.
4 .3  C h a r a c te r i s a t io n  o f  w ild - ty p e , d o m in a n t-n e g a t iv e  a n d  c o n s ti tu t iv e ly  a c tiv e  
r a b S
T h ree  rab 5  c o n stru c ts  w e re  u se d  in  th is  s tu d y : w ild -ty p e  rab 5  (w trab 5 ), d o m in an t- 
n e g a tiv e  ra b 5 -S 3 4 N  (d n rab 5 ) an d  c o n s titu tiv e ly  ac tiv e  rab 5 -Q 7 9 L  (ca rab 5 ). A ll 
w e re  fu se d  to  E G F P . T h e se  p la sm id s  w e re  o b ta in e d  fro m  a  re se a rc h  g ro u p  w h o  u se d  
th e m  to  s tu d y  tra ff ic k in g  o f  G  p ro te in -c o u p le d  re c e p to rs  (G P C R s) (S e a c h iis t &  
F e rg u so n , 2 0 0 3 ). R ab 5  c o n tro ls  fo rm a tio n  o f  ea rly  en d o so m es, an d  w trab 5  sh o u ld  
lo ca lise  to  th is  co m p artm en t.
4 .3 .1  R a b 5  a n d  e a r ly  e n d o s o m a l a n t ig e n  1 (E E A 1 )
E a rly  en d o so m a l a n tig e n  1 (E E A 1 ) is  a  sp ec ific  m a rk e r  fo r  e a rly  en d o so m es. IB R S 2  
ce lls  w e re  tra n sfe c te d  w ith  e x p re ss io n  p la sm id s  fo r  w trabS , dn rab 5  o r  carabS  fu sed  
to  E G F P  (g reen ). A t 6 h o u rs  p o s t- tra n sfe c tio n  th e  ce lls  w e re  fix e d  w ith  
p a ra fo rm a ld eh y d e , p e rm e a b lise d  w ith  T r ito n  X -1 0 0  and  lab e lled  w ith  a  m o n o c lo n a l 
a n tib o d y  to  e a rly  e n d o so m a l an tig e n  1 (E E A -1 ), c o n ju g a ted  w ith  a n  A le x a  5 6 8 n m  
seco n d ary  a n tib o d y  (red ).
F ig u re  4 .2  sh o w s th e  e x p re ss io n  p a tte rn  o f  w trab 5  an d  E E A 1. P a n e l A  sh o w s th a t 
E E A 1 lab e llin g  is  s im ila r  in  ce lls  ex p re ss in g  w trabS  as in  n o n -e x p re ss in g  ce lls .
Chapter four Effects o f  rab GTPases on vesicular trafficking
79
Figure 4.2. Immunofluorescence confocal microscopy showing co-localisation of
wild-tvpe rab5 (wtrab5-EGFP) with early endosomes.
A
c
*
IBRS2 cells were transfected with an expression plasmid for wtrab5 fused to EGFP(green). At 6 
hours post-transfection the cells were fixed with paraformaldehyde, permeablised with Triton X -100  
and labelled with a monoclonal antibody to early endosomal antigen 1(EEA-1); a marker for early 
endosomes and an Alexa 568nm conjugated secondary antibody (red). Cell nuclei were stained with 
DAPI and are shown in blue. Bars=10pm.
Panel A  show s labelling for EEA-1 (red),
Panel B show s wtrab5-EGFP (green)
Panel C  is an overlay o f  panels A  and B show ing co-loca lisation  o f  EEA1 and wtrab5 (ye llow ).
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P a n e l C  sh o w s th a t as  ex p ec ted , w trab 5  co -lo c a lise s  w ith  E E A 1 , in d ic a tin g  th a t rab5  
is  lo ca lised  to  e a rly  e n d o so m e s  an d  th e  p re se n c e  o f  th e  G F P  ta g  d o e s  n o t a ffec t th is  
lo ca lisa tio n .
F ig u re  4 .3 , p an e l B  sh o w s th a t d n rab 5  is  m a in ly  cy to so lic  w ith  a  d iffu se  p a tte rn . 
P an e ls  A  an d  D  sh o w  th a t E E A 1 la b e llin g  in  d n rab 5  ex p re ss in g  c e lls  is  m ark ed ly  
re d u c e d  (a rro w h ead s) co m p ar ed  to  n o n -e x p re ss in g  ce lls  (a rro w s). T h is  in d ica te s  th a t 
e x p re ss io n  o f  dn rab5  in h ib its  th e  b io g e n e s is  o f  ea rly  en d o so m es.
F ig u re  4 .4 , p an e l A  sh o w s th a t e x p re ss io n  o f  carab 5  cau ses  fo rm a tio n  o f  
c h a rac te ris tic  en la rg e d  e n d o so m es. T h e  n o n -e x p re ss in g  ce ll h a s  a  n o rm a l p a tte rn  o f  
E E A 1 d is trib u tio n . P an e l C  sh o w s th a t  carab 5  an d  E E A 1 co -lo ca lise , p ro v id in g  
fu rth e r  ev id en ce  th a t rab 5  is  lo c a lise d  to  ea rly  en d o so m es.
4 .3 .2  R a b 5  a n d  t r a n s f e r r i n  r e c e p to r  (T fR )
T h e  tra n s fe rr in  re c e p to r  (T fR ) is  a  m a rk e r  fo r  ea rly - an d  rec y c lin g  en d o so m es.
IB R S 2  ce lls  w e re  tra n sfe c te d  w ith  e x p re ss io n  p la sm id s  fo r w trab 5 , d n rab 5  o r  carab5  
fu se d  to  E G F P  (g reen ). A t 6 h o rn s  p o s t- tra n s fe c tio n  th e  ce lls  w e re  f ix e d  w ith  
p a ra fo rm a ld eh y d e , p e im e a b lise d  w ith  T r ito n  X -1 0 0  an d  la b e lle d  w ith  a  m o n o c lo n a l 
an tib o d y  to  tra n s fe rr in  re c e p to r  (T fR ), co n ju g a te d  w ith  a n  A le x a  5 6 8 n m  seco n d ary  
an tib o d y  (red ).
F ig u re  4 .5  sh o w s th e  e x p re ss io n  p a tte rn  o f  w trab 5  an d  T fR . P a n e l C  sh o w s th a t 
w trab 5  co -lo c a lise s  w ith  T fR , p re su m a b ly  d u e  to  th e  p re sen ce  o f  so m e  T fR  o n  ea rly  
en d o so m es. U n lik e  E E A -1 , n o t  a ll th e  T fR  is  lo c a lise d  w ith  w trab 5 , th e  rem a in d e r 
lik e ly  to  b e  lo ca ted  o n  re c y c lin g  en d o so m es.
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Figure 4.3. Immunofluorescence confocal microscopy showing inhibition of early
endosome biogenesis in dominant-negative rab5 (dnrab5-EGFP) expressing cells
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IBRS2 cells were transfected with an expression plasmid for dnrab5 fused to EGFP(green). At 6 
hours post-transfection the cells were fixed with paraformaldehyde, permeablised with Triton X-100  
and labelled with a monoclonal antibody to early endosomal antigen 1 (EEA-1); a marker for early 
endosomes and an Alexa 568nm conjugated secondary antibody (red). Cell nuclei were stained with 
DAPI and are shown in blue. Bars=10gm.
Panels A and D show labelling for EEA-1 (red),
Panels B and E show dnrab5-EGFP (green)
Panel C is an overlay o f  panels A and B. Panel F is an overlay o f  panels D and E. Both show that 
dnrab5 expressing cells are unable to form early endosomes.
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Figure 4.4. Immunofluorescence confocal microscopy showing co-localisation of
constitutively active rab5 (carab5-EGFP) with earlv endosomes
( %
J
over lay
IBRS2 cells were transfected with an expression plasmid for carab5 fused to EGFP (green). At 6 
hours post-transfection the cells were fixed with paraformaldehyde, permeablised with Triton X -100  
and labelled with a monoclonal antibody to early endosomal antigen 1 (EEA-1), a marker for early 
endosomes and an Alexa 568nm conjugated secondary antibody (red). Cell nuclei were stained with 
DAPI and are shown in blue. Bars=10pm.
Panel A shows labelling for EEA-1 (red),
Panel B shows carab5-EGFP (green)
Panel C is an overlay o f  panels A and B showing that cells expressing carab5 have enlarged 
endosomes and carab5 co-localises with EEA1 (yellow ).
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Figure 4.5. Immunofluorescence confocal microscopy showing co-localisation of
wild-tvpe rab5 (wtrab5-EGFP) with transferrin receptor positive compartments
A
over lay
1BRS2 cells were transfected with an expression plasmid for wtrab5 fused to EGFP(green). At 6 
hours post-transfection the cells were fixed with paraformaldehyde, permeablised with Triton X-100  
and labelled with a monoclonal antibody to transferrin receptor (TfR); a marker for early endosomes 
and recycling endosom es and an Alexa 568nm conjugated secondary antibody (red). Cell nuclei were 
stained with DAPI and are shown in blue. Bars=10pm.
Panel A  show s labelling for T fR  (red),
Panel B show s wtrab5-EGFP (green)
Panel C  is an overlay o f  panels A  and B show ing partial co-loca lisation  o f  wtrab5 and T fR  (ye llow ).
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F ig u re  4 .6 , p a n e ls  A  an d  D  sh o w  th a t th e  ex te n t o f  T fR  lab e llin g  in  dn rab5  
ex p re ss in g  ce lls  ap p ears  re d u c e d  w h e n  c o m p ared  to  n o n -ex p ress in g  ce lls . T h is  is 
p ro b a b ly  d u e  to  th e  re d u c tio n  in  ea rly  en d o so m e  b io g en esis  in  d n rab 5  ex p ress in g  
ce lls .
F ig u re  4 .7 . p an e l C  sh o w s c o -lo c a lisa tio n  o f  ca rab 5  an d  T fR . A g a in , in  ce lls  
ex p re ss in g  carab 5  a  p ro p o rtio n  o f  th e  T fR  co -lo c a lise s  w ith  rab5  o n  ea rly  
e n d o so m es. w ith  th e  re m a in d e r  lik e ly  to  b e  o n  re c y c lin g  en d o so m es.
4 .3 .3  R a b 5  a n d  m a n n o s e  6 -p h o s p h a te  r e c e p to r  (C I -M P R )
T h e  m a rk e rs  n o rm a lly  u se d  to  s tu d y  la te  e n d o so m es an d  ly so so m es a re  ly so so m al- 
a sso c ia ted  m em b ran e  p ro te in s  (L A M P s). H o w ev e r, c ro ss-reac tiv e  L A M P -1 /L A M P - 
2  an tib o d ie s  fo r  p o rc in e  (IB R S 2 ) ce lls  w e re  n o t id en tified . In s tead  th e  M a n n o se  6- 
p h o sp h a te  re c e p to r  (C I-M P R ), a lso  a  m a rk e r  fo r  la te  en d o so m es an d  ly so so m e s  w as  
u sed . IB R S 2  ce lls  w e re  tra n s fe c te d  w ith  e x p re ss io n  p la sm id s  fo r  w tra b 5 . dn rab5  o r  
carab5  fu se d  to  E G F P  (g reen ). A t 6 h o u rs  p o s t- tra n sfe c tio n  th e  ce lls  w e re  f ix e d  w ith  
p a ra fo rm a ld eh y d e , p e rm e a b lise d  w ith  T rito n  X -1 0 0  an d  lab e lled  w ith  a  m o n o c lo n a l 
a n tib o d y  to  m a n n o se  6-p h o sp h a te  re c e p to r  (C I-M P R ), co n ju g a ted  w ith  a n  A lex a  
5 6 8 n m  seco n d a ry  an tib o d y  (red ).
F ig u re  4 .8  sh o w s th e  e x p re ss io n  p a tte rn  o f  w trab 5  in  pan e l B  an d  d n rab 5  in  p an e l E . 
P an e ls  A  an d  D  sh o w  th e  p a tte rn  o f  C I-M P R  lab e llin g . T h e  o v e rlay s  in  p a n e ls  C  and  
F  sh o w  th a t, as  ex p ec ted , little  o r  n o  c o -lo c a lisa tio n  w as o b se iv e d  b e tw e e n  w trabS  o r  
d n rab 5  w ith  C I-M P R , an d  e x p re ss io n  o f  n e ith e r  fo rm  o f  rab 5  h as  a ffe c ted  th e  p a tte rn  
o f  C I-M P R  labe lling . T h is  su g g es ts  th a t  la te  en d o so m es an d  ly so so m e s  re m a in  
in ta c t in  ce lls  ex p re ss in g  dnrabS .
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Figure 4.6. Immunofluorescence confocal microscopv showing inhibition of early
endosome formation in dominant-negative rab5 (dnrab5-EGFP) expressing cells
B
C
t
IBRS2 cells were transfected with an expression plasmid for dnrab5 fused to EGFP(green). At 6 
hours post-transfection the cells were fixed with paraformaldehyde, permeabiised with Triton X -100  
and labelled with a monoclonal antibody to transferrin receptor (TfR); a marker for early endosom es 
and recycling endosom es and an Alexa 568nm conjugated secondary antibody (red). Cell nuclei were 
stained with DAPI and are shown in blue. Bars=10pm.
Panels A and D show labelling for TfR (red),
Panels B and E show dnrab5-EGFP (green)
Panel C is an overlay o f  panels A and B. Panel F is an overlay o f  panels D and E. Both show that 
dnrab5 expressing cells appear to contain fewer TfR positive compartments.
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F ig u re  4 .7 . Im m u n o flu o re scen ce  co n fo ca l m ic ro sco p y  sh o w in g  pa rtia l co ­
lo ca lisa tio n  o f  co n stitu tiv e ly  ac tiv e  rab5  (ca rab 5 -E G F P ) w ith  tran sfe rrin  recep to r 
p o s itiv e  co m p artm en ts
BA
over lay
IBRS2 cells were transfected with an expression plasmid for carab5 fused to EGFP (green). At 6 
hours post-transfection the cells were fixed with paraformaldehyde, permeablised with Triton X-100  
and labelled with a monoclonal antibody to transferrin receptor (TfR); a marker for early endosomes 
and recycling endosomes and an Alexa 568nm conjugated secondary antibody (red). Cell nuclei were 
stained with DAPI and are shown in blue. Bars=10pm.
Panel A  show s labelling for T fR  (red),
Panel B show s carab5-EG FP (green)
Panel C  is an overlay o f  panels A  and B  show ing partial co-loca lisation  o f  carab5 with T fR  (ye llow ).
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Figure 4.8. Immunofluorescence confocal microscopv showing wild-tvpe rab5
(wtrab5-EGFP) does not co-localise with late endosomes and expression of
dominant-negative rab5 (dnrab5-EGFP) does not inhibit formation of late endosomes
A I D
I!
IBRS2 cells were transfected with expression plasmids for wtrab5 and dnrab5 fused to EGFP (green). 
At 6 hours post-transfection the cells were fixed with paraformaldehyde, permeablised with Triton X- 
100 and labelled with a monoclonal antibody to mannose-6-phosphate receptor (CI-MPR); a marker 
for late endosom es and an Alexa 568nm conjugated secondary antibody (red). Cell nuclei were 
stained with DAPI and are shown in blue. Bars=10pm.
Panels A and D show labelling for CI-MPR (red),
Panel B shows wtrab5-EGFP (green) and panel E show s dnrab5-EGFP (green)
Panel C is an overlay o f  panels A and B, showing that wtrab5 does not co-localise with late 
endosomes. Panel F is an overlay o f  panels D and E, showing that expression o f  dnrab5 does not 
inhibit the biogenesis o f  late endosomes.
88
4 .3 .4  R a b 5  a n d  t r a n s f e r r in  u p ta k e
T h e  e ffe c t o f  dnrabS  ex p re ss io n  o n  u p ta k e  o f  la b e lle d  tra n sfe rr in  w as  in v estig a ted . 
T ran sfe rr in  is  a  lig an d  w h ic h  is  ta k e n  u p  b y  c la th rin -d ep en d en t en d o cy to s is  in to  early  
en d o so m es an d  re cy c led  b a c k  to  th e  p la sm a  m em b ran e  v ia  recy c lin g  en d o so m es. 
IB R S 2  ce lls  w e re  tra n sfe c te d  w ith  e x p re ss io n  p la sm id s  fo r  w trabS  o r  d n rab 5  fu sed  
to  E G F P  (g reen ). A t 6 h o u rs  p o st- tran sfec tio n , A le x a  5 6 8 n m  lab e lled  tran sfe rrin  
(red ) w a s  ta k e n  u p  in to  IB R S 2  ce lls  fo r  5 m in u te s . A t th is  tim e  p o in t th e  tran sfe rrin  
sh o u ld  b e  in  ea rly  co m p artm en ts  (early - o r  re c y c lin g  en d o so m es).
F ig u re  4 .9 , p a n e l B  sh o w s th e  w trabS  e x p ress in g  ce ll, an d  p an e l E  sh o w s th e  dnrabS  
e x p ress in g  ce ll. P an e l A  sh o w s th a t th e  ce lls  ex p re ss in g  w trab 5  h a v e  a  n o rm a l 
p a tte rn  o f  tra n sfe rr in  u p tak e , w ith  so m e  c lea rly  c o -lo c a lis in g  w ith  rab5  (p an e l C ) 
th e re fo re  in  e a rly  en d o so m es. P an e l D  sh o w s th a t c e lls  e x p re ss in g  d n rab 5  h av e  
ta k e n  u p  less  lab e lled  tra n sfe rr in  w h e n  co m p ared  to  n o n -ex p ress in g  ce lls , in d ica tin g  
th a t t ra ff ic k in g  th ro u g h  ea rly  e n d o so m es is  in h ib ited . T h is  d a ta  is  c o n s is te n t w ith  
th a t in  fig u re  4 .3 , w h ic h  sh o w s th a t c e lls  ex p re ss in g  dn rab 5  h av e  fe w e r ea rly  
en d o so m es th a n  th o se  e x p re ss in g  w trabS .
4 .4  C h a r a c te r i s a t io n  o f  w ild - ty p e  a n d  d o m in a n t-n e g a t iv e  r a b 4
T h e  m am m alian  e x p re ss io n  p la sm id s  fo r  ra b 4  u se d  in  th is  s tu d y  are  w ild -ty p e  rab4  
(w trab 4 ) an d  d o m in an t-n eg a tiv e  rab 4 -N 1 2 1 I (d n rab 4 ). B o th  a re  fu sed  to  E G F P .
R ab 4  co n tro ls  ra p id  recy c lin g  d irec tly  fro m  e a r ly  en d o so m es to  th e  p la sm a  
m em b ran e . W t ra b 4  sh o u ld  lo ca lise  to  e a rly  e n d o so m e s  an d  p o ss ib ly  recy c lin g  
endosom es.
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F ig u re  4 .9 . Im m u n o flu o re scen ce  co n fo ca l m ic ro sco p y  sh o w in g  d iffe ren ces  in  up take  
o f  lab e lled  tra n sfe rr in  in  w ild -ty p e  rab5  (w trab 5 -E G F P ) o r d o m in an t-n eg a tiv e  rab5 
(d n rab 5 -E G F P ) ex p ress in g  ce lls
DA
B
c
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IBRS2 cells were transfected with expression plasmids for wtrabS or dnrab5 fused to EGFP(green). 
At 6 hours post-transfection Alexa 568nm labelled transferrin (red) was added to the media at 
50pg/m l and allowed to internalise for 5 minutes. The cells were then fixed with paraformaldehyde. 
At this time point, the red transferrin should still be in early compartments. Cell nuclei were stained 
with DAPI and are shown in blue. Bars=10pm.
Panels A and D show labelling for transferrin (red),
Panel B shows wtrab5-EGFP (green) and panel E shows dnrab5-EGFP (green)
Panel C is an overlay o f  panels A and B, showing that uptake o f  labelled transferrin is not inhibited in 
wtrab5 expressing cells. Panel F is an overlay o f  panels D and E, showing that expression o f  dnrab5 
inhibits uptake o f  labelled transferrin.
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4.4 .1  R a b 4  a n d  e a r ly  e n d o s o m a l a n t ig e n  1 (E E A 1 )
E a rly  en d o so m a l an tig en  1 (E E A 1 ) is  a  sp ec ific  m a rk e r fo r  ea rly  en d o so m es, IB R S 2  
ce lls  w e re  tran sfec ted  w ith  e x p re ss io n  p la sm id s  fo r  w trab 4  o r  d n rab 4  fu sed  to  E G F P  
(g reen ). A t 6 h o u rs  p o s t- tra n sfe c tio n  th e  c e lls  w e re  fix e d  w ith  p a ra fo rm ald eh y d e , 
p e rm eab lised  w ith  T rito n  X -1 0 0  an d  lab e lled  w ith  a  m o n o c lo n a l a n tib o d y  to  early  
en d o so m a l a n tig e n  1 (E E A -1 ), c o n ju g a ted  w ith  a n  A le x a  5 6 8 n m  seco n d ary  an tib o d y  
(red).
F ig u re  4 .1 0  sh o w s th e  p a tte rn  o f  e x p re ss io n  o f  w tra b 4  (p an e l B ) an d  d n rab 4  (pane l 
E ). A s  ex p ec ted , p a n e l C  sh o w s th a t w tra b 4  (g reen ) p a rtia lly  co -lo ca lise s  w ith  E EA 1 
(red , p a n e l A ) in d ica tin g  th a t so m e  w trab 4  is  lo ca ted  o n  ea rly  en d o so m es. T h e  
w trab 4  th a t is  n o t co -lo ca lised  w ith  E E A 1 is  p re su m a b ly  lo ca ted  o n  recy c lin g  
en d o so m es. P an e l D  sh o w s th a t a s  ex p ec ted , ex p re ss io n  o f  dn rab 4  d o es  n o t a ffec t 
E E A 1 lab e llin g  w h e n  c o m p ared  to  n o n -e x p re ss in g  ce lls , in d ica tin g  th a t th e  in teg rity  
o f  ea rly  en d o so m es are  n o t a ffec ted  b y  d n rab 4  ex p ressio n .
4 .4 .2  R a b 4  a n d  t r a n s f e r r in  r e c e p to r  (T fR )
T h e  tra n sfe rr in  re c e p to r (T fR ) is a  sp ec ific  m a rk e r  fo r  ea rly  an d  recy c lin g  
en d o so m es. IB R S 2  ce lls  w e re  tra n sfe c te d  w ith  e x p re ss io n  p la sm id s  fo r  w trab 4  o r  
d n rab 4  fu sed  to  E G F P  (g reen ). A t 6 h o u rs  p o s t- tra n sfe c tio n  th e  ce lls  w e re  f ix e d  w ith  
p a ra fo rm a ld eh y d e , p e rm e a b lise d  w ith  T rito n  X -1 0 0  an d  lab e lled  w ith  a  m o n o c lo n a l 
an tib o d y  to  tra n sfe rr in  re c e p to r (T fR ), co n ju g a ted  w ith  a n  A le x a  5 6 8 n m  seco n d ary  
an tib o d y  (red ).
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F ig u re  4 .1 0 . Im m u n o flu o re scen ce  co n fo ca l m ic ro sco p y  sh o w in g  partia l c o ­
lo ca lisa tio n  o f  w ild -ty p e  rab4  (w trab 4 -E G F P ) w ith  early  en d o so m es and  tha t 
e x p re ss io n  o f  d o m in an t-n eg a tiv e  rab 4  (d n rab 4 -E G F P ) d o es no t a ffec t th e  in teg rity  o f  
ea rly  en d o so m es
A D
B
overlay c vferia^
IBRS2 cells were transfected with expression plasmids for wtrab4 and dnrab4 fused to EGFP (green). 
At 6 hours post-transfection the cells were fixed with paraformaldehyde, permeablised with Triton X- 
100 and labelled with a monoclonal antibody to early endosomal antigen 1 (EEA-1); a marker for 
early endosom es and an Alexa 568nm conjugated secondary antibody (red). Cell nuclei were stained 
with DAPI and are shown in blue. Bars=10pm.
Panels A and D show labelling for EEA1 (red).
Panel B shows wtrab4-EGFP (green) and panel E shows dnrab4-EGFP (green)
Panel C is an overlay o f  panels A and B, showing partial co-localisation o f  wtrab4 with early 
endosomes. Panel F is an overlay o f  panels D and E, showing that expression o f  dnrab4 does not 
affect the integrity o f  early endosomes.
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Figure 4.11. Immunofluorescence confocal microscopy showing expression pattern
of wild-type rab4 (wtrab4-EGFP) with transferrin receptor positive compartments
A n
C
overlay
IBRS2 cells were transfected with an expression plasmid for wtrab4 fused to EGFP(green). At 6 
hours post-transfection the cells were fixed with paraformaldehyde, permeablised with Triton X -100  
and labelled with a monoclonal antibody to transferrin receptor (TfR); a marker for early endosom es 
and recycling endosom es and an Alexa 568nm conjugated secondary antibody (red). Cell nuclei were 
stained with DAPI and are shown in blue. Bars=10pm.
Panels A and D show labelling for TfR (red),
Panels B and E show wtrab4-EGFP(green)
Panel C is an overlay o f  panels A and B. Panel F is an overlay o f  panels D and E. Both show that 
wtrab4 is in the same region o f  the cell as TfR positive compartments.
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la b e llin g  p a tte rn  o f  T fR  (red ) in  p a n e ls  A  a n d  D . T h e  o v erlay s (p an e ls  C  a n d  F ) 
sh o w  th a t th e  m a jo rity  o f  w trab 4  is  in  th e  sam e  re g io n  o f  th e  ce ll as  T fR , a n d  so m e is 
co -lo c a lise d  (y e llo w , p a n e ls  C  an d  F).
F ig u re  4 .1 2  sh o w s th e  e x p re ss io n  p a tte rn  o f  d n ra b 4  in  P an e l B  a n d  T fR  in  p a n e l A . 
E x p re ss io n  o f  d n rab 4  d o es n o t appear* to  h a v e  a  s ig n ifican t e ffec t o n  th e  d is tr ib u tio n  
o f  T fR  w h e n  c o m p ared  to  n o n -e x p re ss in g  ce lls . T h is  in d ica tes  th a t th e  in teg rity  o f  
re c y c lin g  en d o so m es is  n o t d ep e n d e n t o n  th e  p re se n c e  o f  a n  ac tiv e  rab4 .
4 .4 ,3  R a b 4  a n d  m a n n o s e  6 - p h o s p h a te  r e c e p to r  (C I -M P R )
M a n n o se  6-p h o sp h a te  re c e p to r  (C I-M P R ) is  a  m a rk e r  fo r  la te  e n d o so m e s  an d  
ly so so m es. IB R S 2  c e lls  w e re  tra n s fe c te d  w ith  e x p re ss io n  p la sm id s  fo r  w tra b 4  01* 
d n rab 4  fu sed  to  E G F P  (g reen ). A t 6 h o u rs  p o s t- tra n sfe c tio n  th e  ce lls  w e re  fix ed  w ith  
p a ra fo rm a ld eh y d e , p e rm e a b lise d  w ith  T rito n  X -1 0 0  an d  lab e lled  w ith  a  m o n o c lo n a l 
an tib o d y  to  m a n n o se  6-p h o sp h a te  re c e p to r  (C I-M P R ), co n ju g a ted  w ith  a n  A lex a  
5 6 8 n m  seco n d a ry  an tib o d y  (red ).
F ig u re  4 .13  sh o w s th e  e x p re ss io n  p a tte rn  o f  w tra b 4  (g reen ) in  p a n e l B  a n d  C I-M P R  
(red ) in  p a n e l A . A s  ex p ec ted , th e re  d o e s  n o t appeal* to  be  an y  c o -lo c a lisa tio n  
b e tw e e n  w trab 4  an d  C I-M P R  (p an e l C ),
F ig u re  4 .1 4  sh o w s th e  ex p re ss io n  p a tte rn  o f  d n ra b 4  (g reen ) in  p an e ls  B  an d  E  and  
C I-M P R  (red ) in  p an e ls  A  an d  D . A s  e x p ec ted , th e re  d o es n o t a p p e a r  to  b e  an y  c o ­
lo c a lisa tio n  b e tw e e n  d n rab 4  a n d  C I-M P R  (p an e ls  C  an d  F). E x p re ss io n  o f  dn rab 4  
d o es n o t a ffec t th e  d is tr ib u tio n  o f  C I-M P R  w h e n  co m p ared  to  n o n -e x p re ss in g  ce lls . 
T h is  in d ica te s  th a t d n rab 4  e x p re ss io n  is  u n lik e ly  to  a ffec t th e  in te g rity  o f  la te
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f ig u re  4 .12 . im m u n o flu o re scen ce  co n ro ca i m ic ro sco p y  show in g  th a t ex p ressio n  o f  
d o m in an t-n eg a tiv e  rab4  (d n rab 4 -E G F P ) d o es no t a tte c t th e  p a n e m  o f  labe llin g  or 
tran sfe rrin  recep to r-p o sitiv e  co m p artm en ts
IBRS2 cells were transfected with an expression plasmid for dnrab4 fused to EGFP(green). At 6 
hours post-transfection the cells were fixed with paraformaldehyde, permeablised with Triton X-100  
and labelled with a monoclonal antibody to transferrin receptor (TfR); a marker for early endosomes 
and recycling endosomes and an Alexa 568nm conjugated secondary antibody (red). Cell nuclei were 
stained with DAPI and are shown in blue. Bars=10|im.
Panel A shows labelling for TfR (red),
Panel B shows dnrab4-EGFP (green)
Panel C is an overlay o f  panels A and B, showing that expression o f  dnrab4 does not affect the pattern 
o f  TfR positive compartment labelling.
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Figure 4.13. Immunofluorescence confocal microscopy showing wild-type rab4
(wtrab4-EGFP) does not co-localise with late endosomes
BA
overlay
1BRS2 cells were transfected with an expression plasmid for wtrab4 fused to EGFP(green). At 6 
hours post-transfection the cells were fixed with paraformaldehyde, permeablised with Triton X-100 
and labelled with a monoclonal antibody to mannose-6-phosphate receptor (CI-MPR); a marker for 
late endosomes and an Alexa 568nm conjugated secondary antibody (red). Cell nuclei were stained 
with DAPI and are shown in blue. Bars=10pm.
Panel A shows labelling for CI-MPR(red),
Panel B shows wtraM-EGFP(green)
Panel C is an overlay o f  panels A and B, showing that wtrab4 does not co-localise with late 
endosomes.
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F igu re  4 .14 . Im m u n o flu o re scen ce  co n fo ca l m ic ro sco n v  sh o w in g  ex p ress io n  o f  
d o m in an t-n eg a tiv e  rab4  (d n rab 4 -E G F P ) d o es  n o t a ffec t th e  in teg rity  o f  late 
en d o so m es
A
overlay I overlay
IBRS2 cells were transfected with an expression plasmid for dnrab4 fused to EGFP(green). At 6 
hours post-transfection the cells were fixed with paraformaldehyde, permeablised with Triton X-100  
and labelled with a monoclonal antibody to mannose-6-phosphate receptor (CI-MPR); a marker for 
late endosomes and an Alexa 568nm conjugated secondary antibody (red). Cell nuclei were stained 
with DAPI and are shown in blue. Bars=10pm.
Panels A and D show labelling for CI-MPR (red),
Panels B and E show dnrab4-EGFP(green)
Panel C is an overlay o f  panels A and B and panel F is an overlay o f  panels D and E. Both show that 
expression o f  dnrab4 does not affect the integrity o f  late endosomes.
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e n d o so m es o r  ly so so m es.
4 .5  C h a r a c te r i s a t io n  o f  w ild - ty p e  a n d  d o m in a n t-n e g a t iv e  r a b l l
T h e  m am m a lia n  e x p re ss io n  p la sm id s  fo r  r a b l  1 u se d  in  th is  s tu d y  a re  w ild -ty p e  r a b l  1 
(w tra b l 1) an d  d o m in an t-n eg a tiv e  r a b l  1 -S 2 5 N  (d n ra b l 1). B o th  a re  fu se d  to  E G F P . 
R a b l  1 co n tro ls  a  s lo w  rec y c lin g  p a th w a y  fro m  ea rly  en d o so m es to  th e  p la sm a  
m em b ran e  v ia  p e r in u c le a r  rec y c lin g  en d o so m es. W tra b l 1 sh o u ld  lo ca lise  to  early  
a n d  recy c lin g  en d o so m es.
4 .5 .1  R a b l l  a n d  e a r ly  e n d o s o m a l a n t ig e n  1 (E E A 1 )
E a rly  en d o so m a l an tig en  1 (E E A 1 ) is  a  sp ec if ic  m a rk e r fo r ea rly  en d o so m es. IB R S 2  
ce lls  w e re  tran sfec ted  w ith  ex p re ss io n  p la sm id s  fo r  w tra b l 1 o r  d n ra b l  1 fu se d  to  
E G F P  (g reen ). A t 6 hour's p o s t- tra n sfe c tio n  th e  ce lls  w e re  f ix e d  w ith  
p a ra fo rm a ld eh y d e , p e rm e a b lise d  w ith  T rito n  X -1 0 0  an d  lab e lled  w ith  a  m o n o c lo n a l 
an tib o d y  to  e a rly  en d o so m a l an tig en  1 (E E A -1 ), co n ju g a ted  w ith  a n  A le x a  56 8 n m  
seco n d ary  an tib o d y  (red ).
F ig u re  4 .15  sh o w s th e  ex p re ss io n  p a tte rn  o f  w tra b l  1 (g reen ) in  p a n e l B  an d  d n ra b l 1 
(g reen ) in  p a n e l E . E E A 1 (red ) is  sh o w n  in  p a n e ls  A  and  D . P an e l C  sh o w s a  sm all 
a m o u n t o f  w tra b l  1 c o -lo ca lised  w ith  E E A 1 , w ith  th e  rem a in d e r p re su m ab ly  lo ca ted  
o n  re c y c lin g  en d o so m es. P an e l D  sh o w s th a t ex p re ss io n  o f  d n ra b l  1 d o es  n o t a ffec t 
th e  in teg rity  o f  ea rly  en d o so m es, its  a c tio n  b e in g  dow nstr eam  o f  th is  co m p artm en t.
4 .5 .2  R a b l l  a n d  t r a n s f e r r in  r e c e p to r  (T fR )
T h e  tra n sfe rr in  re c e p to r (T fR ) is  a  sp ec ific  m a rk e r  fo r  ea rly  an d  recy c lin g
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F ig u re  4 .15 . Im m u n o flu o rescen ce  co n fo ca l m ic ro sco p y  sh o w in g  th a t ex p ress io n  o f  
w ild -ty p e  ra b l  1 (w tra b l 1 -E G F P ) o r  d o m in an t-n eg a tiv e  ra b l 1 (d n ra b l 1 -E G F P ) do 
no t a ffec t th e  in teg rity  o f  ea rly  en d o so m es
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IBRS2 cells were transfected with expression plasmids for wtrabl 1 or dnrabl 1 fused to EGFP 
(green). At 6 hours post-transfection the cells were fixed with paraformaldehyde, permeablised with 
Triton X -100 and labelled with a monoclonal antibody to early endosomal antigen 1 (EEA-1); a 
marker for early endosomes and an Alexa 568nm conjugated secondary antibody (red). Cell nuclei 
were stained with DAPI and are shown in blue. Bars=10pm.
Panels A and D show labelling for EEA1 (red),
Panel B shows wtrabl 1-EGFP (green) and panel E shows dnrabl 1-EGFP (green)
Panel C is an overlay o f  panels A and B and panel F is an overlay o f  panels D and E. Both show that 
expression o f  wtrabl 1 or dnrabl 1 do not affect the integrity o f  early endosomes.
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en d o so m es. IB R S 2  ce lls  w e re  tra n sfe c te d  w ith  e x p re ss io n  p la sm id s  fo r  w tr a b l  1 o r  
d n rab  11 fu se d  to  E G F P  (g reen ). A t 6 h o u rs  p o s t- tra n sfe c tio n  th e  c e lls  w e re  fix ed  
w ith  p a ra fo rm a ld eh y d e , p e rm e a b lise d  w ith  T r ito n  X -1 0 0  an d  la b e lled  w ith  a  
m o n o c lo n a l a n tib o d y  to  tra n s fe rr in  r e c e p to r  (T fR ), co n ju g a ted  w ith  a n  A le x a  5 6 8 n m  
seco n d a ry  an tib o d y  (red ).
F ig u re  4 .1 6  sh o w s th e  ex p re ss io n  p a tte rn  o f  w tra b l  1 (g reen ) in  p a n e l B  a n d  d n rab  11 
(g reen ) in  p a n e l E . T fR  (red ) is  sh o w n  in  p a n e ls  A  an d  D . A s e x p ec ted , th e re  is 
so m e  co -lo c a lisa tio n  o f  w tra b l  1 w ith  T fR , an d  its  d is tr ib u tio n  is  th e  sam e  in  
e x p re ss in g  an d  n o n -e x p re ss in g  ce lls . E x p re ss io n  o f  d n rab  11 a p p e a ls  to  h a v e  a ffec ted  
th e  p a tte rn  o f  T fR  d is tr ib u tio n  w h e n  co m p ared  to  n o n -ex p re ss in g  ce lls . T h e  T fR  is 
in  a  p a tte rn  m o re  in d ica tiv e  o f  e a rly  e n d o so m es, co n s is ten t w ith  th e  id e a  th a t 
d o m in an t-n eg a tiv e  r a b l  1 in h ib its  th e  fo rm a tio n  o f  p e rin u c le a r  re c y c lin g  en d o so m es.
4 .5 .3  R a b l l  a n d  m a n n o s e  6 -p h o s p h a te  r e c e p to r  (C I-M P R )
M a n n o se  6-p h o sp h a te  re c e p to r (C I-M P R ) is  a  m a rk e r  fo r  la te  e n d o so m e s  and  
ly so so m es. IB R S 2  c e lls  w e re  tra n s fe c te d  w ith  ex p re ss io n  p la sm id s  fo r  w tra b l  1 o r 
d n rab  11 fu sed  to  E G F P  (g reen ). A t 6 h o rn s  p o s t- tra n sfe c tio n  th e  ce lls  w e re  fix ed  
w ith  p a ra fo rm a ld eh y d e , p e rm e a b lise d  w ith  T rito n  X -1 0 0  an d  lab e lled  w ith  a  
m o n o c lo n a l an tib o d y  to  m a n n o se  6-p h o sp h a te  re c e p to r (C I-M P R ), co n ju g a te d  w ith  
a n  A le x a  5 6 8 n m  seco n d a ry  an tib o d y  (red ).
F ig u re  4 .1 7  sh o w s th e  e x p re ss io n  p a tte rn  o f  w tra b l  1 (g reen ) in  p a n e l B  an d  d n rab  11 
(g reen ) in  p a n e l E . C I-M P R  (red ) is  sh o w n  in  p a n e ls  A  an d  D . A s  e x p ec ted , th e re  is 
n o  c o -lo ca lisa tio n  o f  w tra b l  1 w ith  C I-M P R  (p an e ls  C  an d  F ). E x p re ss io n  o f  
d n rab  11 d o es n o t a ffe c t th e  d is tr ib u tio n  o f  C I-M P R  w h e n  c o m p ared  to  n o n -
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F ig u re  4 .16 . im m u n o flu o re scen ce  c o n to ca i m ic ro sco p y  s h o v in g  ex p ressio n  o f  
d o m in an t-n eg a tiv e  ra b l 1 (d n ra b l 1 -E G F P ). bu t no t w ild -tv o e  ra b l 1 (w tra b l 1 -E G F P ) 
leads to  red u ced  lab e llin g  o f  tran sfe rrin  recep to r-p o sitiv e  co m p artm en ts
IBRS2 cells were transfected with expression plasmids for wtrabl 1 and dnrabl 1 fused to EGFP 
(green). At 6 hours post-transfection the cells were fixed with paraformaldehyde, permeablised with 
Triton X-100 and labelled with a monoclonal antibody to transferrin receptor (TfR); a marker for 
early endosom es and recycling endosom es and an Alexa 568nm conjugated secondary antibody (red). 
Cell nuclei were stained with DAPI and are shown in blue. Bars=10pm.
Panels A and D show labelling for TfR (red),
Panel B shows wtrabl 1-EGFP (green) and panel E shows dnrabl 1-EGFP (green)
Panel C is an overlay o f  panels A and B, showing that expression o f  wtrab 11 does not affect the 
pattern o f  labelling o f  transferrin receptor-positive compartments. Panel F is an overlay o f  panels D 
and E, showing that expression o f  dnrabl 1 leads to reduced labelling o f  transferrin receptor-positive 
compartments.
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F ig u re  4 .1 7 . Im m u n o flu o re scen ce  co n fo ca l m ic ro sco p y  sh o w in g  w ild -ty p e  ra b l  1 
(w tra b l 1 -E G F P ) d o es n o t co -lo ca lise  w ith  la te  e n d o so m e s  and  e x p re ss io n  o f  
d o m in an t-n eg a tiv e  ra b l  1 (d n ra b l 1 -E G F P ) d o es  n o t in h ib it fo rm a tio n  o f  late 
en d o so m es
A D
B
C
overlay I cve r‘ay
IBRS2 cells were transfected with expression plasmids for wtrabl 1 or dnrabl 1 fused to EGFP(green). 
At 6 hours post-transfection the cells were fixed with paraformaldehyde, permeablised with Triton X- 
100 and labelled with a monoclonal antibody to mannose-6-phosphate receptor (CI-MPR); a marker 
for late endosom es and an Alexa 568nm conjugated secondary antibody (red). Cell nuclei were 
stained with DAPI and are shown in blue. Bars=10pm.
Panels A and D show labelling for CI-MPR (red),
Panel B shows wtrabl 1-EGFP (green) and panel E shows dnrabl 1-EGFP (green)
Panel C is an overlay o f  panels A and B, showing that wtrab 11 does not co-localise with late 
endosomes. Panel F is an overlay o f  panels D and E, showing that expression o f  dnrabl 1 does not 
inhibit the biogenesis o f  late endosom es.
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ex p re ss in g  c e lls  a n d  th e re fo re  is  u n lik e ly  to  a ffe c t th e  in te g rity  o f  la te  e n d o so m e s  o r  
ly so so m es.
4 .5 .4  R a b l l  a n d  t r a n s f e r r in  u p ta k e
T h e  e ffec t o f  d n ra b l  1 ex p re ss io n  o n  u p ta k e  o f  la b e lle d  tra n sfe rr in  w as  in v es tig a ted . 
T ra n sfe rrin  is  a  lig an d  w h ic h  is  ta k e n  u p  b y  c la th r in -d e p en d e n t en d o cy to s is  in to  ea rly  
e n d o so m e s  a n d  re cy c led  b a c k  to  th e  c e ll su rface  v ia  re c y c lin g  en d o so m es. IB R S 2  
ce lls  w e re  tra n sfe c te d  w ith  a n  e x p re ss io n  p la sm id  fo r  d n ra b l  1 fu sed  to  E G F P  
(g reen ). A t 6 h o u rs  p o s t- tra n sfe c tio n , A le x a  5 6 8 n m  la b e lle d  tra n sfe rrin  w a s  ta k e n  
u p  in to  IB R S 2  ce lls  fo r  5 m in u te s  a n d  th e n  c h a se d  w ith  u n la b e lle d  tra n s fe rr in  fo r  25 
m in u te s . A t th is  t im e  p o in t th e  re d  tra n s fe rr in  sh o u ld  h a v e  b e e n  c h ased  o u t o f  ea rly  
c o m p a rtm e n ts  (ea rly - an d  re c y c lin g  e n d o so m e s) a n d  re cy c led  o u t o f  th e  ce ll.
F ig u re  4 ,1 8 , p a n e l A  sh o w s d n ra b l  1 ex p re ss in g  ce lls . In  p a n e l B  th e  n o n -e x p re ss in g  
ce lls  h a v e  re d u c e d  lev e ls  o f  re d  tra n s fe rr in  a s  i t  h a s  b e e n  c h ased  o u t b y  th e  
u n la b e lle d  tran sfe rrin . H o w ev e r, in  th e  d n ra b l  1 e x p re ss in g  ce lls , th e  re d  tra n s fe rr in  
h a s  b e e n  tra p p e d  in  e a rly  co m p artm en ts , in d ic a tin g  th a t d n ra b l  1 b lo c k s  re c y c lin g  o f  
lig an d s  to  th e  c e ll su rface .
4 .6  C h a r a c te r i s a t io n  o f  w ild - ty p e  a n d  d o m in a n t-n e g a t iv e  r a b ?
T h e  m a m m a lia n  ex p re ss io n  p la sm id s  fo r  ra b 7  u se d  in  th is  s tu d y  a re  w ild -ty p e  ra b ?  
(w tra b ? )  an d  d o m in an t-n eg a tiv e  rab 7 -N 1 2 5 I (d n ra b ? ). B o th  a re  fu se d  to  E G F P .
R ab 7  co n tro ls  tra ff ick in g  fro m  e a r ly  to  la te  e n d o so m e s  an d  ly so so m es, an d  w trab 7  
sh o u ld  lo ca lise  to  ea rly  en d o so m es, la te  en d o so m es  a n d  ly so so m es. A n o th e r  fo rm  o f  
d o m in an t-n eg a tiv e  ra b 7  (T 2 2 N ) w ill b e  u se d  la te r  in  th is  s tu d y  (see  c h a p te r  six ).
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F igu re  4 .18 . Im m u n o flu o rescen ce  co n fo ca l m ic ro sco p y  sh o w in g  recy c lin g  o f  
lab e lled  tran sfe rrin  is in h ib ited  in  d o m in an t-n eg a tiv e  ra b l 1 (d n rab  1 1-E G FP) 
e x p ress in g  ce lls
A B
c
overlay
IBRS2 cells were transfected with an expression plasmid for dnrab 11 fused to EGFP (green). At 6 
hours post-transfection Alexa 568nm labelled transferrin (red) was added to the media at 50gg/m l and 
and then chased with unlabelled transferrin for 25 minutes. The cells were then fixed with 
paraformaldehyde. At this time point the red transferrin should have been chased out o f  early 
compartments (early- or recycling endosom es) and recycled. Cell nuclei were stained with DAPI and 
are shown in blue. Bars=10pm.
Panel A shows dnrab 11-EGFP(green)
Panel B shows transferrin(red)
Panel C is an overlay o f  panels A and B, showing that expression o f  dnrab 11 inhibits recycling o f  
labelled transferrin from early compartments.
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4 .6 .1  R a b ?  a n d  e a r ly  e n d o s o m a l a n t ig e n  1 (E E A 1 )
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E arly  e n d o so m a l an tig en  1 (E E A 1 ) is  a  sp ec if ic  m a rk e r  fo r  e a rly  en d o so m es. IB R S 2  
ce lls  w e re  tra n sfe c te d  w ith  e x p re ss io n  p la sm id s  fo r  w tra b ?  o r  d n ra b ?  fu se d  to  E G F P  
(g reen ). A t 6 h o u rs  p o s t- tra n sfe c tio n  th e  c e lls  w e re  fix e d  w ith  p a ra fo rm a ld eh y d e , 
p e rm e a b lise d  w ith  T rito n  X -1 0 0  an d  la b e lle d  w ith  a  m o n o c lo n a l a n tib o d y  to  ea rly  
e n d o so m a l a n tig e n  1 (E E A -1 ), c o n ju g a ted  w ith  a n  A le x a  5 6 8 n m  seco n d a ry  an tib o d y  
(red).
F ig u re  4 .1 9  sh o w s th e  e x p re ss io n  p a tte rn  o f  w tra b 7  (g reen ) in  p an e l B  a n d  d n rab 7  
(g reen ) in  p a n e l E . E E A 1 (red ) is  sh o w n  in  p a n e ls  A  a n d  D . P an e l C  sh o w s a  sm all 
a m o u n t o f  w tra b ?  c o -lo c a lise d  w ith  E E A 1 , in d ic a tin g  th a t it c an  b e  fo u n d  o n  ea rly  
en d o so m es. T h e  m a jo rity  o f  w tra b 7  is  p re su m a b ly  o n  la te  en d o so m es an d  
ly so so m es. E x p re ss io n  o f  d n ra b ?  d o es  n o t a ffec t th e  in teg rity  o f  th e  e a rly  e n d o so m e  
(p an e l D ), its  a c tio n  b e in g  d o w n stre a m  o f  th is  co m p artm en t.
4 .6 .2  R a b 7  a n d  t r a n s f e r r in  r e c e p to r  (T fR )
T h e  tra n s fe rr in  re c e p to r  (T fR ) is  a  sp ec ific  m a rk e r  fo r  e a rly  an d  recy c lin g  
en d o so m es. IB R S 2  ce lls  w e re  tra n sfe c te d  w ith  e x p re ss io n  p la sm id s  fo r  w tra b ?  o r  
d n rab 7  fu se d  to  E G F P  (g reen ). A t 6 h o u rs  p o s t- tra n sfe c tio n  th e  ce lls  w e re  fix e d  w ith  
p a ra fo rm a ld eh y d e , p e rm e a b lise d  w ith  T rito n  X -1 0 0  a n d  lab e lled  w ith  a  m o n o c lo n a l 
an tib o d y  to  tra n s fe rr in  re c e p to r (T fR ), co n ju g a te d  w ith  a n  A le x a  5 6 8 n m  seco n d a ry  
a n tib o d y  (red).
F ig u re  4 ,2 0  sh o w s th e  ex p re ss io n  p a tte rn  o f  w tra b ?  (g reen ) in  p an e l B  a n d  d m ab 7  
(g reen ) in  p a n e l E . T fR  (red ) is  sh o w n  in  p a n e ls  A  an d  D . P an e l C  sh o w s n o  co -
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F ig u re  4 .19 . Im m u n o flu o rescen ce  co n fo ca l m ic ro sco p y  sh o w in g  ex p re ss io n  o f  w ild - 
ty p e  rab 7  (w trab 7 -E G F P ) o r d o m in an t-n eg a tiv e  rab 7  (d n rab 7 -N 1 2 5 I-E G F P ) do  no t 
a ffec t th e  in teg rity  o f  ea rly  en d o so m es
A
------ I
B
C
. •
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overlay overlay
IBRS2 cells were transfected with expression plasmids for wtrab7 or dnrab7-N125I fused to 
EGFP(green). At 6 hours post-transfection the cells were fixed with paraformaldehyde, permeablised 
with Triton X-100 and labelled with a monoclonal antibody to early endosomal antigen 1 (EEA-1); a 
marker for early endosomes and an Alexa 568nm conjugated secondary antibody (red). Cell nuclei 
were stained with DAPI and are shown in blue. Bars=10(xm.
Panels A and D show labelling for E EA l(red),
Panel B shows wtrab7-EGFP(green) and panel E shows dnrab7-N125I-EGFP(green)
Panel C is an overlay o f  panels A and B and panel F is an overlay o f  panels D and E. Both show that 
expression o f  wtrabl 1 or dnrab 11 does not affect the integrity o f  early endosomes.
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Figure 4.20. Immunofluorescence confocal microscopy showing expression of wild-
type rab7 (wtrab7-EGFP) or dominant-negative rab7 (dnrab7-EGFP) do not affect
labelling of transferrin receptor-positive compartments
A
C
over lay
IBRS2 cells were transfected with expression plasmids for wtrab7 or dnrab7 (used to EGFP(green). 
At 6 hours post-transfection tbe cells were fixed with paraformaldehyde, permeablised with Triton X- 
100 and labelled with a monoclonal antibody to transferrin receptor (TfR); a marker for early 
endosomes and recycling endosomes and an Alexa 568nm conjugated secondary antibody (red). Cell 
nuclei were stained with DAPI and are shown in blue. Bars=10pm.
Panels A and D show labelling for TfR (red),
Panel B shows wtrab7-EGFP (green) and panel E shows dnrab7-EGFP (green)
Panel C is an overlay of panels A and B and panel F is an overlay of panels D and E. Both show that 
expression of wtrab7 or dnrab7 do not affect labelling of transferrin receptor-positive compartments.
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localisation of wtrab? with TfR, and expression of dnrab? has not affected the 
pattern of TfR distribution when compared to non-expressing cells (panel F). This 
shows that early- and recycling endosomes remain intact in dnrab7 expressing cells.
4.6.3 Rab7 and mannose 6-phosphafe receptor (CI-MPR)
Mannose 6-phosphate receptor (CI-MPR) is a marker for late endosomes and 
lysosomes. IBRS2 cells were transfected with expression plasmids for wtrab7 or 
dnrab? fused to EGFP (green). At 6 hours post-transfection the cells were fixed with 
paraformaldehyde, permeablised with Triton X-100 and labelled with a monoclonal 
antibody to mannose 6-phosphate receptor (CI-MPR), conjugated with an Alexa 
568nm secondary antibody (red).
Figure 4.21 shows the expression pattern of wtrab7 (green) in panel B and dnrab7 
(green) in panel E. CI-MPR (red) is shown in panels A and D. There no co­
localisation of wtrab7 with CI-MPR and expression of dnrab7 does not affect its 
distribution. This is surprising, as CI-MPR is a marker for the late compartments 
whose biogenesis rab? is supposed to control. However, there is evidence in the 
literature that CI-MPR does not always co-localise with rab? (Meresse et al, 1995).
4.6.4 Rab7 and uptake of labelled low density lipoprotein (Dil-LDL)
The effect of dnrab7 expression on labelled low-density lipoprotein, Dil-LDL (red) 
uptake was investigated. Dil-LDL is a ligand which is taken up by clathrin- 
dependent endocytosis into early endosomes and traffics to late endosomes. IBRS2 
cells were transfected with expression plasmids for wtrab7 or dnrab7 fused to EGFP 
(green).
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Figure 4.21. Immunofluorescence confocal microscopy showing wild-type rab7
(wtrab7-EGFP) does not co-localise with late endosomes and expression of
dominant-negative rab7 (dnrab7-EGFP) does not inhibit formation of late endosomes
: DA
c
l E
overlay overla '
IBRS2 cells were transfected with expression plasmids for wtrab7 or dnrab7 fused to EGFP(green). 
At 6 hours post-transfection the cells were fixed with paraformaldehyde, permeablised with Triton X- 
100 and labelled with a monoclonal antibody to mannose-6-phosphate receptor (CI-MPR); a marker 
for late endosomes and an Alexa 568nm conjugated secondary antibody (red). Cell nuclei were 
stained with DAPI and are shown in blue. Bars=10gm.
Panels A and D show labelling for CI-MPR (red),
Panel B shows wtrab7-EGFP (green) and panel E shows dnrab7-EGFP (green)
Panel C is an overlay of panels A and B, showing that wtrab7 does not co-localise with late 
endosomes. Panel F is an overlay of panels D and E, showing that expression of dnrab7 does not 
inhibit the biogenesis of late endosomes.
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At 6 hours post-transfection, Dil-LDL (red) was taken up into IBRS2 cells for 30 
minutes. At this time point the Dil-LDL should have reached late endosomes.
Figure 4.22, panel A shows the wtrab7 expressing cell, and panel B shows the 
dnrab7 expressing cell. In panel C all cells have high levels of Dil-LDL in large 
vesicles close to the nucleus, in a distribution indicative of late endosomes. This 
shows that uptake of Dil-LDL is not inhibited by expression of wtrab7. However, in 
panel D, the dnrab7 expressing cell has an altered distribution of Dil-LDL when 
compared to non-expressing or wtrab? expressing cells. The Dil-LDL is in smaller 
vesicles near to the periphery of the cell, suggesting that it has become tr apped in 
early compartments. This indicates that dnrab? expression inhibits trafficking of 
ligands to late endosomes.
4.6.5 Rab7 and labelling of acidic compartments with lysotracker red
The effect of dnrab7 expression on formation of acidic compartments was also 
investigated. Lysotracker red is a dye which labels highly acidic compartments such 
as late endosomes and lysosomes. IBRS2 cells were transfected with expression 
plasmids for wtrab7 or dnrab7 fused to EGFP (green). At 6 hours post-tr ansfection, 
Lysotracker red was taken up into IBRS2 cells for 30 minutes. At this time point, 
lysotr acker permeates acidic compartments, labelling them red.
Figure 4.23, panel A shows the wtrab7 expressing cell, and panel B shows the 
dnrab7 expressing cell. In panel C, all cells have high levels of red lysotracker in 
large vesicles close to the nucleus, in a distribution indicative of late endosomes and 
lysosomes. This shows that the uptake of lysotracker into late endosomes and 
lysosomes is not inhibited by expression of wtrab7. However, in the panel D, the
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Figure 4.22 immunofluorescence confocal microscopy showing expression of 
dominant-negative rab7 (dnrab7-EGFP). but not wild-type rab7 (wtrab7-EGFP) 
inhibits earlv- to late endosome trafficking of labelled low density lipoprotein (Dil- 
LDL)
C
IBRS2 cells were transfected with expression plasmids for wtrab7 and dnrab7 fused to EGFP(green). 
At 6 hours post-transfection Dil-LDL (red) was added to the media and allowed to internalise for 30 
minutes. The cells were then fixed with paraformaldehyde. At this time point, the Dil-LDL should 
have reached late endosomes. Cell nuclei were stained with DAPI and are shown in blue. 
Bars=10gm.
Panel A shows the wtrab7 expressing cell (green), and panel C shows Dil-LDL (red). The wtrab7 
expressing cell has an equal level of Dil-LDL when compared to non-expressing cells. Panel B 
shows the dnrab7 expressing cell (green), and panel D shows Dil-LDL (red). The dnrab7 expressing 
cell has a reduced level of Dil-LDL when compared to non-expressing cells, suggesting an inhibition 
in trafficking from early endosomes to late endosomes when dnrab7 is expressed.
I ll
Figure 4.23 Immunofluorescence confocal microscopy showing expression of
dominant-negative rab7 (dnrab7-EGFP), but not wild-type rab7 (wtrab7-EGFP)
inhibits biogenesis of late endosomes and lysosomes
IBRS2 cells were transfected with expression plasmids for wtrab7 and dnrab7 fused to EGFP(green). 
At 6 hours post-transfection lysotracker red was added to the media and allowed to label acidic 
compartments for 30 minutes. The cells were then fixed with paraformaldehyde. At this time point, 
lysotracker red should label highly acidic compartments such as late endosomes and lysosomes. Cell 
nuclei were stained with DAPI and are shown in blue. Bars=10pm.
Panel A shows the wtrab7 expressing cell (green), and panel C shows labelling for lysotracker red. 
The wtrab7 expressing cell has an equal level of lysotracker red labelling when compared to non­
expressing cells. Panel B shows the dnrab7 expressing cell (green), and panel D shows labelling for 
lysotracker red. The dnrab7 expressing cell has a reduced level of lysotracker red labelling when 
compared to non-expressing cells, suggesting an inhibition in biogenesis of late endosomes and 
lysosomes when dnrab7 is expressed.
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dnrab7 expressing cell has an altered distribution of red lysotracker when compared 
to non-expressing or wtrab7 expressing cells. The lysotracker is labelling smaller 
vesicles near to the periphery of the cell, suggesting labelling of early compartments 
only. This shows that dnrab7 expression inhibits biogenesis of late endosomes and 
lysosomes.
4,7 Characterisation of dominant-negative rab9
The only construct used for rab9 in this study is dominant-negative rab9-S21N 
(dnrab9) fused to EGFP. The reason for this is that overexpression of wild-type rab9 
also acts as a dominant-negative inhibitor of rab9 function. Rab9 controls trafficking 
from late endosomes to the Golgi and wtrab9 localises to both of these 
compartments.
4.7,1 Rab9, early endosomal antigen 1 (EEA1) and transferrin receptor (TfR)
Early endosomal antigen 1 (EEA1) is a specific marker for early endosomes, and the 
transferrin receptor (TfR) is a specific marker for early and recycling endosomes. 
IBRS2 cells were transfected with an expression plasmid for dnrab9 fused to EGFP 
(green). At 6 hours post-transfection the cells were fixed with paraformaldehyde, 
permeablised with Triton X-100 and labelled with monoclonal antibodies to early 
endosomal antigen 1 (EEA-1) or transferrin receptor (TfR), both conjugated with an 
Alexa 568nm secondary antibody (red).
Figure 4.24, panels B and E show the expression pattern of dnrab9 (green). Panel A 
shows EEA1 labelling and panel D, TfR (red). As expected, expression of dnrab9 
does not appear to affect the integrity of early- or recycling endosomes.
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Figure 4.24. Immunofluorescence confocal microscopy showing that expression of
dominant-negative rab9 (dnrab9-EGFP) does not affect the integrity of early
endosomes or transferrin receptor-positive compartments
.
overlay . e riay
IBRS2 cells were transfected with an expression plasmid for dnrab9 fused to EGFP(green). At 6 
hours post-transfection the cells were fixed with paraformaldehyde, permeablised with Triton X-100 
and labelled with monoclonal antibodies to early endosomal antigen 1 (EEA-1), or transferrin receptor 
(TfR); both with Alexa 568nm conjugated secondary antibodies (red). Cell nuclei were stained with 
DAP1 and are shown in blue. Bars=10gm.
Panel A shows labelling for EEA-1 (red), and panel D shows labelling for TfR (red)
Panels B and E show dnrab9-EGFP (green)
Panel C is an overlay of panels A and B, showing that expression of dnrab9 does not affect the 
integrity of early endosomes. Panel F is an overlay of panels D and E, showing that expression of 
dnrab9 does not affect the pattern of labelling of transferrin receptor-positive compartments.
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4.7.2 Rab9, mannose 6-phosphate receptor (CI-MPR) and Golgi (GM130)
Mannose 6-phosphate receptor (CI-MPR) is a marker for late endosomes and 
lysosomes. GM130 is an antibody to p-COP, a subunit of the Golgi coatomer 
complex. IBRS2 cells were transfected with an expression plasmid for dnrab9 fused 
to EGFP (green). At 6 hours post-transfection the cells were fixed with 
paraformaldehyde, permeablised with Triton X-100 and labelled with monoclonal 
antibodies to mannose 6-phosphate receptor (CI-MPR) or GM130, both conjugated 
with an Alexa 568nm secondary antibody (red).
Figure 4.25, panels B and E show the expression pattern of dnrab9 (green). Panel A 
shows CI-MPR labelling and panel D, GM130 (red). Expression of dnrab9 does 
not affect the distribution of CI-MPR, and they do not co-localise (panel C). 
However, dnrab9 does co-localise with GM130 (panel F).
4.8 Discussion
The effects of expression of both wild-type and dominant-negative rab GTPases on 
vesicular trafficking have been characterised in many previous studies. Rab5 
controls formation of, and trafficking through, early endosomes. Previous studies 
have shown that rab5 co-localises with EEA1 on early endosomes (Stenmark et a l , 
1996). In this study, wtrab5 can be seen to co-localise with EEA1 in figure 4.2 and 
expression of wtrab5 does not affect the labelling pattern of markers of recycling 
endosome or late endosomes (figures 4.5 and 4.8). Expression of dnrab5 inhibits 
formation of early endosomes, with an accumulation of smaller vesicles being seen 
(Stenmark et al, 1994). In this chapter, inhibition of early endosome biogenesis by 
expression of dnrab5 is shown in figures 4.3 and 4.6 by reduced labelling of EEA1
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Figure 4.25. Immunofluorescence confocal microscopy showing that expression of
dominant-negative rab9 (dnrab9-EGFP) does not affect the integrity of late
endosomes or the Golgi network
A
C
overlay overlay
IBRS2 cells were transfected with an expression plasmid for dnrab9 fused to EGFP(green). At 6 
hours post-transfection the cells were fixed with paraformaldehyde, permeablised with Triton X-100 
and labelled with monoclonal antibodies to mannose-6-phosphate receptor (CI-MPR), or the Golgi 
marker GM130; both with Alexa 568nm conjugated secondary antibodies (red). Cell nuclei were 
stained with DAPI and are shown in blue. Bars=10|im.
Panel A shows labelling for CI-MPR (red), and D shows labelling for GM130 (red)
Panels B and E show dnrab9-EGFP (green)
Panel C is an overlay of panels A and B, showing that expression of dnrab9 does not affect the 
integrity of late endosomes. Panel F is an overlay of panels D and E, showing that expression of 
dnrab9 does not affect the Golgi network. There is some co-localisation between dnrab9 and GM130.
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and TfR. Previous studies have observed an inhibition in endocytosis of transferrin 
when dnrab5 was expressed (Bucci et al., 1992; Papini et al, 1997; Stenmark et al, 
1994), and these results were replicated in figure 4.9 by showing reduced uptake of 
labelled transferrin in dnrab5 expressing cells. Neither wtrab5 nor dnrab5 co- 
localise with, or affect the distribution of, a marker for late endosomes (figure 4.8).
Rab4 controls rapid recycling from the early endosome back to the plasma 
membrane (Sheff et al, 1999; van der Sluijs et a l, 1992). It has been shown that 
wtrab4 is localised mainly to the early endosome and is thought to exert its effects on 
this compartment, but in some studies it also localises to recycling endosomes 
(Sonnichsen et al., 2000) The co-localisation of wtrab4 and EEA1 can be seen in 
figure 4.10 and with TfR (though to a lesser extent) in figure 4.11. Also in figure 
4.10, it can be seen that expression of dnrab4 does not affect the integrity of the early 
endosome. In figure 4.12 it appears that expression of dnrab4 does not affect the 
distribution of TfR, in contrast to a study showing a moderate redistribution of TfR 
to the perinuclear area (McCaffrey et a l, 2001). This may be due to cell type 
differences. Neither form of rab4 co-localises with, or affects the distribution of, a 
marker for late endosomes (figures 4.13 and 4.14).
Rabl 1 controls slower recycling via the perinuclear recycling endosome (Ullrich et 
al, 1996). There is a small amount of co-localisation between wtrabl 1 and EEA1 
(figure 4.15), consistent with rabl 1 being found on early endosomes as well as 
recycling endosomes. The same figure shows that expression of dnrabl 1 does not 
affect the integrity of the early endosome. As expected, the distribution of wtrabl 1 
overlaps with that of TfR and the pattern of TfR labelling changes on expression of 
dnrabl 1 (figure 4.16). The pattern of TfR labelling in dnrabl 1 expressing cells is
Chapter four Effects o f rab GTPases on vesicular trafficking
117
more indicative of early endosome labelling, suggesting that the TfR can enter the 
early endosome, blit its trafficking from here to the recycling endosome is impaired. 
This is consistent with observations made in previous studies (Ullrich et al.. 1996). 
Expression of dnrabl 1 also inhibits recycling of transferrin (Ren et al., 1998: Ullrich 
et al.. 1996), in common with the result seen in figure 4.18. Neither form of rabl 1 
co-localises with, or affects the distribution of. a marker for late endosomes (figure 
4.17).
Rab7 controls vesicular trafficking from early- to late endosomes (Feng et a l. 1995). 
and from late endosomes to lysosomes (Meresse et al. 1995). It has been shown 
recently that early endosomes may also contain rab7-positive domains, from which 
vesicles detach during transport to late endosomes (Vonderheit & Helenius. 2005). 
This explains the partial co-localisation seen between wtrab7 and EEA1 in figure 
4.19. It is important to note also that in the same figure, expression of dnrab7 does 
not affect the integrity of the early endosome. Neither fonn of rab7 co-localises 
with, or affects the distribution of, TfR (figure 4.20). The ideal marker for late 
endosomes and lysosomes would have been lysosomal-associated membrane 
proteins (LAMPs), but unfortunately none of the antibodies available labelled in 
IBRS2 cells. The lack of a specific marker for late endosomes and lysosomes makes 
it difficult to show that wtrab? is localised to the correct compartment and that 
expression of dnrab7 blocks trafficking to late endosomes. CI-MPR does not usually 
co-localise with wtrab7 (Meresse et a l, 1995), in agreement with figure 4.21. One 
study shows a redistribution of CI-MPR from perinuclear areas to more peripheral 
vesicles in dnrab7 expressing cells (Press et a l , 1998), however, this was not seen in 
figure 4.21. This may be due to differences in cell type. More convincingly,
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expression of dnrab? blocks trafficking of labelled LDL from early endosomes to 
late endosomes in figure 4.22. It also appeal's to inhibit biogenesis of highly acidic 
compartments such as late endosomes and lysosomes, as seen by labelling with the 
dye lysotracker red in figure 4.23. These reagents have been used to similar effect in 
previous studies (Bucci et al., 2000).
Rab9 controls vesicular trafficking from late endosomes to the Golgi (Lombardi et 
al., 1993). Figure 4.24 shows that as expected, expression of dmab9 has no effect on 
early compartments. Similarly, figure 4.25 shows that expression of dnrab9 has no 
significant effect on the distribution of CI-MPR. This is may seem surprising, as 
movement of CI-MPR cargo from the late endosome to the Golgi is impaired in cells 
deficient in rab9 function (Riederer et al, 1994). However, it has been reported in 
the same study that steady-state distribution of CI-MPR itself is not affected in cells 
expressing dnrab9. The localisation of dnrab9 in the same study is in the perinuclear 
region (presumably late endosomes) whereas in figure 4.24, dnrab9 predominantly 
co-localises with the Golgi marker GM130. This may be due to differences in cell 
type.
To conclude, the majority of EGFP-tagged rab proteins appear to localise to the 
correct compartments, and all have the expected effects on vesicle trafficking.
FMDV proteins co-localise with markers for early and recycling endosomes at early 
time points during infection. FMDV is thought to require early endosomes for pH 
dependent capsid disassembly and release of the viral RNA genome (Berryman et 
a l, 2005). It is therefore likely that expression of dominant-negative rab5 will 
inhibit FMDV infection, as the results in this chapter show that the compartment is 
not formed correctly in cells expressing dnrab5. Expression of dnrab4,7 ,9 , and 11
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do not affect the integrity of the early endosome and for this reason may not be 
expected to inhibit FMDV infection. If there is a requirement for recycling 
endosomes, as suggested by the co-localisation of FMDV with markers of this 
compartment at early time points (Berryman et al., 2005), it may be predicted that 
dnrabl 1 could also inhibit infection. The effects of dnrab protein expression on 
FMDV infection will be investigated in chapter five.
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Chapter five:Effects of rab GTPases on FMDV uptake and infection
Chapter five Effects o f rab GTPases on FMDV uptake and infection
5.1 Introduction
The results presented in chapter four verified that the wild-type and dominant- 
negative rab proteins were having the expected effects on vesicular trafficking in 
IBRS2 cells. Each rab GTPase specifically controls one or more stages of 
endocytosis and expression of dominant-negative rab proteins in IBRS2 cells was 
shown to inhibit biogenesis of cellular compartments and normal trafficking of 
ligands through these compartments (see chapter four). Therefore, it should be 
possible to investigate the route o f FMDV infection by expressing dominant- 
negative rab proteins and determining their effects on FMDV uptake and infection.
5.2 Effect of dominant-negative mb GTPase expression on infection by FMDV
The effects of dominant-negative rab protein expression on FMDV infection of 
IBRS2 cells were determined by transient expression of wild-type and dominant- 
negative rab proteins fused to enhanced green fluorescent protein (EGFP) in IBRS2 
cells. The cells, on coverslips, were transfected with mammalian expression 
plasmids containing rab-EGFP fusion proteins and their effects on FMDV infection 
were determined by immunofluorescence confocal microscopy. The rab expressing 
cells emitted green fluorescence. FMDV was labelled with rabbit polyclonal serum 
recognising the FMDV capsid and a goat anti-rabbit secondary antibody conjugated 
to Alexa 568nm which emits red fluorescence. To verify that the vims detected was 
new progeny vims rather than input vims, guanidine hydrochloride was added to 
control cells on coverslips in order to inhibit vims replication (Black & Brown, 
1969). The levels of red fluorescence detected in infected, guanidine hydrochloride
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treated cells was low, and set as the background level for the infection assay (data 
not shown). To quantify the effects of rab-EGFP expression on infection, fields of 
vision viewed down the confocal microscope were selected at random and images 
collected. The cells were then counted to determine 1) the proportion of non­
expressing cells that were infected, and 2) the proportion of rab-expressing cells that 
were infected.
5.2.1 Effect of dominant-negative rabS on FMDV infection of IBRS2 cells
The first rab protein investigated was rab5. This rab protein controls biogenesis of 
early endosomes (Bucci et a l, 1992; Goivel et a l, 1991) and in IBRS2 cells 
expression of dominant-negative rab5 blocked formation of (figure 4.3), and ligand 
trafficking through (figure 4.9), these compartments. FMDV is transported to early 
endosomes in SW480 cells expressing aVp6 via clathrin-dependent endocytosis 
(Berryman et al, 2005). The results in chapter three show that FMDV also uses this 
pathway to gain entry into IBRS2 cells. Expression of dominant-negative rab5 in 
IBRS2 cells would therefore be expected to reduce the number of early endosomes 
and inhibit FMDV infection.
IBRS2 cells were transfected with expression plasmids for wild-type (wtrab5), 
dominant-negative (dnrabS) or constitutively active rab5 (carabS) fused to EGFP. At 
6 hours post-transfection, the cells were infected with FMDV 01Kcad2 for 3 hours. 
The cells were then fixed with paraformaldehyde, permeablised with Triton X-100 
and labelled with a rabbit polyclonal serum recognising the FMDV capsid proteins 
and an Alexa 568nm conjugated secondary antibody (red). Figure 5.1 shows that 
although cells expressing wtrab5 (green, panel A) or carab5 (green, panel C) can be
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D
rab5(wt) dnrab5(S34N) carab5(Q67L)
Total cells 2983 2803 2194
% Non-expressing Cells 
Infected 25.5% 25.9% 26.3%
% Expressing Cells Infected 17.5% 4.2% 19.5%
% Expressing/non-expressing 71% 16% 71%
Wild Type=100% 100 23% 106%
% Knockdown
------------------------------------------------- ___________
77%
________________
-6%
.........  .......
Figure 5.1 Effect of dominant-negative rabS on FMDV infection of IBRS2 cells
1BRS2 cells were transfected with expression plasmids for wtrab5, dnrab5 or carab5 fused to EGFP. 
At 6 hours post-transfection, cells were infected with FMDV 01Kcad2 for 3 hours. Cells were fixed 
with paraformaldehyde, permeablised with Triton X-100 and labelled with rabbit polyclonal serum 
recognising the FMDV capsid proteins and an Alexa 568nm conjugated secondary antibody (red). 
Cell nuclei were stained with DAPI and are shown in blue. Bars=20pm.
Panel A shows wtrab5 and FMDV. Panel B shows dnrab5 and FMDV. Panel C shows carab5 and 
FMDV. In panels A and C rab5 expressing, infected cells are arrowed. Panel D shows percentage 
knockdown due to expression of dnrab5 and carab5.
infected by FMDV (red), the cells expressing dnrabS (green, panel B) are rarely 
infected.
Figure 5.1, panel D quantifies the effect of expression of each form of rab5 on 
FMDV infection. This was achieved by counting 1) wtrab5, dnrab5 or carabS 
expressing, FMDV“infected cells, and 2) non-expressing FMDV-infected cells on 
randomly selected fields of view on the confocal microscope (see above).
Expression of wtrab5 results in a -2 9 %  reduction in infection when compared to 
non-expressing cells on the same coverslip. This suggests that overexpression of 
wtrabS has a slight inhibitory effect on FMDV infection. However, the inhibition 
due to expression of dnrabS is greater, -84% . When normalised to wtrab5 (i.e. the 
number of infected cells expressing wtrabS), the inhibition due to expression of 
dnrab5 is -77% . This suggests that FMDV infection depends on the integrity of 
early endosomes. Expression of carab5 has little effect on FMDV infection when 
compared to wtrab5, despite the characteristic enlarged endosomes being clearly 
seen in carab5 expressing cells.
5.2.2 Effect of dominant-negative rab4 on FMDV infection of IBRS2 cells
Rab4 localises to early endosomes and is involved in receptor recycling back to the 
plasma membrane. A  number of studies in different cell types have shown that rab4 
is required for the rapid recycling of receptors directly from early endosomes to the 
cell surface (McCaffrey et a l , 2001; Sheff et a l, 1999; van der Sluijs et al, 1992; 
Ward et a l, 2005). Some recent studies have also suggested a role for rab4 in the 
formation of recycling endosomes from early endosomes (Pagano et al, 2004; Ward 
et al, 2005). FMDV capsid proteins are localised to early- and recycling endosomes
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at early times after infection (Berryman et a l, 2005; O'Donnell et a l, 2005). 
Therefore it is possible that the virus may need to enter recycling endosomes for 
infection.
IBRS2 cells were transfected with expression plasmids for wtrab4 or dnrab4 fused to 
EGFP. At 6 hours post-transfection, the cells were infected with FMDV 01Kcad2 
for 3 hours. The cells were then fixed with paraformaldehyde, permeablised with 
Triton X-100 and labelled with rabbit polyclonal serum recognising the FMDV 
capsid proteins and an Alexa 568nm conjugated secondary antibody (red). Figure
5.2 shows that cells expressing wtrab4 (panel A) or dnrab4 (panel B) can be infected 
to a similar extent.
These observations were quantified (figure 5.2, panel C), by counting 1) wtrab4 or 
dnrab4 expressing, FMDV-infected cells, and 2) non-expressing FMDV-infected 
cells on randomly selected fields of view on the confocal microscope. Expression of 
wtrab4 results in a 19% reduction when compared to non-expressing cells on the 
same coverslip. This suggests that overexpression of wtrab4 has a slight inhibitory 
effect on FMDV infection. The inhibition when dnrab4 is expressed is very similar, 
13%. If the proportion of wtrab4 expressing cells infected is set at 100%, there is 
very little difference when dnrab4 is expressed. These results show that rab4 is not 
required for FMDV entry and infection, suggesting that successful infection does not 
require delivery to recycling endosomes.
5.2,3 Effect of dominant-negative rabll on FMDV infection of IRRS2 ceils
Similar to rab4, rabl 1 is involved in receptor recycling to the plasma membrane. A  
number of studies have implicated rabl 1 in recycling of receptors from early- and
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rab4(wt) rab4(N121l)
Total cells 3741 3573
% Non-expressing Cells Infected 11.3% 10.5%
% Expressing Cells Infected 9.1% 9.1%
% Expressing/non-expressing 81% 87%
Wild Type=100% 100 109%
% Knockdown -9%
Figure 5.2 Effect of dominant-negative rab4 on FMDV infection of IBRS2 cells
IBRS2 cells were transfected with expression plasmids for wtrab4 and dnrab4 (used to EGFP. At 6 
hours post-transfection, cells were infected with FMDV 01Kcad2 for 3 hours. Cells were fixed with 
paraformaldehyde, permeablised with Triton X-100 and labelled with rabbit polyclonal serum 
recognising the FMDV capsid proteins and an Alexa 568nm conjugated secondary antibody (red). 
Cell nuclei were stained with DAPI and are shown in blue. Bars=20pm.
Panel A shows wtrab4 and FMDV. Panel B shows dnrab4 and FMDV. In panels A and B, rab4
expressing, infected cells are arrowed. Panel C shows percentage knockdown due to expression of
dnraM.
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recycling endosomes to the plasma membrane (Casanova et at, 1999; Green et a l, 
1997; Sheff et a l, 1999; Ullrich et a l, 1996). Recent studies have also implicated 
rabl 1 in the formation o f recycling endosomes from early endosomes (Pagano et al, 
2004; Ward et al, 2005). As mentioned above, FMDV capsid proteins are localised 
to early- and recycling endosomes at early times after infection (Berryman et al, 
2005; O'Donnell et a l, 2005). Therefore it is possible that the virus may enter 
recycling endosomes for infection.
IBRS2 cells were transfected with expression plasmids for wtrabl 1 or dnrabl 1 fused 
to EGFP. At 6 hours post-transfection, the cells were infected with FMDV 01ICcad2 
for 3 hours. The cells were then fixed with paraformaldehyde, permeablised with 
Triton X-100 and labelled with rabbit polyclonal serum recognising the FMDV 
capsid proteins and an Alexa 568nm conjugated secondary antibody (red). Figure
5.3 shows that cells expressing both wtrabl 1 (panel A) or dnrabl 1 (panel B) can be 
infected to a similar extent.
These observations were quantified (figure 5.3, panel C), by counting 1) wtrabl 1 or 
dnrab 11 expressing, FMDV-infected cells, and 2) non-expressing FMDV-infected 
cells on randomly selected fields of view on the confocal microscope. Expression of 
wtrabl 1 results in a 19% reduction when compared to non-expressing cells on the 
same coverslip. This suggests that overexpression of wtrabl 1 has a slight inhibitory 
effect on FMDV infection. However, the inhibition when dnrabl 1 is expressed is 
higher, 49%. If the proportion o f wtr abl 1 expressing cells infected is set at 100%, 
there is an inhibition of 35% when dnrabl 1 is expressed. This suggests that FMDV 
may have a requirement for recycling endosomes for infection.
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rab11(wt) rab11(S34N)
Total cells 3229 3380
% Non-expressing Cells Infected 10.5% 13.3%
% Expressing Cells Infected 8.5% 6.8%
% Expressing/non-expressing 82% 51%
Wild Type=100% 100% 65%
% Knockdown 35%
Figure 5.3 Effect of dominant-negative rabll on FMDV infection of IBRS2 cells
IBRS2 cells were transfected with expression plasmids for wtrabl 1 and dnrabl 1 fused to EGFP. At 6 
hours post-transfection, cells were infected with FMDV 01Kcad2 for 3 hours. Cells were fixed with 
paraformaldehyde, permeablised with Triton X-100 and labelled with rabbit polyclonal serum 
recognising the FMDV capsid proteins and an Alexa 568nm conjugated secondary antibody (red). 
Cell nuclei were stained with DAPI and are shown in blue. Bars=20pm.
Panel A shows wtrabl 1 and FMDV. Panel B shows dnrabl 1 and FMDV. In panels A and B, rabl 1
expressing, infected cells are arrowed. Panel C shows percentage knockdown due to expression of
dnrabl 1.
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5.2.4 Effect of dominant-negative rab? on FMDV infection of IBRS2 cells
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Rab? regulates the degradative endocytic pathway from early- to late endosomes and 
from there to lysosomes (Feng et al., 1995) (Vitelli et al, 1997). FMDV does not 
co-localise with markers of these compartments during entry of SW480-p6 cells 
(Berryman et a l, 2005). Movement o f cargo from early- to late endosomes is 
dependent on the microtubule network (De Brabander et al, 1988), and disruption of 
this network with nocodazole has no effect on FMDV infection (see chapter three). 
These observations strongly suggest that FMDV does not need to enter late 
endosomes or lysosomes for infection.
IBRS2 cells were transfected with expression plasmids for wtrab? or dnrab7 fused to 
EGFP. At 6 hours post-transfection, the cells were infected with FMDV 01Kcad2 
for 3 hours. The cells were then fixed with paraformaldehyde, permeablised with 
Triton X-100 and labelled with rabbit polyclonal serum recognising the FMDV 
capsid proteins and an Alexa 568mn conjugated secondary antibody (red). Figure
5.4 (panel A) shows that, as expected, expression of wtrab7 does not affect infection 
by FMDV. However, surprisingly, it appears that expression of dnrab? inhibits 
infection (panel B) as the majority of rab? expressing cells are not infected by 
FMDV.
These observations were quantified (figure 5.4, panel C), by counting 1) wtrab7 or 
dnrab? expressing, FMDV-infected cells, and 2) non-expressing FMDV-infected 
cells on randomly selected fields o f view on the confocal microscope. Expression of 
wtrab? results in a 32% reduction when compared to non-expressing cells on the 
same coverslip. This suggests that overexpression of wtrab7 has a slight inhibitory
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rab7(wt) rab7(N125l)
Total cells 3833 3593
% Non-expressing Cells Infected 25.3% 25.9%
% Expressing Cells Infected 17.2% 3.8%
% Expressing/non-expressing 71% 14%
Wild Type=100% 100% 22%
% Knockdown 78%
Figure 5.4 Effect of dominant-negative rab7 on FMDV infection of IBRS2 cells
IBRS2 cells were transfected with expression plasmids for wtrab7 and dnrab7 fused to EGFP. At 6 
hours post-transfection, cells were infected with FMDV 01Kcad2 for 3 hours. Cells were fixed with 
paraformaldehyde, permeablised with Triton X-100 and labelled with rabbit polyclonal serum 
recognising the FMDV capsid proteins and an Alexa 568nm conjugated secondary antibody (red). 
Cell nuclei were stained with DAPI and are shown in blue. Bars=20pm.
Panel A shows wtrab7 and FMDV. Panel B shows dnrab7 and FMDV. In panel A, rab7 expressing,
infected cells are arrowed. Panel C shows percentage knockdown due to expression of dnrab7.
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effect on FMDV infection. However, the inhibition when dnrab7 is expressed is 
much higher, 85%. If the proportion of wtrab? expressing cells infected is set at 
100%, there is an inhibition of 78% when dnrab? is expressed. This is unexpected, 
given that FMDV is thought not to require entry into late endosomes or lysosomes 
for infection. However, it appears that rab? has a role in FMDV infection.
5.2.5 Effect of dominant-negative rab9 on FMDV infection of 1BRS2 cells
Rab9 controls movement of cargo from late endosomes to the Golgi (Lombardi et 
a l, 1993). It is not thought that FMDV enters late endosomes or the Golgi after 
internalisation, however, the Golgi may be a source of membranes for FMDV 
replication (see chapter one, section 1.4.5).
IBRS2 cells were transfected with an expression plasmid for dmab9 fused to EGFP. 
At 6 hours post-transfection, the cells were infected with FMDV 01Kcad2 for 3 
hours. The cells were then fixed with paraformaldehyde, permeablised with Triton 
X-100 and labelled with rabbit polyclonal serum recognising the FMDV capsid 
proteins and an Alexa 568nm conjugated secondary antibody (red). Figure 5.5 
(panel A) shows that cells expressing dnrab9 can be infected by FMDV to a similar 
extent as non-expressing cells.
These observations were quantified (figure 5.5, panel C), by counting 1) dnrab9 
expressing, FMDV-infected cells, and 2) non-expressing FMDV-infected cells on 
randomly selected fields of view on the confocal microscope. The proportion of 
non-expressing cells infected is set at 100%, in the absence of a wild-type rab9 
control. Expression of dnrab9 inhibits FMDV infection by only 10%. This suggests 
that rab9 does not have a major role in FMDV infection and the virus does not
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rab9(S21N)
Total cells 3133
% Non-expressing Cells Infected 9.4%
% Expressing Cells Infected 8.4%
% Expressing Cells Infected (Corrected) 90%
% Knockdown 10%
Figure 5.5 Effect of dominant-negative rab9 on FMDV infection of IBRS2 cells
1BRS2 cells were transfected with an expression plasmid for dnrab9 fused to EGFP. At 6 hours post­
transfection. cells were infected with FMDV 01Kcad2 for 3 hours. Cells were fixed with 
paraformaldehyde, permeablised with Triton X-100 and labelled with rabbit polyclonal serum 
recognising the FMDV capsid proteins and an Alexa 568nm conjugated secondary antibody (red). 
Cell nuclei were stained with DAPI and are shown in blue. Bars=20pm.
Panel A shows dnrab9 and FMDV. Rab9 expressing, infected cells are arrowed. Panel B shows 
percentage knockdown due to expression of dnrab9.
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require trafficking from late endosomes to the Golgi.
5.3 Effect of dominant-negative rab GTPase expression on aVp8 expression
As rab proteins regulate endocytosis and receptor recycling, it is important to verify 
that the effects of dominant-negative rab protein expression on FMDV infection are 
not due to a reduction in receptor abundance at the cell surface, Integrins, the 
receptors for FMDV, are normally internalised via endocytosis and recycled back to 
the plasma membrane (Roberts et a l , 2001). Inhibition of receptor recycling by 
expression of dominant-negative rab proteins could therefore reduce the abundance 
of receptors on the cell surface, inhibiting virus binding and therefore infection.
Both wtrab5 and dnrabS, along with dnrab4 and dnrabl 1 (the rab proteins involved 
in recycling) were transiently expressed in IBRS2 cells as described previously.
This was followed by labelling with an antibody to the primary receptor on these 
cells, aVp8, and an Alexa 568nm conjugated secondary antibody (red). All labelling 
was carried out at 4°C to prevent antibody internalisation. The cells were fixed at 
the end of the experiment and then processed for immunofluorescence confocal 
microscopy.
Figure 5.6 shows expression of wtrab5 (panel A) or dnrab5 (panel C). Labelling of 
aVp8 on the cell surface can be seen more clearly in panels B and D. The levels of 
receptor expression are similar on rab-expressing and non-expressing cells. 
Therefore, the inhibition of FMDV infection in dnrabS expressing cells is unlikely to 
be due to reduced receptor availability.
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Figure 5.6 Integrin aV08 expression is not altered in wtrab5 or dnrab5 expressing ceils
1BRS2 cells were transfected with expression plasmids for wtrab5 or dnrab5 fused to EGFP. At 6 
hours post-transfection, cells were labelled with an antibody against aV{38 (14E5), and an Alexa 568nm 
conjugated secondary antibody (red). All labelling was carried out at 4°C, the cells fixed with 4% 
paraformaldehyde at the end of the experiment. Cell nuclei were stained with DAPI and are shown in 
blue. Bars=10|im.
Panel A (wtrab5) and panel C (dnrab5) show aVfi8 labelling (red) on rab expressing (green) and non­
expressing cells. For clarity, panels B and D show the same images as panels A and C with aV08 
labelling only.
For both wtrab5 and dnrab5 expressing cells the level of integrin labelling appears similar to the non­
expressing cells, indicating that dnrab5 does not inhibit cell surface expression of aV(38.
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Figure 5.7 shows a similar experiment for dnrab4 and dnrabl 1. Expression of 
dnrab4 (panel A) and dnrabl 1 (panel C) have little or no effect on surface aVp8 
expression when compar ed to non-expressing cells. For clarity, panels B and D 
show the same cells as in panels A  and C, but with integrin expression only shown in 
red.
5.4 Effect of dominant-negative rab GTPase expression on FMDV binding
As there is no discemable effect of dominant-negative rab GTPase expression on cell 
surface receptor abundance, it is unlikely that vims binding will be impaired in cells 
expressing these rabs. This was verified by expression of dnrab5 and dnrabl 1 in 
IBRS2 cells, followed by labelling with an FMDV anti-VP 1 antibody (Mab D9) and 
an Alexa 568nm conjugated secondary antibody (red). These rab proteins were 
chosen as both had inhibitory effects on FMDV infection. All labelling was carried 
out at 4°C, the cells being fixed at the end and processed for immunofluorescence 
confocal microscopy. Figure 5.8 shows expression of wtrab5 (panel A) or dnrab5 
(panel C) and FMDV binding at the cell surface (red). Panels B and D show the 
same cells as panels A  and C with FMDV binding shown as a series of stacked 
layers of the upper region of the cells. The cells expressing wtrab5 and dnrab5 
appear to have similar levels of FMDV bound to the cell surface when compared to 
the adjacent non-expressing cells. Figure 5.9 shows a similar experiment for 
dnrabl 1. Similarly, expression of dnrabl 1 did not appear to reduce the level of vims 
binding when compared to the adjacent non-expressing cells.
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Figure 5.7 Integrin aV08 expression is not altered in dnrab4 or dnrabll expressing cells
IBRS2 cells were transfected with expression plasmids for dnrab4 or dnrab 11 fused to EGFP. At 6 
hours post-transfection, cells were labelled with an antibody against aVP8 (14E5), and an Alexa 568nm 
conjugated secondary antibody (red). All labelling was carried out at 4°C, the cells fixed with 4% 
paraformaldehyde at the end of the experiment. Cell nuclei were stained with DAP1 and are shown in 
blue. Bars=10pm.
Panel A (dnrab4) and panel C (dnrab 11) show aVp8 labelling (red) on rab expressing (green) and non­
expressing cells. For clarity, panels B and D show the same images as panels A and C with aVp8 
labelling only.
For both dnrab4 and dnrab 11 expressing cells the level of integrin labelling appears similar to the non­
expressing cells, indicating that dnrab4/l 1 does not inhibit cell surface expression of aVP8.
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Figure 5.8 FMDV binding is not altered in wtrab5 or dnrab5 expressing cells
IBRS2 cells were transfected with expression plasmids for wtrab5 or dnrab5 fused to EGFP. At 6 
hours post-transfection, purified FMDV was bound to the cell surface at 4 °C for 45 minutes. This 
was followed by labelling with an antibody against FMDV VP1 (D9), and an Alexa 568nm 
conjugated secondary antibody (red). All labelling was carried out at 4°C, the cells being fixed with 
4% paraformaldehyde at the end of the experiment. Cell nuclei were stained with DAPI and are 
shown in blue. Bars=10pm.
Panel A (wtrab5) and panel C (dnrab5) show FMDV binding (red) on rab expressing (green) and non­
expressing cells. Panels B and D show the same images as panels A and C with FMDV binding 
shown as a series of layers through the upper region of the cells. The amount of virus detected on rab 
expressing and non-expressing cells is similar, indicating that expression of wtrab5 or dnrab5 do not 
inhibit virus binding.
AFigure 5.9 FMDV binding is not altered in dnrabl 1 expressing cells
IBRS2 cells were transfected with an expression plasmid for dnrabl 1 fused to EGFP. At 6 hours 
post-transfection, purified FMDV was bound to the cell surface at 4 °C for 45 minutes. This was 
followed by labelling with an antibody against FMDV VP1 (D9), and an Alexa 568nm conjugated 
secondary antibody (red). All labelling was carried out at 4°C, the cells being fixed with 4% 
paraformaldehyde at the end of the experiment. Cell nuclei were stained with DAPI and are shown in 
blue. Bars=10pm.
Panel A (dnrabl 1) shows FMDV binding (red) on rab expressing (green) and non-expressing cells. 
Panel B shows the same image as panel A with FMDV binding shown as a series of layers through 
the upper region of the cells. The amount of virus detected on dnrabl 1 expressing and non- 
expressing cells is similar, indicating that expression of dnrabl 1 does not inhibit virus binding.
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5.5 Effect of dominant-negative rab GTPase expression on FMDV uptake
As expression of dnrab5 and dnrab7 both inhibited FMDV infection, it was 
important to verify whether the block in infection was at the stage of virus uptake. 
With dnrab5, it is likely that the inhibition is at this stage, but it is less likely for 
dnrab7. To investigate vans entry in dnrab5 and dnrab? expressing cells, dnrab5 and 
dnrab7 were expressed in IBRS2 cells, followed by uptake of purified FMDV for 20 
minutes at 37°C. The cells were then fixed with par aformaldehyde, permeablised 
with Triton X-100 and labelled with an FMDV anti-VP 1 antibody (Mab D9) and an 
Alexa 568nm conjugated secondary antibody (red). Figure 5.10 shows expression of 
dnrab5 (panel A) and dnrab7 (panel C) and FMDV uptake (panels B and D). Cells 
expressing dnrabS can be seen to take up a lesser amount of virus, consistent with the 
cells having fewer early endosomes (see figure 4.3). In contrast, expression of 
dnrab7 did not appear to inhibit virus internalisation.
5.6 Discussion
The use of dominant-negative rab GTPases to block specific stages of endocytosis 
has been well documented (see chapter one, section 1.5). The results presented here 
have given some insights into which endocytic compartments are required for 
FMDV infection. Expression of dnrab5 inhibits FMDV infection by ~76% when 
compared to wtrabS, suggesting that the vims requires intact early endosomes for 
infection. This supports previous data showing co-localisation between FMDV and 
EEA1 (a marker for early endosomes) in SW480-{36 cells at early time points post­
entry (Berryman et al., 2005). The inhibition of FMDV infection by dnrab5 
expression seen in this study is therefore consistent with studies using other viruses.
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Figure 5.10 FMDV uptake is inhibited in dnrab5, but not dnrab7 expressing cells
IBRS2 cells were transfected with expression plasmids for wtrab5 or dnrab5 fused to EGFP. At 6 
hours post-transfection, purified FMDV was taken up into cells at 37°C for 20 minutes. Cells were 
fixed with 4% paraformaldehyde and permeablised with Triton X-100. This was followed by 
labelling with an antibody against FMDV VP1 (D9), and an Alexa 568nm conjugated secondary 
antibody (red). Cell nuclei were stained with DAP1 and are shown in blue. Bars=10pm.
Panel B shows FMDV labelling, with panel A showing which is the dnrab5 expressing cell. These 
pictures show that dnrab5 expressing cells do not internalise purified FMDV to the same extent as 
non-expressing cells. Panel D shows FMDV labelling, with panel C showing which is the dnrab7 
expressing cell. These pictures show that dnrab7 expressing cells internalise purified FMDV to the 
same extent as non-expressing cells.
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The first study showing an inhibition of virus infection by dnrab5 was carried out 
using adenovirus. This study documented a -5 0 %  inhibition of infection in dnrab5 
expressing cells (Rauma et al., 1999). In a similar study, Influenza virus infection 
was found to be inhibited by -61%  in dnrabS expressing cells (Sieczkarski & 
Whittaker, 2003). The same study showed an inhibition in infection of other 
enveloped viruses, semliki forest virus (SFV) and vesicular stomatitis virus (VSV) 
when dnrab5 was expressed, although these effects were not quantified. A  recent 
study investigating calicivirus infection showed an inhibition of infection of -80%  
when dnrab5 was expressed (Stuart & Brown, 2006).
Lack of infection in dnrab5 expressing cells is consistent with virus uptake by 
clathrin-dependent endocytosis, as formation of early endosomes and uptake of 
labelled transferrin into early and recycling endosomes was inhibited in dnrab5 
expressing cells (see chapter four). In the case of FMDV, it seems likely that 
inhibition of infection by dnrabS is at the stage of virus uptake. In dnrabS expressing 
cells, FMDV appeared to be taken up into small peripheral vesicles, most likely 
‘nude’ clathrin-coated vesicles. As there were no early endosomes for these vesicles 
to fuse with, the virus would be unable to gain access to these acidic compartments 
for capsid uncoating. In wtrab5 expressing cells, FMDV uptake was normal as 
compared to non-expressing cells.
It was important to verify that the effects of dominant-negative rab protein 
expression on FMDV infection were not due to inhibition of receptor recycling, 
reducing the amount of available receptors on the cell surface. Expression of wtrabS 
or dnrabS did not affect the cell surface expression levels of aV|38. Virus binding at 
the cell surface was also investigated in dnrabS expressing cells. There was no
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detectable reduction in virus binding in cells expressing dnrab5, when compared to 
non-expressing cells. This suggests that inhibition of FMDV infection in dnrab5 
expressing cells is unlikely to be due to reduced receptor availability, or an inhibition 
in virus binding.
Expression of constitutively active rab5 (carab5) had little effect on FMDV infection 
when compared to wild-type. Although there is evidence that expression of carab5 
enhances the rate of early endosome fusion, forming enlarged endosomes (Stenmark 
et al., 1994), there is no evidence that it increases rates of ligand uptake or recycling 
(Ceresa et al., 2001). This may explain why there is no significant increase in 
FMDV infection in cells expressing this mutant rab5 protein.
Expression of dnrab4 did not inhibit FMDV infection. This suggests that the rapid 
recycling pathway directly from early endosomes to the plasma membrane is not 
required for FMDV infection. Expression of dnrabl 1 has a slight inhibitory effect 
on FMDV infection and reduced recycling of labelled transferrin out of the cell. It 
seems therefore that the rabl 1-dependent recycling pathway may be more important 
than the rapid rab4-dependent pathway for FMDV infection. This may be due to the 
observation that the majority of integrins studied so far appeal* to use the rabl 1 
dependent pathway for recycling (Jones et al., 2006) and incoming FMDV particles 
may follow the same trafficking route as their receptor. As recycling endosomes are 
less acidic than early endosomes (Gagescu et a l , 2000), it is difficult to see any 
advantage to the virus entering the recycling pathway. It is possible that some vims 
particles do not uncoat in early endosomes and are carried rapidly into the recycling 
pathway along with the receptor. The vims may then experience a prolonged 
exposure to the acidic pH in recycling endosomes. However, the data in chapter five
Chapter five Effects o f rab GTPases on FMDV uptake and infection
142
show that FMDV has a greater requirement for early endosomes than recycling 
endosomes for infection. Expression of dnrab4 or dnrabl 1 did not appear to affect 
the cell surface expression levels of aV[)8. Similarly, there was also no detectable 
reduction in virus binding in cells expressing dnrabl 1 when compared to non­
expressing cells. This suggests that the partial inhibition of FMDV infection in 
dnrabl 1 expressing cells is unlikely to be due to reduced receptor availability, or an 
inhibition in virus binding. It is important to note that in cells expressing dnrab4 and 
dnrabl 1, the early endosomes are intact, and therefore the virus has access to this 
acidic compartment for capsid uncoating.
Unexpectedly, expression of dnrab? inhibited infection by FMDV. The inhibition is 
comparable to that seen with dnrab5. All evidence so far argues against a 
requirement for rab7-dependent compartments such as late endosomes and 
lysosomes in virus entry. In SW480-j36 cells, FMDV protein does not co-localise 
with LAMP-2, a marker for lysosomes (Berryman et a l, 2005). Trafficking of 
ligands from early- to late endosomes needs microtubules; however FMDV has no 
requirement for these structures during infection as infection is not inhibited in cells 
treated with the microtubule-dismpting agent nocodazole (see chapter three). Other 
viruses shown to require rab7 for infection are known to enter late endosomes and 
require the lower pH in these compartments for genome release (for example, human 
rhinovirus (Prchla et a l, 1994)). The study on influenza virus mentioned previously 
found that dnrab? expression inhibited infection by -5 0 %  (Sieczkarski 8c Whittaker, 
2003). The reason given for this is that influenza virus requires a pH of 5.5 for 
infection. The pH in early endosomes is around 6.0 and in late endosomes it is 5.0 to 
5.5. Therefore influenza virus must traffic to the late endosome in a rab7-dependent
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maimer for infection. In this same study, infection by Semliki Forest Virus (SFV) 
and Vesicular Stomatitis Virus (VSV) did not require rab7. This can be explained as 
the pH required for infection by these viruses are 6.2 and 6.3, respectively 
(Sieczkarski & Whittaker, 2003), which would permit infection to take place from 
within early endosomes. FMDV requires a pH just below neutral for uncoating and 
the environment in early endosomes is certainly sufficiently acidic for uncoating to 
occur (Curry et a l , 1995). The data in chapter four showed that expression of 
dnrab7 inhibited trafficking of Dil-LDL and lysotracker to late compartments, and 
the data in this chapter showed that uptake of FMDV was not inhibited in dnrab7 
expressing cells. These data suggest that FMDV does not require transport to late 
endosomes and rab? is not required for virus uptake. It is therefore possible that 
rab7 may play some other role in FMDV infection. This will be further investigated 
in chapter six.
Expression of dnrab9 did not appear to inhibit FMDV infection. Rab9 controls 
trafficking of ligands from late endosomes to the Golgi. FMDV is not thought to 
enter either compartment, although the Golgi is know to disperse during infection 
(O'Donnell et a l , 2001). FMDV does not co-localise with the Golgi at early time 
points post infection (O'Donnell et al, 2005) although the non-structural protein 2C 
does co-localise to some extent with markers of both the ER and Golgi during 
replication (Moffat et a l, 2005). There is a possibility that the Golgi is a source of 
membranes for formation of the vesicles required for replication (see chapter one, 
section 1.4.5. An inhibition of trafficking from late endosomes to the Golgi is 
unlikely to affect the integrity of the Golgi itself. Expression of dnrab9 in CHO cells 
does not affect the morphology of the Golgi as seen by immunofluorescence
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(Riederer et al., 1994). It is interesting to note that dnrab9 in uninfected IBRS2 cells 
is distributed in a Golgi-like pattern, and in chapter four was seen to co-localise 
strongly with markers of the Golgi apparatus. In FMDV infected IBRS2 cells, 
dnrab9 was dispersed, consistent with the fragmentation of die Golgi during FMDV 
infection seen in the studies mentioned above (data not shown).
In summary, the results of chapter five show that early endosomes, and to a lesser 
extent recycling endosomes are required for infection by FMDV. Although 
expression of dnrab7 inhibited trafficking of Dil-LDL and lysotr acker, it also 
inhibited FMDV infection, suggesting that rab? may have a role in the virus life 
cycle.
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Chapter six: The role of rab? in FMDV infection
6.1 Introduction
Although the inhibitory effect of dominant-negative rab5 expression on FMDV 
infection was as expected, the inhibitory effect of dominant-negative rab7 expression 
was surprising (see chapter five). It is likely that inhibition by dnrab7 is not at the 
stage of virus uptake, as FMDV is internalised by IBRS2 cells to a similar extent in 
dnrab7 expressing cells when compared to non-expressing cells (figure 5.10). One 
possibility is that a later stage of infection, such as intracellular virus replication, is 
being inhibited. It is known that extensive membrane rearrangements take place 
within cells infected with positive-strand RNA viruses (see chapter one, section 
1.4.5). Recent papers have suggested a link between the vesicles formed during 
positive-strand RNA virus infection and autophagosomes (Jackson et a l , 2005; 
Prentice et a l, 2004). It has also been shown that rab7 is involved in a late stage of 
autophagy (Gutierrez et a l, 2004; Jager et al, 2004). This suggests a possible role 
for rab7 in FMDV infection. To further investigate the role of rab7 in FMDV 
infection, a second dominant-negative rab? was obtained (from Maria Coiumbo, 
Argentina) with the rabS/T-N mutation, (T22N) rather than the rabN-I, (N125I) used 
in chapter five. The N125I mutant is unable to bind GTP or GDP and consequently 
remains primarily cytosolic. The T22N mutant binds preferentially to GDP and is 
inactive and therefore unable to recruit effector proteins. However GDP-bound rab 
proteins interact transiently with the cellular membranes they target (Seabra & 
Wasmeier, 2004). In HeLa cells, rab7-T22N has increased membrane binding ability 
when autophagy is activated (Gutierrez et a l, 2004).
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6.2 Expression of rab?-T22N inhibits trafficking of labelled low density 
lipoprotein (Dil-LDL)
The effect of dominant-negative rab7-N125I expression on trafficking of labelled 
low density lipoprotein, Dil-LDL (red) was investigated in chapter four. Dil-LDL is 
a ligand which is taken up by clathrin-dependent endocytosis into early endosomes 
from where it traffics to late endosomes and lysosomes. This experiment was 
repeated with the new dominant-negative rab7-T22N, to verify that this mutant also 
inhibits trafficking from early endosomes to late endosomes. Following transfection 
with an expression plasmid containing wtrab?-EGFP or rab7-T22N-EGFP, Dil-LDL 
(red) was taken up into IBRS2 cells for 30 minutes. At this time point the Dil-LDL 
should have reached late endosomes. Figure 6.1, panel A  shows the wtrab7 
expressing cell, and panel B shows the rab7-T22N expressing cell. In panel C, all 
cells have a similar level of Dil-LDL in large vesicles close to the nucleus, in a 
distribution indicative of late endosomes. This shows that trafficking of Dil-LDL is 
not inhibited by expression of wtrab?. However, in the panel D, the rab7-T22N 
expressing cell has an altered distribution of Dil-LDL when compared to non­
expressing or wtrab7 expressing cells. The Dil-LDL is in smaller vesicles near* to 
the periphery of the cell, suggesting that it has become trapped in early 
compartments. This indicates that rab7-T22N blocks trafficking of ligands from 
early endosomes to late endosomes.
6.3 Expression of rab?-T22N inhibits trafficking of lysotracker red
The effect of rab7-T22N expression on tr afficking of lysotracker red was also 
investigated, Lysotracker red is a dye which labels highly acidic compartments such
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Figure 6.1 Immunofluorescence confocal microscopy showing expression of 
dominant-negative rab7 (rab7-T22N-EGFP), but not wild-type rab7 (wtrab7-EGFP) 
inhibits early- to late endosome trafficking of labelled low density lipoprotein (Dil- 
LDL)
A
IBRS2 cells were transfected with expression plasmids for wtrab7 and rab7-T22N fused to EGFP. At 
6 hours post-transfection Dil-LDL (red) was added to the media and allowed to internalise for 30 
minutes. The cells were then fixed with paraformaldehyde. At this time point the Dil-LDL should 
have reached late endosomes. Cell nuclei were stained with DAPI and are shown in blue.
Bars=10pm.
Panel A shows the wtrab7 expressing cell (green), and panel C shows Dil-LDL (red). The wtrab7 
expressing cell has a similar level of Dil-LDL when compared to non-expressing cells. Panel B 
shows the rab7-T22N expressing cell (green), and panel D shows Dil-LDL (red). The rab7-T22N 
expressing cell has a reduced level of Dil-LDL when compared to non-expressing cells, suggesting an 
inhibition in trafficking from early- to late endosomes when rab7-T22N is expressed.
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as late endosomes and lysosomes. Following transfection with an expression 
plasmid containing wlrab7-EGFP or rab7-T22N-EGFP, lysotracker red was taken up 
into IBRS2 cells for 30 minutes. At this time point, strongly acidic compartments 
would be expected to be labelled red. Figure 6.2, panel A  shows the wtrab7 
expressing cell, and panel B shows die rab7-T22N expressing cell. In panel C, all 
cells have a similar level of red lysotracker in large vesicles close to the nucleus, in a 
distribution indicative of late endosomes and lysosomes. This shows that trafficking 
to late endosomes and lysosomes is not inhibited by expression of wtrab7. However, 
in the panel D, the rab7-T22N expressing ceil has an altered distribution of red 
lysotracker when compared to non-expressing or wtrab7 expressing ceils. The 
lysotracker is labelling smaller vesicles near to the periphery of the cell, suggesting 
labelling of mildly acidic early compartments only. This indicates that rab7-T22N 
inhibits trafficking from early endosomes to late endosomes and lysosomes. This is 
in agr eement with the results seen using rab7-N125I to inhibit trafficking of Dil- 
LDL and lysotracker described in chapter four'.
6.4 Expression of rab7-N125I, but not rab?-T22N inhibits FMDV infection
After showing that both forms of dominant-negative rab? inhibit trafficking from 
early endosomes to late endosomes and lysosomes, the next stage was to repeat the 
FMDV infection assay used in chapter five with rab7-T22N. IBRS2 cells were 
transfected with expression plasmids for wild-type (wtrab7), dominant-negative 
rab7-T22N or dominant-negative rab7-N125I fused to EGFP. At 6 hours post­
transfection, the cells were infected with FMDV 01Kcad2 for 3 hours. The cells 
were then fixed with paraformaldehyde, permeablised with Triton X-100 and 
labelled with a rabbit polyclonal serum recognising the FMDV capsid proteins and
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Figure 6.2 Immunofluorescence confocal microscopy show ing expression of
dominant-negative rab7 (rab7-T22N-EGFP), but not wild-tvpe rab7 (\vtrab7-EGFP)
inhibits trafficking of lysotracker to late endosomes and lysosomes
1BRS2 cells were transfected with expression plasmids for wtrab7 and rab7-T22N fused to EGFP. At 
6 hours post-transfection lysotracker red was added to the media and allowed to internalise for 30 
minutes. The cells were then fixed with paraformaldehyde. At this time point, lysotracker red should 
label highly acidic compartments such as late endosomes and lysosomes. Cell nuclei were stained 
with DAPI and are shown in blue. Bars=10gm.
Panel A shows the wtrab7 expressing cell (green), and panel C shows labelling for lysotracker red. 
The wtrab7 expressing cell has an equal level of lysotracker red labelling when compared to non­
expressing cells. Panel B shows the rab7-T22N expressing cell (green), and panel D shows labelling 
for lysotracker red. The rab7-T22N expressing cell has a reduced level of lysotracker red labelling 
when compared to non-expressing cells, suggesting an inhibition in the trafficking of lysotracker into 
late endosomes and lysosomes when rab7-T22N is expressed.
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an Alexa 568nm conjugated secondary antibody (red).
Figure 6.3 shows that although cells expressing wtrab? (green, panels A  and B) or 
rab7-T22N (green, panels C and D) can be infected by FMDV (red), the cells 
expressing rab7-N125I (green, panels E and F) are rarely infected.
Figure 6.3, panel G quantifies the effect of expression of each form of rab7 on 
FMDV infection. This was achieved by counting 1) wtrab7, rab7-T22N or rab7- 
N125I expressing, FMDV-infected cells, and 2) non-expressing FMDV-infected 
cells on randomly selected fields of view on the confocal microscope. Expression of 
wtrab7 results in an -18%  reduction in infection when compared to non-expressing 
cells on the same coverslip. This suggests that overexpression of wtrab7 has a slight 
inhibitory effect on FMDV infection (as in chapter five). Overexpression of rab7~ 
T22N inhibits FMDV infection by -27% . However, the inhibition when rab7-N125I 
is expressed is much greater, -82% . If the proportion of wtrab? expressing cells 
infected is normalised at 100%, there is an inhibition of only -9 %  when rab7-T22N 
is expressed, but -7 9 %  when rab7-N125I is expressed. This is represented 
graphically in panel H. This suggests that the two dominant-negative rab7 proteins 
differ in their ability to inhibit infection by FMDV.
6.5 Expression of rab7-N125I, but not rab7-T22N inhibits intracellular FMDV 
replication
It is possible that the inhibition of FMDV infection by rab7-N125I is at an 
intracellular stage of replication rather than entry. This was investigated by 
expressing wtrab7, dominant-negative rab7-T22N or dominant-negative rab7-N125I
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Gwtrab7 rab7-T22N rab7-N125l
Total cells 3375 3037 5278
% Non-expressing Cells Infected 16.3% 15.0% 16.3%
% Expressing Cells Infected 13.4% 10.9% 2.9%
% Expressing/non-expressing 82% 74% 17%
Wild Type=100% 100% 91% 21%
% Knockdown 9% 79%
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Figure 6.3 Expression of rab7-N125I inhibits FMDV infection but rab7-T22N does not
IBRS2 cells were transfected with expression plasmids for wtrab7, rab7-T22N and rab7-N1251 fused 
to EGFP. At 6 hours post-transfection, cells were infected with FMDV 01Kcad2 for 3 hours. Cells 
were fixed with paraformaldehyde, permeablised with Triton X-100 and labelled with rabbit 
polyclonal serum recognising the FMDV capsid proteins and an Alexa 568nm conjugated secondary 
antibody (red). Cell nuclei were stained with DAP1 and are shown in blue. Bars=10pm.
Panels A and B show wtrab7 and FMDV. Panels C and D show rab7-T22N and FMDV. Panels E 
and F show rab7-N125I and FMDV. Panel G shows percentage knockdown due to expression of 
rab7-T22N and rab7-N125I. This is represented graphically in panel H (error bars +/- one standard 
deviation).
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in IBRS2 cells, followed by electroporation of FMDV RNA into the cells. This 
bypasses endocytosis, delivering the viral RNA directly into the cytoplasm. In this 
way, any effects of dominant-negative rab? expression can be assumed to be acting 
after the stage of virus endocytosis.
Figure 6.4 shows that consistent with the data shown in figure 6.3, expression of 
rab?-T22N had little effect on FMDV infection, inhibiting by -17%  when the 
proportion of wtrab? expressing infected cells was normalised at 100%. Under these 
conditions, expression of rab7-N125I inhibited infection by -90% , again agreeing 
with the data in figure 6.3. These data show that inhibition of FMDV infection by 
rab7-N125I is at a stage after cell entry, during intracellular virus replication.
6.6 Expression of dnrab5 inhibits BEV infection
In order to see whether a requirement for rab? was a feature of all picomaviruses, 
effects of dnrabS and dnrab? on bovine enterovirus (BEV) infection were 
investigated. BEV is an enterovirus, in the same family as poliovirus. It differs 
from FMDV in its sensitivity to brefeldin A, being sensitive when FMDV is not 
(Gazina et al., 2002). Another difference is that enteroviruses form ‘A ’ particles and 
do not require low pH for infection.
BEV infects IBRS2 cells poorly, so for this experiment CHO cells were used. The 
cells were transfected with expression plasmids for wtrabS or dnrabS fused to EGFP. 
At 6 hours post-transfection, ceils were infected with BEV for 5 hours. Cells were 
fixed with paraformaldehyde, permeablised with Triton X-100 and labelled with 
11C5, an anti-BEV antibody and an Alexa 568nm conjugated secondary antibody 
(red).
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rab7-T22N rab7-N125l
Total cells 4341 4439 4321
% Non-expressing Cells Infected 5.9% 5.7% 5.9%
% Expressing Cells Infected 10.4% 8.3% 1.0%
% Expressing/non-expressing 177% 147% 18%
Wild Type=100% 100% 83% 10%
% Knockdown 17% 90%
H
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Figure 6.4 Expression of rab7-N125I inhibits FMDV replication but rab7-T22N does not
IBRS2 cells were transfected with expression plasmids for wtrab7. rab7-T22N and rab7-N125I fused to 
EGFP. At 6 hours post-transfection, cells were electroporated with FMDV RNA and incubated at 37°C 
for 6 hours. Cells were fixed with paraformaldehyde, permeablised with Triton X-100 and labelled 
with rabbit polyclonal serum recognising the FMDV capsid proteins and an Alexa 568nm conjugated 
secondary antibody (red). Cell nuclei were stained with DAPI and are shown in blue. Bars=10|im.
Panels A and B show wtrab7 and FMDV. Panels C and D show rab7-T22N and FMDV. Panels E and 
F show rab7-N 1251 and FMDV. Panel G shows percentage knockdown due to expression of rab7- 
T22N and rab7-N125I. This is represented graphically in panel H.
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Figure 6.5 shows that although cells expressing wtrab5 (green, panels A  and B) can 
be infected by BEV (red), the cells expressing dnrab5 (green, panels C and D) are 
rarely infected. Panel E quantifies the effect of expression of each form of rab5 on 
BEV infection. This was achieved by counting 1) wtrab5 or dnrabS expressing, 
BEV-infected cells, and 2) non-expressing BEV-infected cells on randomly selected 
fields of view on the confocal microscope (see above). Expression of wtrab5 results 
in a -9 %  reduction in BEV infection when compared to non-expressing cells on the 
same coverslip. However, the inhibition when dnrab5 is expressed is much higher, 
-67% . If the proportion of wtrabS expressing cells infected is normalised at 100%, 
there is an inhibition of -63%  when dnrab5 is expressed. This suggests that BEV 
infection may require early endosomes.
6.7 Expression of wtrab? and rab7-N125I inhibit BEV infection, but rab?-T22N 
does not
The effects of dominant-negative rab7-T22N and rab7-N125I on BEV infection were 
also investigated. CHO cells were transfected with expression plasmids for wtrab7, 
rab7-T22N or rab7-N125I fused to EGFP. At 6 hours post-transfection, cells were 
infected with BEV for 5 hours. Cells were fixed with paraformaldehyde, 
permeablised with Triton X-100 and labelled with 11C5, an anti-BEV antibody and 
an Alexa 568nm conjugated secondaiy antibody (red).
Figure 6.6 shows that although cells expressing wtrab7 (green, panel A), rab7-T22N 
(green, panel B) or rab7-N125I (green, panel C) can all be infected by BEV (red).
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wtrab5 dnrab5
Total cells 10040 11380
% Non-expressing Cells Infected 21.93% 21.55%
% Expressing Cells Infected 19.08% 7.08%
%Expressing/non-expressing 91% 33%
Wild Type=100% 100% 37%
% Knockdown 63%
Figure 6.5 Effect of dominant-negative rab5 (dnrab5) on infection by BEV
CHO cells were transfected with expression plasmids for wtrab5 or dnrab5 fused to EGFP. At 6 
hours post-transfection, cells were infected with BEV for 5 hours. Cells were fixed with 
paraformaldehyde, permeablised with Triton X-100 and labelled with 11C5, an anti-BEV antibody 
and an Alexa 568nm conjugated secondary antibody (red). Cell nuclei were stained with DAPI and 
are shown in blue. Bars=10|im.
Panels A and B show wtrab5 and BEV. Panels C and D show dnrab5 and BEV. Panel E shows 
percentage knockdown due to expression of dnrab5.
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wtrab7 rab7-T22N rab7-N125l
Total cells 9446 7285 7997
% Non-expressing Cells Infected 27.14% 24.65% 23.78%
% Expressing Cells Infected 15.28% 19.99% 12.15%
%Expressing/non-expressing 56% 82% 55%
Wild Type=100% 100% 147% 104%
% Knockdown +47% +4%
Figure 6.6 Effect of wtrab7, rab7-N125I and rab7-T22N on infection by BEV
CHO cells were transfected with expression plasmids for wtrab7, rab7-T22N or rab7-N125I fused to 
EGFP. At 6 hours post-transfection, cells were infected with BEV for 5 hours. Cells were fixed with 
paraformaldehyde, permeablised with Triton X-100 and labelled with 11C5, an anti-BEV antibody 
and an Alexa 568nm conjugated secondary antibody (red). Cell nuclei were stained with DAPI and 
are shown in blue. Bars=10pm.
Panel A shows wtrab7 and BEV. Panel B shows rab7-T22N and BEV. Panel C shows rab7-N125I 
and BEV. Panel D shows percentage knockdown due to expression of rab7-T22N or rab7-N125I.
159
Figure 6.6, panel D quantifies the effect of expression of each form of rab7 on BEV 
infection. This was achieved by counting 1) wtrab?, rab7-T22N or rab7-N125I 
expressing, BEV-infected cells, and 2) non-expressing BEV-infected cells on 
randomly selected fields of view on the confocal microscope. Expression of wtrab7 
results in a -44%  reduction when compared to non-expressing cells on the same 
coverslip. This suggests that overexpression of wtrab7 has a more significant 
inhibitory effect on BEV infection than FMDV. Overexpression of rab7-N125I 
inhibits BEV infection by a similar amount, -45% . This is less than the inhibition 
seen for FMDV. However, the inhibition when rab?-T22N is expressed is only 
-18% . This is similar to FMDV. If the proportion of wtrab? expressing cells 
infected is normalised at 100%, there is an enhancement of -47%  when rab7-T22N 
is expressed, but little difference when rab7-N125I is expressed.
As these experiments were carried out in CHO cells, FMDV infection was also 
quantified in these cells to verify that the effects of rab5 and rab? on BEV infection 
were not due to differences in cell type. The results are shown graphically in figure 
6.7, with 1) FMDV infection in IBRS2 cells (blue), 2) FMDV infection in CHO cells 
(red), and 3) BEV infection in CHO cells (yellow). The FMDV results are similar 
for both cell lines. These data show that the effects of dnrab5 and dnrab? on FMDV 
infection can be reproduced in two different cell lines, and the difference in the 
effects of dnrab5 and dnrab? on BEV infection when compared to FMDV are most 
likely due to differences in the viruses and not cell type.
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Figure 6.7 Comparison of effects of dnrab5, rab7-T22N and rab7-N125I on infection by FMDV and BEV in CHO and IBRS2 cells
Shown on the graph are percentage infection rates for dnrab5, rab7-T22N and rab7-N125I expressing cells with wtrabS or wtrab7 normalised at 100%.
1) FMDV infection in IBRS2 cells (blue), 2) FMDV infection in CHO cells (red), and 3) BEV infection in CHO cells (yellow).
wtrab5 dnrabS wtrab 7 rab7-T22N rab7-N125l
!»IBRS2-FMDV ■CHO-FMDV □CHO-BEV
161
Chapter six The role o f rab7 in FMDV infection
6.8 Discussion
Two different dominant-negative mutants of rab? have been investigated in this 
chapter. The first mutant, rab7-N125I, is unable to bind nucleotides and is primarily 
cytosolic. The second, rab7-T22N, has a higher affinity for GDP than GTP. It is 
inactive and unable to recruit effector proteins, but in its GDP bound form can bind 
membranes and shows an increased membrane binding in cells when autophagy is 
activated (Gutierrez et a l, 2004). Expression of both dominant-negative rab7 
proteins has been shown to inhibit trafficking of labelled LDL from early to late 
endosomes. They also reduce labelling of late endosomes and lysosomes with 
lysotracker red. As FMDV is not thought to traffic to late endosomes or lysosomes 
for infection, it would be predicted that expression of either form of dominant- 
negative rab7 would have no effect on FMDV entry and infection.
However, although expression of rab7-T22N had little effect on FMDV infection, 
expression of rab7-N125I inhibited FMDV infection by 78% (similar to the 
inhibition seen in chapter five). When viral RNA was electroporated into cells, 
bypassing endocytosis, the effects on virus replication were similar'. Compared to 
cells expressing wtrab7, the inhibition of FMDV replication by expression of rab7- 
N125I was -9 0 %  whereas expression of rab7-T22N again had little effect on virus 
replication. This suggests that inhibition of FMDV infection by rab7-N125I is at a 
stage after entry, during intracellular virus replication.
The natur e and origin of the membrane vesicles formed during infection with 
positive-strand RNA viruses has been the subject of much resear ch in recent year s.
It has been recently suggested that the vesicles formed during polio- and coronavirus
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infection have characteristics of autophagosomes (Jackson et ah, 2005; Prentice et 
al, 2004). FMDV is also believed to stimulate autophagy (E. Brooks, personal 
communication). It has also been shown that rab? is involved in a late stage of 
autophagy (Gutierrez et a l, 2004; Jager et a l, 2004). It has long been believed that 
there are host factors involved in the formation of the viral replication complex 
(Ahlquist et al, 2003). It is possible that rab? is one of these factors, and could be 
acting as a tethering protein helping to anchor the replication complex to the 
membrane, or to attract other cellular proteins to the site of replication.
Alternatively, rab? may be required to maintain the integrity of the replication 
vesicle. Recent studies have suggested a role for ADP ribosylation factors (ARFs) in 
anchoring the poliovirus replication complex to the replication vesicles (Belov et al, 
2005), and these ARFs are thought to be the targets for brefeldin A  inhibition of 
poliovirus infection (Morinaga et al, 1996). It is tempting to speculate that rab? has 
an equivalent role in FMDV infection, and as rab7 is not affected by brefeldin A, this 
could explain the difference in sensitivity of poliovirus and FMDV to brefeldin A  
treatment.
The observation that the cytosolic form of dominant-negative rab?-N125I inhibits 
FMDV infection suggests that the membrane binding ability of rab7 is required for 
FMDV infection. The observation that a membrane bound yet inactive form of rab7 
(rab7-T22N) supports FMDV infection argues against a role for rab7 in formation or 
movement of the replication vesicles and suggests a more passive role. It may be 
that rab? is required on the membrane, but it does not need to be in its active, GTP 
bound form. It is also interesting to note that the presence of an active form of rab? 
on the replication vesicle might promote fusion with acidic lysosomes which would
Chapter six The role o f rah7 in FMDV infection
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presumably be detrimental to vims replication. The bacterium Salmonella 
typhimurium replicates in rab7-positive vesicles and encodes a bacterial protein.
SifA, which substitutes for the rab7 effector RILP and therefore prevents recruitment 
of microtubules and thus fusion with lysosomes (Harrison et a l , 2004). It may 
therefore be advantageous for FMDV replication to also maintain rab7 in an inactive 
form.
The effect of dominant-negative rab5 expression on infection by BEV was similar to 
that seen for FMDV. Although the inhibition was a little lower, 63% for BEV 
compared to 77% for FMDV, there still appears to be some requirement for early 
endosomes. BEV is an enterovirus and therefore is stable to low pH and would not 
be expected to require exposure to the low pH within endosomes for infection. 
However, successful infection may require transport of BEV to early endosomes. 
Recent evidence has shown that eoxsackie B vims forms ‘A ’ particles on binding its 
receptor but viral RNA escape is delayed and occurs following uptake into caveolae 
(Coyne & Bergelson, 2006). It is possible that for BEV, viral RNA escape takes 
place from within vesicles following vims uptake.
The effect of dominant-negative rab7-T22N or rab7-N125I expression on infection 
by BEV was different to that seen for FMDV infection. When compared to cells 
expressing wtrab7, expression of rab7-T22N appeared to enhance BEV infection, but 
expression of rab7-N125I had little effect. However, when compared to non­
expressing cells, expression of wtrab7 and rab7-N125I appeared to inhibit infection 
by -45% . It is difficult to conclude a role for rab7 during BEV infection. Future 
experiments targeting rab7 by RNA interference would be helpful in clarifying this 
issue.
Chapter six The role o f rab 7 in FMD V infection
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Chapter seven: Depletion of rab? by RNA interference
7.1 Introduction
The results presented in chapter six suggest that two different forms of dominant- 
negative rab7 have different effects on FMDV infection. Expression of rab7-T22N 
does not inhibit FMDV infection and the protein is able to bind membranes (Seabra 
& Wasmeier, 2004), whereas expression of rab7-N125I inhibits FMDV infection and 
the protein is primarily cytosolic, due to a reduced membrane binding capacity. The 
purpose of the work earned out in chapter seven is to confirm whether rab7 is 
required for FMDV infection. This will be investigated using RNA interference, a 
technique by which a protein can be specifically depleted from cells. Specific 
depletion of rab7 may have a different effect when compared to overexpression of 
dominant-negative proteins, as dominant-negative proteins may still be able to bind 
regulatory proteins. These regulatory proteins include chaperone proteins (such as 
GDI) and also the two regulatory proteins involved in the GTPase cycle, known as 
GAPs (GTPase-activating proteins) and GEFs (guanine nucleotide exchange factors, 
see chapter one, section 1.5).
The technique of RNA interference has been developed to selectively inhibit the 
expression of a specific protein (Hannon, 2002). The aim of the studies described in 
this chapter are to deplete cells of rab7 using siRNA (short interfering RNA) 
duplexes specific to rab7. It should then be possible to see if there is an effect on 
FMDV infection when rab7 is absent from the cells, as compared to overexpression 
of a dominant-negative form.
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Although there have been a number of studies carried out using RNA interference to 
tar get viral proteins, fewer have been undertaken targeting cellular proteins required 
for virus replication and quantifying the effects of their depletion on virus infection. 
A  recent study investigating poliovirus infection used RNA interference to deplete 
the cells of components required for cellular autophagy (Jackson et al., 2005), These 
included ATG12 and LC3 (see chapter one, section 1.6.1). Inhibition of intracellular 
poliovirus infection was quantified as three-fold following a 70% depletion of 
ATG12 and four-fold following a 90% depletion of LC3. The effects on 
extracellular poliovirus production were repotted to be greater. A  recent study 
depleted cells of polypyrimidine tract-binding protein (PTB), a protein required for 
translation of picomavirus RNA. Its depletion lead to a decrease in calicivirus 
infection (Karakasiliotis et al., 2006), A  recent study has been carried out depleting 
host cellular factors that inhibit FMDV infection. In this study, depletion of double­
stranded RNA-dependent protein kinase R (PKR) by RNA interference lead to an 
increase in FMDV infection (de los Santos et al., 2006).
7.2 Depletion of human rab7 by RNA!
A number of companies produce pre-validated siRNAs directed to commonly 
studied cellular’ genes. These companies only develop pre-validated siRNA for the 
most commonly used species, i.e. human, mouse and rat. Human siRNA and 
therefore human cells were used in initial experiments for this reason. Dharmaeon’s 
siGLO, a stable, fluorescent, non-targeting siRNA can be transfected into cells and 
visualised by immunofluorescence confocal microscopy. This was used as a control 
to determine tr ansfection efficiency and to test a number of transfection reagents.
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Figure 7.1 shows transfection of red siGLO siRNA (Dharmacon) in HeLa cells using 
a variety of transfection reagents. Transfection efficiencies were determined as: 
Dhaimafect 73%, Lipofectamine 69%, siPORTamine 85% and siPORTlipid 0%.
The siPORT amine reagent was selected and used in all further experiments in this 
chapter.
The siPORT amine reagent was used to deliver a pool of four human rab7-specific 
duplexes into HeLa cells. Cell lysates were prepared for western blotting (see 
chapter two, section 2.8.1) at 24,48 and 72 hours post-transfection. A  western blot 
using an anti-rab7 antibody (obtained from S. Pfeffer) is shown in figure 7.2. There 
is a strong band for rab7 at 24 hours, showing that rab7 protein was still being 
expressed at this time point. A  partial knockdown for rab7 expression was seen at 48 
horns, increasing at to near complete at 72 hours. There is some recovery of rab7 
expression at 96 hours. This suggested that 72 hours is the optimum time point for 
further siRNA studies.
The western blots were repeated, including an anti-p-actin control for sample 
loading. A  further control was included to show that rab7 was specifically depleted 
by the rab7 tar geted siRNA. In order to do this, an anti-rab5 blot was included as 
this protein is similar to rab7, but should not be affected by the rab7-specific siRNA. 
Cell lysates were prepared at 72 hours post-transfection. Figure 7.3 shows western 
blots for actin, rab5 and rab7. The first lane shows a mock transfection, the second 
is the rab7-specific siRNA and the third lane is a non-targeting control siRNA 
(Dharmacon). This is a pool of siRNA duplexes which have been found to have no 
significant homology to the human, mouse or rat genomes by BLAST search. 
Although a good knockdown is seen in the rab7 western blot with rab7-specific
Chapter seven Depletion o f rab7 by RNA interference
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Figure 7.1 Transfection efficiencies for siGLO siRNA delivery in HeLa cells
siGLO labelled siRNA (red) was transfected into HeLa cells at 20pmol per coverslip. A variety of 
transfection reagents were used, each according to the manufacturer’s protocol. Cell nuclei were 
stained with DAPI and are shown in blue. Bars=40pm. Transfection efficiencies are: Dharmafect 
73%, Lipofectamine 69%, siPORTamine 85%, siPORTlipid 0%. The most efficient reagent appears 
to be siPORTamine (Ambion).
Figure 7.2 Time course of rab7 depletion by siRNA in HeLa cells
A pool of four human rab7-specific duplexes were transfected into HeLa cells using siPORTamine. 
Samples were taken for western blotting at 24,48 and 72 hours post-transfection. Rab7 was detected 
by an anti-rab7 antibody and a goat anti-rabbit IgG (H+L) HRP conjugate (Promega). At 24 hours 
rab7 was still being expressed. A clear knockdown can be seen by 48 hours, increasing at 72 hours 
and then some recovery of rab7 expression by 96 hours.
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Figure 7.3 Depletion of rab7 by siRNA in HeLa cells
A mock transfection with no siRNA, a pool of four human rab7-specific duplexes or a non-targeting 
siRNA were transfected into HeLa cells using siPORTamine. Samples were taken for western 
blotting at 72 hours post-transfection. Actin was detected using an anti-actin antibody (Sigma) and a 
goat anti-mouse IgG (H+L) HRP conjugate (Promega). Rab5 was detected using an anti-rab5 
antibody (Stressgen) and a goat anti-rabbit IgG (H+L) HRP conjugate (Promega). Rab7 was detected 
by an anti-rab7 antibody and a goat anti-rabbit IgG (H+L) HRP conjugate (Promega). Although a 
good knockdown is seen in the rab7 western blot with rab7-specific siRNA, there is no reduction in 
rab 7 in either control. There is no difference in levels o f actin or rab5, showing that the rab 7 siRNA 
is specific.
siRNA when compared to the mock transfection, there is no significant reduction in 
rab? in the non-targeting control transfected cells. There is no significant difference 
in levels of actin or rab5 in any lane, showing that the rab? siRNA is specific. This 
means that a non-specific reduction in protein expression induced by the introduction 
of double-stranded RNA into the cells can be discounted. The introduction of 
dsRNA into cells can cause activation of a non-specific interferon response, which 
reduces expression levels of all cellular proteins.
7.3 Transfection with porcine rab7-specific siRNA inhibits intracellular virus 
replication
As the human rab7-specific siRNA appeared to be working, the next stage was to 
obtain a porcine rab7-specific siRNA. The facility to design custom siRNA for 
species other than human, mouse and rat has recently become available. Firstly, 
IBRS2 cells were tested for their ability to take up the red fluorescent siGLO control 
siRNA. This is shown in figure 7.4, with a transfection efficiency of approximately 
63%, slightly lower than the HeLa cells.
No complete sequence for porcine rab? is available. A  number of partial sequences 
were combined in order to design porcine rab7-specific siRNA. A  pool of four 
porcine rab7-specific siRNAs (Dharmacon) was obtained and was transfected into 
IBRS2 cells in a 96-well plate. The rab7 antibody used for western blot assay in the 
HeLa cells did not cross-react with porcine rab7, meaning that the level of rab7 
depletion could not be quantified. At 48 or 72 hours post-transfection with rab7- 
specific siRNA, cells were infected with FMDV 01Kcad2 and processed for ELIspot 
assay as previously described in chapter three. The numbers of infected cells were
Chapter seven Depletion o f rab7 by RNA interference
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Figure 7.4 Transfection efficiencies for siGLO siRNA delivery in IBRS2 cells
siGLO labelled siRNA (red) was transfected into IBRS2 cells using siPORTamine (Ambion) at 
20pmol per coverslip. Cell nuclei were stained with DAPI and are shown in blue. Bars=20|im. 
Transfection efficiency is -63%.
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averaged over 6 wells. The results are represented graphically in figure 7.5. At 48 
hours post-transfection, the number of FMDV infected cells is reduced by -28%  
when compared to mock transfected cells. Transfection with the non-targeting 
control siRNA had little or no effect on the number of FMDV infected cells. At 72 
hours post-transfection, the time point at which rab7 levels should be at their lowest, 
the number of FMDV infected cells is reduced by -42%  when compared to mock 
transfected cells. Transfection with the non-targeting control siRNA did not reduce 
the number of FMDV infected cells. The experiment was repeated once more, 
looking only at 72 hours post-transfection, but this time using two control siRNAs; 
the non-targeting siRNA used in the previous experiment and a RISC-free siRNA. 
This siRNA cannot be processed by the RNA-induced Silencing Complex (RISC) 
and therefore discounts effects on the cell induced by the presence of the siRNA. 
Figure 7.6 shows that again, transfection with rab7-targeting siRNA caused the 
number of FMDV infected cells to be reduced by -4 4 %  at 72 hours post­
transfection. This is in agreement with the inhibition of -42%  at 72 horns post­
transfection seen in figure 7.5.
7.4 Transfection with porcine rab7-specific siRNA reduces virus yield
It seems that transfection with rab7-targeting siRNA inhibits the number of FMDV 
infected cells by -42% -44% . The effect of this depletion on FMDV yield was also 
assayed. IBRS2 cells in a 24-well plate were transfected with no siRNA (mock 
transfection) or with a pool of four porcine rab7-specific siRNAs. At 72 hours post­
transfection, cells were infected with FMDV 01Kcad2 and incubated at 37°C for 1 
horn-. Cells were then acid washed to remove virus that had not yet been 
internalised. After washing with serum-free media to restore pH, the cells were
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Figure 7.5 Transfection with rab7 targeting siRNA causes a reduction in the number of FMDV 
infected felK
IBRS2 cells in a 96-well plate were transfected with no siRNA (mock), porcine rab7-speciric siKNA, 
or a non-targeting siRNA. After 48 or 72 hours, cells were incubated with FMDV 0ikcad2 tor i 
hour at 37°C. The cells were washed to remove excess virus and infection was allowed to continue 
for a further 4 hours. An anti-3 A antibody was used to label infected cells (see chapter two), followed 
by a biotinylated secondary antibody and streptavadin-conjugated alkaline phosphatase. On addition 
of the enzyme substrate, infected cells are stained blue/black. Numbers of infected cells were 
quantified using an ELIspot plate reader (see chapter two).
The graph shows the number of infected cells +/- one standard deviation. Infection is expressed as a 
percentage o f the number of virus infected cells in mock transfected wells.
At 48 hours post-transfection, transfection with porcine rab7-specific siRNA leads to a 28% inhibition 
in the number of FMDVinfected cells when compared to mock transfected cells. By 72 hours, this 
inhibition is 42%.
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Figure 7.6 Transfection with rab7 targeting siRNA causes a reduction in the number of FMDV 
infected cells
IBRS2 cells in a 96-well plate were transfected with no siRNA (mock), porcine rab7-specific siRNA, 
a RISC-free siRNA or a non-targeting siRNA. After 72 hours, cells were incubated with FMDV 
01Kcad2 for 1 hour at 37°C. The cells were washed to remove excess virus and infection was 
allowed to continue for a further 4 hours. An anti-3 A antibody was used to label infected cells (see 
chapter two), followed by a biotinylated secondary antibody and streptavadin-conjugated alkaline 
phosphatase. On addition of the enzyme substrate, infected cells are stained blue/black. Numbers of  
infected cells were quantified using an ELIspot plate reader (see chapter two).
The graph shows the number of infected cells +/- one standard deviation. Infection is expressed as a 
percentage of the number of virus infected cells in mock transfected wells.
At 72 hours post-transfection, transfection with porcine rab7-specific siRNA causes a 44% reduction 
in the number of FMDV infected cells when compared to mock transfected cells.
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again incubated at 37°C, Samples of cell media were taken at two hour intervals and 
titrated on BHK cells to determine virus yield from the infected cells. Figure 7.7 
shows plaque assays for samples taken 6 horns after the acid washing step. The 
figure shows dilutions of 10° and HT*. The samples from mock transfected cells 
have produced more virus than the rab7 siRNA transfected cells. This suggests an 
inhibition in virus yield when cells are transfected with rab7~targeting siRNA.
7.5 Discussion
Due to time constraints, the results in this chapter are incomplete and should be 
considered as preliminary. The system for depletion of cellular rab7 by RNA 
interference was set up using a pool of four human rab7 specific siRNA duplexes 
(Dharmacon). When these were transfected into HeLa cells, a clear knockdown of 
cellular rab7 could be seen by western blot analysis at 72 hour s post-transfection. A  
similar* pool of four porcine rab7 specific siRNA duplexes were obtained in order to 
carry out studies in IBRS2 cells, the cell line used in the majority of experiments 
carried out in this thesis. Using these cells, a knockdown in cellular rab7 could not 
be determined as the anti-rab7 antibody used with the HeLa cells did not cross-react 
with porcine rab7. However, it appears that transfection with rab7-targeting siRNA 
in IBRS2 cells has an inhibitory effect on FMDV infection, reducing both the 
number of infected cells and virus yield. In two separ ate experiments, the reduction 
in the number of infected cells as seen by ELIspot was 42% and 44% at 72 hour s 
post-transfection. This is compared to the -7 9 %  inhibition seen when dominant- 
negative rab7-N125I was expressed (see chapter five, figure 5.4 and chapter six, 
figur e 6.3). One possible explanation for this difference is that not all the cellular 
rab7 was depleted. The inhibition of infection in the rab7-N125I expressing cells
Chapter seven Depletion o f rab7 by RNA interference
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Figure 7.7 Transfection with rab7 targeting siRNA causes a reduction in FMDV yield
IBRS2 cells were transfected with no siRNA (mock) or a pool of porcine rab7-specific siRNAs. After 
72 hours, cells were infected with FMDV 01Kcad2. After 1 hour incubation at 37°C, cells were 
washed with citric acid to remove virus not internalised. Samples of media were taken at intervals 
and assayed for virus yield by plaque assay on BHK cells. This figure shows samples taken 6 hours 
post-infection. Two virus dilutions are shown.
Panels A and B are at a dilution of 10-3. Panel A shows virus yield from mock transfected cells.
Panel B shows a reduction in virus yield from porcine rab7-specific siRNA transfected cells.
Panels C and D are at a dilution of 10-4. Panel C shows virus yield from mock transfected cells.
Panel D again shows a reduction in virus yield from porcine rab7-specific siRNA transfected cells. 
The estimated titres are 3.1X1 O'3 in the mock transfected cells and 9X1 O'4 in the porcine rab7-specific 
siRNA transfected cells. This is 3.4-fold reduction.
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was calculated using only cells expressing the dominant-negative protein, therefore 
assuming 100% inhibition. A  real-time PCR assay could be used to quantify 
reduction in rab7 mRNA levels. Total mRNA has been extracted from IBRS2 cells 
transfected with rab7 siRNA and cDNA has been made from this, but the assays 
have not yet been carried out due to lack of time.
The effect on virus yield was also investigated, with a time course experiment being 
carried out at the same time as the ELIspot. When cells were transfected with rab7- 
targeting siRNA, there appears to be a reduction in FMDV yield at 6 horns post­
infection.
The preliminary data presented in this chapter supports the theory that FMDV 
requires rab7 for infection. Transfection with rab7 targeting siRNA reduces the 
number of FMDV infected cells, and vims yield. However, the plaque assays and 
ELIspot assays need to be repeated, and the extent of the porcine rab? knockdown 
must be quantified. If more time could have been devoted to this investigation, a 
good starting point would have been to clone porcine rab7. The sequence used for 
the siRNA design was based on partial sequences available on the internet which 
need to be confirmed. It would also be useful to obtain or to make an anti-rab7 
antibody that cross-reacts with porcine rab? for use in western blot assays. This 
could then be used to quantify knockdown of the rab7 protein, supporting real-time 
PCR assays showing knockdown of rab7 mRNA.
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Chapter eight Conclusions
The data presented in chapter three confirmed that aV(38-mediated infection of 
IBRS2 cells by FMDV proceeds via clathrin-dependent endocytosis and is 
dependent on the low pH within endosomes. This was shown using specific 
inhibition of clathrin-dependent endocytosis by expression of AP180C (figure 3.1), 
and by inhibition of the vacuolar ATPase responsible for maintaining low endosomal 
pH by treatment with concanamycin A (figure 3.2). These data are in agreement 
with those presented for aVp6-mediated FMDV entry into SW480 cells (Berryman 
etal,  2005).
To further investigate which compartments of the acidic endosomal system are 
required by FMDV during infection, dominant-negative rab GTPases were used. 
Although the exact site of infection by FMDV (defined here as translocation of the 
viral RNA across an endosomal membrane into the cytoplasm) is unknown, likely 
candidates are early- or recycling endosomes as viral capsid proteins accumulate in 
these vesicles during cell entry. However, FMDV is not thought to require 
trafficking to late endosomes or lysosomes for infection. The effects of expression 
of each dominant-negative rab GTPase on FMDV infection of IBRS2 cells are 
summarised in figure 8.1.
Rab5 is required for the fusion of early endocytic vesicles to form early endosomes. 
Expression of dominant-negative rab5 (dnrabS) was shown to inhibit both the 
formation of early endosomes and uptake of labelled transferrin through these 
compartments (figures 4.3 and 4.9). As seen in figure 8.1, expression of dnrab5 
inhibited FMDV infection by -7 7 %  when compared to wild-type rab5 (wtrab5),
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indicating that FMDV requires intact early endosomes for infection. This inhibition 
is not due to reduced receptor expression (figure 5.6) or virus binding (figure 5.8). 
However, delivery of FMDV to early endosomes was inhibited in dnrabS expressing 
cells (figure 5.10), consistent with a depletion of early endosomes by dnrab5. Virus 
was seen to enter cells expressing dnrab5 but remains in small puncta at the cell 
periphery, suggesting that rab5 is not required for formation of incoming endocytic 
vesicles. Expression of constitutively active rab5 (carabS) resulted in the formation 
of ‘giant’ early endosomes but had little effect on FMDV infection (figure 5.1).
Rab4 is involved in the rapid recycling pathway from early endosomes back to the 
plasma membrane. Expression of dnrab4 had little effect on the integrity of early- or 
recycling endosomes (figures 4.10 and 4.12). Expression of dnrab4 had little effect 
on FMDV infection, indicating that the steps of the recycling pathway regulated by 
rab4 are not required for FMDV infection.
Rabl 1 is involved in the slower recycling pathway from early endosomes back to the 
plasma membrane via recycling endosomes. Expression of dnrabl 1 resulted in a 
change in the pattern of labelling of transferrin receptor-positive compartments 
(figure 4.16). In dnrabl 1 expressing cells, labelled transferrin was not recycled in 
the normal way and became trapped in compartments with a similar distribution to 
early endosomes (figure 4.18). These data suggest that the number of recycling 
endosomes may be reduced in dnrabl 1 expressing cells. The abundance and 
distribution of early endosomes was not reduced in dnrabl 1 expressing cells (figure 
4.15). Expression of dnrabl 1 inhibited FMDV infection by -35% , indicating that 
recycling endosomes may play a role in FMDV infection. However, the virus is less 
reliant on these than on early endosomes for infection. This inhibition did not appear
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to be due to reduced receptor expression (figure 5.7) or virus binding to the cells 
(figure 5.9). It may be that some virus particles do not uncoat in early endosomes 
and are earned into the recycling pathway where the virus experiences a prolonged 
exposure to acidic pH.
Rab9 regulates trafficking from late endosomes to the Golgi. Expression of dnrab9 
had little effect on the pattern o f labelling for all cellular- endocytic compartments 
investigated (figures 4.24 and 4.25). Similarly, expression of dnrab9 had little effect 
on FMDV infection, indicating that the virus does not require trafficking from late 
endosomes to the Golgi.
These results in this thesis therefore provide further evidence for FMDV cell entry 
occurring by clathrin-dependent endocytosis, followed by uptake into early 
endosomes, where the low pH in this compartment causes capsid uncoating and 
translocation of the viral RNA genome into the cytoplasm. The mechanism by 
which this translocation occurs is unknown, and would be a subject for future work.
A number of viruses require a low pH step for capsid uncoating and infection. For 
some viruses, early endosomes are not sufficiently acidic and they require the lower 
pH found in late endosomes and lysosomes (Prchla et al., 1994). There is no 
evidence that FMDV infection requires conditions any more acidic than those found 
in early endosomes, as the FMDV capsid is extremely sensitive to acid and uncoats 
at pH 6.5, just below neutral pH (Curry et a l , 1995). The FMDV capsid proteins 
have not been co-localised with markers for late endosomes or lysosomes at early 
time points during infection (Berryman et a l,  2005; O'Donnell et a l,  2005). 
Furthermore, treatment of SW480 cells with nocodazole, a drug which disrupts the
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microtubule network and prevents trafficking from early to late endosomes, has no 
effect on FMDV infection (Berryman et a l , 2005). This was also shown in chapter 
three to be the case for FMDV infection of IBRS2 cells (figure 3.3). All evidence 
therefore suggests that FMDV does not traffic to late endosomes during cell entry.
The observations above predict that as expression of dominant-negative rab? inhibits 
trafficking from early- to late endosomes and lysosomes, it would not be expected to 
have an effect on FMDV infection. Expression of dominant-negative rab? was 
shown to inhibit trafficking of labelled LDL and lysotracker (figures 4.22 and 4.23), 
both of which ar e known to traffic from early- to late endosomes. Surprisingly, 
expression of the N125I version of dnrab7 inhibited FMDV infection by -78% 
compared to cells expressing wtrab7, suggesting a requirement for rab? dur ing 
FMDV infection. Cellular uptake of FMDV was not inhibited in dnrab? expressing 
cells when compared to non-expressing cells (figure 5.10). In addition, early 
endosome formation was not inhibited in cells expressing dnrab? (figure 4.19). 
These observations suggest that FMDV is internalised into early endosomes in the 
normal way and that rab7 could be required for FMDV infection at a stage after 
endocytosis, i.e. during intracellular virus replication.
In common with dnrab7-N125I, expression of dnrab7-T22N was shown to inhibit 
trafficking of labelled LDL and lysotracker (figures 6.1 and 6.2). However, rab7- 
T22N had a different effect on FMDV infection. When expressed in IBRS2 cells, 
rab7-N125I had little effect on infection (figure 6.3). Rab7-N125I is unable to bind 
GTP or GDP and therefore has a reduced capacity to bind membranes and is 
primarily cytosolic. Rab7-T22N is predominantly GDP bound and retains the 
capacity to bind membranes. It has also been shown to have increased membrane
Chapter eight Conclusions
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binding during autophagy (Gutierrez et a l , 2004). This suggests that a form of rab? 
able to bind membranes may be required for FMDV infection.
To verify that the inhibition of FMDV infection by rab7-N125I is at a stage after 
endocytosis, viral RNA was electroporated into cells expressing wtrab7, rab7-T22N 
or rab7-N125I. This method of introducing the viral RNA into the cells bypasses 
endocytosis and delivers the RNA directly into the cytoplasm. Figure 6.4 shows that 
expression of rab?-T22N had little effect on intracellular FMDV replication, whereas 
the rab7-N125I inhibited by 90%. This verifies that the inhibition of FMDV 
infection by rab7-N125I is at a stage after endocytosis, during intracellular virus 
replication.
In cells infected by FMDV, extensive membrane rearrangements occur, resulting in 
the formation of membrane vesicles on which the viral replication complex is 
assembled (Monaghan et al., 2004). Studies on poliovirus replication vesicles have 
suggested that the double-membraned vesicles induced on infection are similar* to 
autophagosomes (Jackson et a l , 2005; Suhy et al., 2000). Autophagy is a cellular 
response to amino acid starvation and autophagosomes are the only cellular vesicles 
surrounded by a double membrane. Rab? is required for the late maturation of 
autophagic vacuoles, and can be found on autophagosomes from an early stage of 
autophagy (Gutierrez et a l , 2004; Jager et al., 2004). FMDV infection stimulates 
autophagy (E. Brooks, personal communication), which suggests a link between rab7 
and FMDV replication. However, it must be noted that FMDV replication vesicles 
are predominantly single membraned (Monaghan et a l , 2004).
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In chapter six, experiments were carried out using bovine enterovirus (BEV). Like 
poliovirus, BEV is an enterovirus and induces the formation of vesicles 
morphologically similar to those seen in poliovirus infected cells (Monaghan et a l, 
2004). Expression of dnrabS inhibited BEV infection by -63%  when compared to 
wtrab5 (figure 6.5). This suggests that BEV may be taken up into early endosomes 
during infection, although this virus is stable to low pH and does not require 
exposure to acid for infection. However, the requirement for rab? appears different 
to that obseived for FMDV. When compared to cells expressing wtrab7, expression 
of rab7-T22N appeared to enhance BEV infection, whereas expression of rab7- 
N125I had little effect. However, when compared to non-expressing cells, 
expression of wtrab7 and rab7-N125I appeared to inhibit infection by -45%  (figure 
6.6). These differences are not due to differences in cell type (figure 6.7). It is 
difficult to conclude a role for rab7 during BEV infection, but further studies using 
rab7-specific RNA interference may help to clarify whether there is a role for rab7 in 
enterovirus infection.
Two forms of dominant-negative rab7 had different effects on FMDV infection. To 
further define the role of rab7 during FMDV infection, experiments were designed 
using RNA interference targeted to cellular rab7. The results presented in chapter 
seven show that transfection with porcine rab7-targeted siRNA in IBRS2 cells 
reduced both the number of FMDV infected cells (figures 7.5 and 7.6) and virus 
yield (figure 7.7). These experiments must be considered preliminary, as a cross­
reactive antibody to rab7 was not identified and a knockdown of rab7 in IBRS2 cells 
could not be demonstrated. An alternative to western blotting could be using real
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time PCR to quantify levels of rab? mRNA after transfection with rab?-targeted 
siRNA.
The results presented in this thesis suggest a requirement for cellular rab? during 
FMDV infection. The electroporation results show that the inhibition of FMDV 
infection by expression of rab?-N125I is at a stage after translocation of the vRNA 
into the cytoplasm. Stages at which the inhibition could occur include polyprotein 
synthesis and processing, host cell membrane rearrangements and formation of the 
replication complex, negative-strand vRNA synthesis, positive-strand vRNA 
synthesis and virus assembly. In future experiments, the effects of rab?-N125I 
expression or depletion of rab? by RNAi on the different stages of the FMDV life 
cycle could be investigated in order to determine precisely where the inhibition 
occurs.
It is believed that host factors are involved in the formation of the viral replication 
complex (Ahlquist et al., 2003). It is possible that rab? could be one such factor. 
Rab? could be required for formation of the replication complex or to act as a 
tethering protein to anchor it to the membrane. In addition, rab? could be needed to 
attract other cellular proteins to the replication complex. Alternatively, it may be 
required to maintain the integrity of the replication vesicle. Recent studies have 
suggested a role for ADP ribosylation factors (ARFs) in anchoring the poliovirus 
replication complex to the replication vesicles (Belov et a l, 2005). These ARFs are 
thought to be the targets for brefeldin A inhibition of poliovirus infection (Morinaga 
et a l,  1996). As FMDV infection is not affected by brefeldin A, it is tempting to 
speculate that rab? has an equivalent role in FMDV infection to the ARFs in 
poliovirus infection.
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These possibilities could be further explored in future experiments to demonstrate 
co-localisation of rab? with the replication complex. This could be shown by co­
localisation of rab7 with FMDV non-structural proteins or isolation of the replication 
membranes and western blotting for rab7. Alternatively, the replication membranes 
could be visualised by electron microscopy (EM) and labelled with rab? antibodies. 
However, if  the interaction of rab? with the replication vesicles is transient, this may 
not be possible. To confirm whether the membrane binding ability of rab? is 
required for infection, the membrane binding domain of rab7-T22N could be 
mutated to see if  this protein would then be able to support infection.
The observation that a membrane bound but inactive fonn of rab? (rab7-T22N) can 
support infection argues against a role for rab? in the formation of replication 
vesicles as only an active, OTP-bound rab protein can recruit effectors and drive 
vesicle formation. It would be interesting to see whether the replication vesicles are 
formed in dnrab? expressing cells, or cells depleted of rab? by siRNA.
Alternatively, rab? could be acting as an anchoring factor, stabilising the replication 
complex on the membrane vesicle. Demonstrating a direct interaction between rab? 
and FMDV non-structural proteins could be done by FRET/FRAP in infected cells 
or in vitf'o by direct binding assays or pull-down assays.
To conclude, the results in this thesis show that FMDV enters IBRS2 cells 
expressing aVp8 via clathrin-dependent endocytosis. FMDV requires low pH and 
intact early endosomes for infection. It may also enter recycling endosomes, but 
these compartments appear less important for infection. FMDV does not require 
intact microtubules and therefore is unlikely to traffic to late endosomes. These 
observations identify the early endosome as the critical compartment for FMDV
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infection. Although rab? is not required for trafficking of FMDV to late endosomes 
or lysosomes for infection, it appears to be required for intracellular virus replication. 
These observations lay the foundation for future experiments to explore the role of 
rab? in intracellular FMDV replication.
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Appendix I 
T-Test Calculations
exptl expt2 expt3 mean diff of mean
wtrab4 100.0 74.2 67.4 80.5
dnrab4 99.4 76.5 83.8 86.6 6.1
standard deviations
wtrab4 19.47 -6.34 -13.12
dnrab4 12.85 -10.04 -2.80
variance
wtrab4 379 40 172
dnrab4 165 101 8
sum of variances
wtrab4 591
dnrab4 274
divide both by number of samples (3)
wtrab4 197.138
dnrab4 91.25572
add both together 
288.3937 
square root 
16.98216
divide difference of means (6.1) by this number
0.357343
degrees of freedom = (3+3)-2 
=4
from t-table not significant
exptl expt2 expt3 expt4 mean diff of mean
wtrab5
dnrab5
wtrabS
dnrabS
wtrab5
dnrab5
wtrab5
dnrab5
wtrab5
dnrabS
74.93878 81.98246 62.05449 64.26047 70.8
21.31336 9.307652 13.2438 18.93266 15.7
standard deviations
4.13 11.17
5.61 -6.39
variance
17 125
32 41
sum of variances
261 
89
divide both by number of samples (4)
65.35651 
22.21375
add both together
87.57026
square root
9.357898
divide difference of means (55.1) by this number
5.889109
degrees of freedom = (4+4)-2  
=6
-8.75 6.5
-2.46 -3.2
77 43
6 10
55.1
from t-table significant at 0.01
exptl expt2 expt3 mean diffofm ean
wtrab5 81.98246 62.05449 64.26047 69.43247
carab5 54.2522 81.44953 78.31401 71.33858 1.9
standard deviations
wtrab5 -12.55 7.38 5.17
carab5 17.09 -10.11 -6.98
variance
wtrabS 158 54 27
carab5 292 102 49
sum of variances
wtrab5 239
carabS 443
divide both by number of samples (3)
wtrab5 79.56217
carab5 147.6108
add both together 
227.1729 
square root 
15.07226
divide difference of means (1.9) by this number
0.126460
degrees of freedom = (3+3)-2 
=4
from t-tabie, not significant
exptl expt2 expt3 mean diff of mean
wtrab7 71.42 90.40 51.85 71.2
dnrab7 12.89 7.58 20.41 13.6 57.6
standard deviations
wtrab? 0.20 19.17 -19.37
dnrab? -0.73 -6.05 6.78
variance
wtrab7 0 368 375
dnrab7 1 37 46
sum of variances
wtrab7 743
dnrab7 83
divide both by number of samples (3)
wtrab7 247.6249
dnrab7 27.71597
add both together 
275.3408  
square root 
16.5934
divide difference of means (57.6) by this number
3.471199
degrees of freedom = (3+3)-2 
=4
from t-table significant at 0.05
exptl expt2 expt3 mean diff of mean
non expressing cells 8.5 9.6 10.1
dnrab9 9.4 8.1 7.7
standard deviations
non expressing cells -0.86 0.15 0.71
dnrab9 1.02 -0.30 -0.71
variance
non expressing cells 0.74 0.02 0.51
dnrab9 1.04 0.09 0.51
sum of variances
non expressing cells 1.27
dnrab9 1.64
divide both by number of samples (3)
non expressing cells 0.423637 
dnrab9 0.54592
add both together 
0.969557  
square root 
0.984661
divide difference of means (1.0) by this number 
1.053848
degrees of freedom = (3+3)-2 
=4
from t-table not significant
9.4
8.4 1.0
expti expt2 expt3 mean diff of mean
wtrabl 1 
dnrabl 1
wtrabl 1 
dnrabl 1
wtrabl 1 
dnrabl 1
wtrabl 1 
dnrabl 1
wtrabl 1 
dnrabl 1
96.4 83.2
44.6 61.3
standard deviations
14.71 1.51
-6.78 9.89
variance
216 2
46 98
sum of variances
482 
153
divide both by number of samples (3)
160.6361
51.13163
add both together
211.7678
square root
14.55224
divide difference of means (30.3) by this number
2.078991
degrees of freedom = (3+3)-2 
=4
from t-table not significant
65.4
48.3
81.7
51.4 30.3
-16.22
-3.10
263
10
wtrab7
rab7T22N
wtrab?
rab7T22N
wtrab?
rab7T22N
wtrab7
rab7T22N
wtrab?
rab7T22N
83.2 80.8
60.6 88.4
standard deviations
1.18 -1.18
-13.91 13.91
variance
1 1
193 193
sum of variances
3
387
divide both by number of samples (2)
1.40333
193.3528
add both together
194.7562
square root
13.95551
divide difference of means (7.6) by this number
0.541828
degrees of freedom = (2+2)-2 
=2
exptl expt2 expt3
from t-table not significant
82.0
74.5 7.6
mean diff of mean
wtrab7
rab7N125l
wtrab7
rab7N125l
wtrab?
rab7N125l
wtrab7
rab7N125l
wtrab7
rab7N125l
exptl expt2 expt3 mean diffofm ean
83.2 80.8 82.0
22.28283 15.6401 13.46855 17.1 64.9
standard deviations
1.18 -1.18
-5.15 1.49 3.66
variance
1 1
27 2 13
sum of variances
3
42
divide both by number of samples (2/3)
1.40333
14.05922
add both together
15.46256
square root
3.932246
divide difference of means (64.9) by this number
16.50498
degrees of freedom = (2+3)-2 
=3
from t-tabie significant at 0.001
